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Head and neck squamous cell carcinoma (HNSCC) is the 6th most common 
cancer worldwide. Epigenetic mechanisms including changes in DNA 
methylation (5mC) and hydroxymethylation (5hmC) are major contributors to 
HNSCC progression and can be altered by the use of epigenetic therapies 
such as the DNA demethylating agent, 5-aza-2’-deoxycytidine (DAC). Here, 
the potential use of DAC in the treatment of HNSCC was investigated and a 
subset of HNSCC cell lines determined to respond to nanomolar 
concentrations of the drug. Furthermore, the efficacy of DAC was 
significantly increased by co-treatment with the common analgesic, 
paracetamol, providing an appealing new therapeutic option.  
Genome-wide sequencing methods were used to compare the distribution of 
5mC and 5hmC between normal oral keratinocytes and an HNSCC cell line 
and investigate how this is altered by DAC. In addition to causing global 
DNA demethylation, DAC partially restores 5mC and 5hmC patterns to those 
of normal oral keratinocytes. In normal cells, 5mC and 5hmC mark clusters of 
Alu elements in gene rich regions; this is dramatically reduced in HNSCC.  
Treatment with DAC restores DNA modifications to Alu elements, leading to 
repression of Alu RNA. Furthermore, DAC caused demethylation and 
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Chapter 1. Introduction 
1.1. Head and neck squamous cell carcinoma (HNSCC) 
1.1.1. Occurrence and aetiology 
Head	and	neck	cancer	is	the	6th	most	common	cancer	worldwide	with	up	to	650,000	
new	 cases	 diagnosed	 each	 year	 [1,	 2].	Most	 cases	 are	 squamous	 cell	 carcinomas,	
referred	 to	as	head	and	neck	 squamous	 cell	 carcinoma	or	HNSCC	 [3,	 4].	 This	 term	
refers	 to	 tumours	 that	 develop	 from	more	 than	 15	 different	 anatomical	 subsites,	
however	 the	 majority	 of	 cases	 arise	 in	 the	 oral	 cavity	 or	 the	 oropharynx	 (oral	
squamous	cell	 carcinomas	 (OSCC))	or	 the	 larynx	 (Laryngeal	cancer)	 [4-6].	The	most	
important	 risk	 factors	 for	 HNSCC	 are	 tobacco	 and	 alcohol	 consumption,	 with	 a	
synergistic	 relationship	 described	 between	 the	 two	 [1,	 7].	More	 recently,	 cases	 of	
HNSCC	 have	 been	 attributed	 to	 infection	 with	 oncogenic	 forms	 of	 the	 human	
papilloma	virus	(HPV).	These	cancers	are	found	to	be	restricted	to	the	oral	pharynx	
and	could	be	responsible	for	more	than	60%	of	HNSCC	cases	in	Europe	[1].	
1.1.2. Genetic landscape of HNSCC 
Cancer	 is	 a	 complex	disease;	an	accumulation	of	genetic	mutations	and	epigenetic	
alterations	 lead	 to	 changes	 in	 gene	 expression	 that	 drive	 the	 progressive	
transformation	 of	 a	 healthy	 cell	 into	 a	 malignant	 one	 [8].	 The	 genetic	 and	
transcriptomic	 signatures	 differ	 greatly	 between	 different	 cancers.	 HNSCC,	 for	





and	progression	(Figure	1.1)	 [8,	9].	Mutations	 in	 the	tumour	suppressor	gene	TP53	
are	found	in	46-73%	of	HNSCC	cases	[12].	This	mutation	often	occurs	early	in	HNSCC	





(found	 in	 34-56%	 of	 HNSCC)	 can	 control	 the	 tumour	 suppressor	 protein	 RB	 and	
activate	 oncogenes	MYC	 and	NF-kB,	 leading	 to	 cell	 cycle	 progression	 and	 survival	
(Figure	 1.1)	 [8].	 Epidermal	 growth	 factor	 receptor	 (EGFR)	 is	 involved	 in	 various	
pathways	associated	with	growth	and	survival	and	 is	upregulated	 in	21%	of	HNSCC	
cases,	 leading	 to	 increased	 proliferation,	 metastasis,	 migration,	 angiogenesis	 and	
inhibition	of	apoptosis	(Figure	1.1)	[8,	11].	Numerous	other	pathways	contribute	to	
HNSCC	 development	 including	 promotion	 of	 angiogenesis	 through	 VEGF	
overexpression,	 mutations	 in	 the	 tumour	 suppressor	 gene	 CDKN2A	 and	
overexpression	of	immune-related	genes	such	as	cyclooxygenase-2	(COX-2	encoded	
for	 by	 PTGS2)	 (Figure	 1.1)	 [3,	 9,	 11,	 12].	 Furthermore,	 HNSCC	 tumours	 show	 an	
average	 of	 141	 copy	 number	 alterations	 per	 tumour,	 including	 losses	 of	
chromosomal	regions	3p,	8p,	9p	and	18q	(Figure	1.1)	[7,	8].		
While	 many	 pathways	 overlap,	 the	 genetic	 landscape	 of	 HNSCC	 differs	 between	
those	associated	with	HPV	infection,	and	those	attributed	to	smoking	or	alcohol	[8].	





E7	 [8,	 13].	 E7	 binds	 to	 and	 degrades	 RB	 causing	 increased	 proliferation,	 while	 E6	
causes	 the	 degradation	 of	 P53	 and	 activates	 telomerase	 activity	 allowing	 cells	 to	
evade	apoptosis	[13].	
	
Figure 1.1. Molecular alterations contributing to HNSCC development 
Mutations	 and	 epigenetic	 alterations	 contribute	 to	 the	 accumulation	 of	 transcriptional	
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1.1.3. Current therapies  
When	presented	at	an	early	stage	(stage	I-II)	HNSCC	treatment	usually	comprises	a	
single	 agent,	 either	 surgery	 or	 radiotherapy	 [14].	 	 However,	 approximately	 two-
thirds	 of	 HNSCC	 patients	 present	 with	 late	 stage	 disease	 and	 a	 more	 complex	
response	 is	 required,	 often	 involving	multiple	 different	 types	 of	 treatment	 [7,	 14].	
Traditionally	this	would	be	surgery	followed	by	radiotherapy,	however	 locoregional	
relapse	 and	 distant	metastasis	 are	 common	 [15].	 Furthermore	 the	 5-year	 survival	
rate	 is	 less	 than	 40%	 [15].	 In	 2004	 two	 clinical	 trials	 described	 the	 benefits	 of	
combining	 radiotherapy	with	 chemotherapy	 instead	of	 surgery:	One	examined	 the	
effects	 of	 radiotherapy	 followed	 by	 cisplatin,	 while	 the	 other	 examined	 the	
concurrent	 use	 of	 the	 two	 treatments;	 both	 found	 a	 significant	 increase	 in	
progression	 free	 survival	 [14,	 15].	 Treatment	 of	 HNSCC	 is	 not	 currently	 based	 on	
molecular	markers,	instead	the	decisions	are	primarily	based	on	the	stage	of	disease	
at	 presentation	 and	 the	 age	 and	 fitness	 of	 the	 individual	 [14].	 Due	 to	 the	
heterogeneity	of	HNSCC,	clinically	 identical	 tumours	can	 respond	differently	 to	 the	
same	treatment,	therefore	biological	markers	and	targeted	therapies	are	needed	to	
improve	the	clinical	outcomes	[14].		
Cetuximab	 is	a	monoclonal	antibody	 targeted	against	EGFR,	which,	as	described	 in	
section	1.1.2,	is	commonly	upregulated	in	HNSCC.	Its	approval	in	2006	was	the	first	
new	HNSCC	drug	on	the	market	for	50	years	[16].	While	cetuximab	proved	successful	
in	 preclinical	 models,	 it	 is	 only	 effective	 in	 a	 subset	 of	 HNSCC	 patients	 [16,	 17].		
Several	possibilities	have	been	proposed	to	explain	resistance	to	cetuximab	including	








Programmed	 cell	 death	 1	 (PD-1)	 and	 programmed	 cell	 death	 ligand	 1	 (PD-L1)	 are	
upregulated	 via	 various	 mechanisms	 in	 HNSCC,	 including	 activation	 by	 EGFR	 or	
PIK3CA	 [19].	 The	 results	 of	 two	 clinical	 trials	 in	 2016	 led	 to	 USA	 Food	 and	 drug	
agency	 (FDA)	 approval	 for	 the	 PD-1/PD-L1	 antagonists’	 pembrolizumab	 and	
nivolumab	and	the	 inclusion	of	these	drugs	 into	the	standard	therapeutic	response	
to	HNSCC	 [19].	 DNA	 and	 RNA	 sequencing	 of	 HNSCC	 patients	 has	 uncovered	 other	
potential	 targets	 for	 molecular	 targeted	 therapy,	 including	 inhibition	 of	 VEGF,	
PI3K/mTOR	and	COX-2	 [3,	8,	16].	Early	 results	suggest	 these	drugs	may	have	some	
promise	 either	 as	 single	 agents	 or	 combined	 with	 conventional	 HNSCC	 treatment	
regimens	[16].		
Despite	the	advances	in	traditional	therapies	and	the	discovery	of	molecular	targets,	
the	 survival	 rate	 for	 HNSCC	 has	 not	 significantly	 improved	 in	 recent	 decades	 [3].	









1.2. Epigenetics  
1.2.1.  Introduction to epigenetics 




can	 give	 rise	 to	 complex	 phenotypes	 during	 development	 [21-23].	 This	 can	 be	
summarised	by	his	now	famous	drawing	of	 the	 ‘epigenetic	 landscape’;	a	 single	cell	
faces	 several	 potential	 fates,	 the	 decision	 of	 which	 to	 go	 down	 is	 determined	 by	
epigenetics	 (Figure	 1.2)	 [22].	 The	 current	 definition	 of	 epigenetics	 is	 less	 well	
defined,	 and	 subject	 to	 some	 controversies	 [21].	 It	 is	 a	 broad	 term	 that	 covers	 a	
range	of	mechanisms	that	regulate	gene	expression	without	altering	the	sequence	of	
DNA	[21,	22,	24].		
Figure 1.2. Waddington’s 
Epigenetic landscape 
This	 image	 was	 proposed	 by	 Conrad	
Waddington	 to	 represent	 embryonic	
development.	 The	 ball	 at	 the	 top	
represents	 a	 pluripotent	 cell	 and	 the	
valleys	 show	 the	 different	 pathways	 a	
single	 cell	 can	 go	 down	 to	 reach	 a	







1.2.2.  Gene structure and chromatin 
The	 central	 dogma	 of	molecular	 biology	 states	 that	 genetic	 information	 stored	 as	
DNA	is	first	transcribed	into	RNA	and	then	translated	into	protein	[25].	However	only	
about	2%	of	the	human	genome	is	translated	into	proteins	[26].	Eukaryotic	genes	are	
composed	 of	 introns	 and	 exons,	 where	 exons	 encode	 proteins,	 and	 introns,	
containing	 transposable	elements	and	regulatory	sequences,	are	spliced	out	of	 the	
RNA	 prior	 to	 translation.	 Promoters	 mark	 the	 start	 of	 gene	 transcription,	 where	
transcription	 factors	 and	 RNA	 polymerase	 bind	 to	 the	 DNA	 and	 transcribe	 RNA.	
Therefore,	 one	 mechanism	 of	 epigenetic	 regulation	 involves	 modifying	 access	 of	
transcription	machinery	to	promoters.	An	additional	 level	of	complexity	is	added	in	
the	form	of	enhancers	and	insulators,	these	are	DNA	sequences	situated	at	variable	










Figure 1.3. The structure of a typical	human gene 














H2B,	 H3	 and	 H4)	 [31].	 Nucleosomes	 are	 separated	 by	 10-80bp	 of	 DNA	 and	 are	
further	 packaged	 into	 a	 30nm	 thick	 fibre	 with	 the	 help	 of	 the	 linker	 histone	 H1	
(Figure	1.4)	 [28].	 In	 its	most	compact	 form	 (termed	heterochromatin)	 chromatin	 is	
inaccessible;	 therefore	 the	 positioning	 of	 nucleosomes	 can	 determine	 gene	
expression	 by	 regulating	 the	 access	 of	 transcription	 machinery	 to	 promoters	 and	
regulatory	 elements	 [28,	 29].	 This	 can	 be	 altered	 in	 several	 ways:	 complexes	 can	
remodel	 the	 chromatin	 in	 an	 ATP-dependent	 process;	 the	 core	 histones	 can	 be	
replaced	with	more	permissive	 histone	 variants;	 and	 ‘tails’	which	 extend	 from	 the	
core	histones	can	be	modified	[28].	Histone	tails	are	subject	to	more	than	100	post-
translational	 modifications;	 some	 of	 these	 are	 associated	 with	 a	 permissive	
chromatin	state	(e.g.	acetylation	of	 lysine	residues	and	methylation	of	 lysine	4	(K4)	
of	 histone	H3);	 and	 some	are	 associated	with	heterochromatin	 and	 gene	 silencing	
(e.g.	methylation	of	lysine	9	(K9)	or	lysine	27	(K27)	of	H3)	[24,	30].		These	cooperate	








Figure 1.4: Packaging of DNA 
The	double	helix	of	DNA	is	packaged	into	nucleosomes,	which	are	then	packed	together	to	
form	a	30nm	 thick	 fibre.	 This	 fibre	 is	 condensed	 further	 to	 form	 the	 chromosomes.	 Some	
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methylation	would	be	 found	at	 symmetrical	 sites	and	 that	 the	enzyme	responsible	
for	 adding	 the	methyl	moiety	would	have	 a	 preference	 for	 hemi-methylated	DNA.	
Furthermore,	he	proposed	that	methylation	of	the	5’	position	of	the	pyrimidine	ring	
of	cytosine	 (5mC)	would	 interfere	with	protein-DNA	 interactions	 [20].	Holliday	and	





The	 methyl	 moiety	 of	 5mC	 sits	 in	 the	 major	 groove	 of	 DNA.	 This	 is	 where	
transcription	factors	usually	bind	and,	as	predicted	by	Riggs	in	1975,	several	proteins	
are	 unable	 to	 bind	 to	 the	 DNA	 in	 the	 presence	 of	 methylated	 CpGs	 [24,	 30].	 An	
example	of	this	is	at	the	imprint	control	region	of	H19/Igf2.	The	maternal	locus	is	not	
methylated,	allowing	the	transcriptional	repressor	CTCF	to	bind,	prevent	the	activity	






Figure 1.5. The structure of 5-methylcytosine	
Left	panel	shows	cytosine	(C)	and	the	right	panel	shows	5-methylcytosine	(5mC).		
	
1.3.1. CpG islands (CGIs) 
CpG	dinucleotides	are	underrepresented	in	the	human	genome,	perhaps	due	to	the	
spontaneous	 deamination	 of	 5mC	 to	 thymine	 [33-35].	 While	 mismatch	 repair	




the	 rest	 of	 the	 genome	 (1	 per	 10bp	 vs.	 1	 in	 100bp).	 CGIs	 are	 located	 around	 the	
promoters	of	human	genes	and	are	unmethylated;	perhaps	explaining	how	such	high	
densities	of	CpGs	persisted	throughout	evolution	[33,	34].	 
1.3.2. DNA methyltransferases (DNMTs) 











DNMT1,	 the	maintenance	methyltrasferase,	 has	 a	 preference	 for	 hemi-methylated	
DNA	 [20,	 31,	 36,	 37].	 After	 DNA	 replication	 the	 DNA	 is	 hemi-methylated,	 as	 the	
parental	 strand	 retains	 the	previous	pattern	of	5mC	but	 the	daughter	 strand	 lacks	
the	modification	[38].	At	the	replication	fork	the	UHRF1	protein	preferentially	binds	
to	hemi-methylated	DNA	and	recruits	DNMT1	to	copy	the	pattern	of	5mC	from	the	
original	 strand	 onto	 the	 daughter	 strand;	 so	 5mC	 is	 heritable	 across	 cellular	
generations	(Figure	1.6)[37,	38].		
DNMT3A	 and	 DNMT3B	 are	 de	 novo	 methyltransferases	 that	 do	 not	 differentiate	
between	 hemi-methylated	 or	 unmethylated	 DNA	 [39].	 The	 catalytically	 inactive	
homologue,	DNMT3L,	aids	de	novo	methylation	during	embryogenesis	by	increasing	
the	ability	of	DNMT-3A	and	-3B	to	bind	to	the	methyl	donor,	SAM	[39].	Both	DNMT3s	
are	 expressed	 highest	 in	 undifferentiated	 embryonic	 stem	 cells	 (ESCs),	
downregulated	after	differentiation	and	maintained	at	a	 low	 level	 in	adult	 somatic	
tissue	[40].	Therefore,	 it	 is	proposed	that	the	de	novo	methyltransferases	establish	
the	 pattern	 of	 5mC	 during	 development	 and	 this	 is	 then	 maintained	 by	 DNMT1	
throughout	adult	life	(Figure	1.6)	[40,	41].		













Figure 1.6. The role of DNA methyltransferases in the establishment and 









1.3.3. Transcriptional silencing by 5mC 
Two	 mechanisms	 contribute	 to	 transcriptional	 silencing	 by	 DNA	 methylation:	
preventing	 access	 of	 transcription	 factors	 to	 DNA,	 as	 is	 the	 case	 for	 the	 imprint	
control	region	of	Igf2	(1.3)	and	interaction	with	methyl-CpG	binding	domain	proteins	
(MBPs)	 (MeCP2,	MBD1,	MBD2,	MBD3,	and	MBD4)	 [30,	34,	44].	MBPs	bind	 to	5mC	
and	associate	with	 transcriptional	 repressors	 such	as	histone	deacetylases	 (HDACs)	
and	chromatin	remodelling	complexes	to	promote	transcriptional	silencing	[30,	44].		
DNMTs	 and	 histone	modifying	 enzymes	 cooperate	 to	maintain	 the	 distribution	 of	
heterochromatin	 and	 euchromatin	 during	DNA	 replication	 (Figure	 1.7)	 [43].	 Active	
and	 nucleosome-depleted	 regions	 (accessible	 chromatin)	 are	 characterised	 by	
unmethylated	CGIs	while	 inactive	 regions	 are	maintained	 stably	 repressed	by	5mC	
and	 H3K9me3	 [27].	 UHRF1	 is	 required	 for	 DNMT1	 localisation	 to	 replicating	
heterochromatic	regions	and	has	an	affinity	for	the	repressive	histone	modification,	
H3K9me	 [38].	 DNMT-3A,	 -3B	 and	 -3L	 were	 found	 to	 directly	 bind	 to	 all	 four	 core	
histones	[45].	DNMT3L	can	only	bind	to	H3	tails	that	are	not	methylated	at	lysine	4.	
There	 it	 can	 activate	 DNMT	 -3A	 and	 –3B	 to	 de	 novo	 methylate	 the	 DNA	 [45].	
Therefore,	 while	 UHRF1	 may	 regulate	 a	 feedback	 loop	 to	 maintain	 5mC	 and	
H3K9me3	 at	 transcriptionally	 silenced	 regions,	 methylation	 of	 H3K4	 prevents	 de	
novo	DNA	methylation	 at	 sites	 of	 permissive	 chromatin	 [38,	 45].	 Furthermore,	 in	
mESCs,	SETD2-mediated	tri-methylation	of	H3K36	has	been	shown	to	be	involved	in	
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1.3.4. Genome wide 5mC patterns 
Most	CGIs	are	unmethylated	and	this	is	understood	to	allow	for	transcription	factor	
binding	 and	 expression	 of	 the	 corresponding	 gene.	 Methylation	 of	 CGIs	 is	
uncommon	 and	 tends	 to	 be	 associated	 with	 long	 term,	 stable	 silencing	 of	 gene	
expression	 [27].	 A	 key	 example	 of	 this	 is	 X	 chromosome	 inactivation	 where	 DNA	
methylation	 interacts	 with	 other	 epigenetic	 mechanisms	 to	 stably	 silence	 one	 X	
chromosome	 in	 female	 cells	 and	 allow	 for	 dosage	 compensation	 [27].	 Other	
examples	 include	 imprinted	genes	and	gamete-specific	genes	that	are	not	required	
in	adult	somatic	cells	[27].	Outside	of	CGIs	the	majority	of	CpGs	in	the	genome	are	
methylated	 [47].	 50-70%	 of	 the	 human	 genome	 is	 composed	 of	 transposable	
elements	and	other	repetitive	DNA	[48,	49].	These	are	highly	methylated	to	maintain	
genome	 stability	 [27].	 Unlike	 promoters,	 gene	 bodies	 tend	 to	 be	 CpG	 poor	 and	





cell	 type-specific	 [50,	 51].	 	 Unlike	most	 genomic	 regions,	 some	 enhancers	 show	 a	
partially	methylated	phenotype	where	a	given	CpG	will	be	methylated	in	some	cells	









Figure 1.8: The DNA methylation landscape in mammalian cells 
DNA	 methylation	 is	 located	 in	 low	 density	 genome	 wide,	 and	 at	 repeat	 sequences.	 CpG	
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1.4. DNA hydroxymethylation 
For	many	years	5mC	was	understood	to	be	the	only	covalent	modification	to	DNA.	
However,	 in	 2009,	 an	 issue	 of	 Science	 was	 released	 in	 which	 two	 papers	
simultaneously	reported	the	rediscovery	of	a	modification	to	mammalian	DNA	called	
5-hydroxymethylcytosine	(5hmC)	[50,	51].	5hmC	is	the	oxidised	form	of	5mC	(Figure	
1.9)	 [52].	The	base	was	already	known	to	exist	 in	bacteriophages	and	 in	 the	1970s	
5hmC	was	 found	 in	 the	 DNA	 of	 frog	 and	 rodent	 brains	 [52].	 For	many	 years	 this	
result	could	not	be	reproduced	and	hence	 it	was	not	until	5hmC	was	rediscovered	
that	 its	 presence	 in	 mammalian	 DAC	 was	 accepted	 [52].	 Kriaucionis	 and	 Heintz	
revealed	5hmC	serendipitously	when	comparing	the	abundance	of	5mC	 in	Purkinje	
neurons	 and	 granule	 cells.	 Liquid	 chromatography	 mass	 spectrometry	 (LC-MS)	
determined	 the	 presence	 of	 an	 unexpected	modified	 form	 of	 cytosine	 which	 was	
determined	 to	 be	 5hmC	 [53].	 Simultaneously,	 in	 a	 search	 for	 mammalian	
homologues	 of	 trypanosome	 proteins,	 JBP1	 and	 JBP2,	 which	 are	 involved	 in	 the	




Since	 then,	 research	 into	 the	 potential	 function	 of	 5hmC	 has	 become	 a	 vastly	
expanding	 field	of	epigenetics	with	 the	abundance	of	 the	base	now	determined	 in	
the	majority	of	mouse	and	human	tissues	[52,	53,	55-61].	The	level	of	5hmC	varies	
greatly	 between	 tissues	 and	 stages	 of	 development	 and	 appears	 to	 be	 inversely	




proteins	can	 lead	to	 further	conversion	of	5hmC	 into	5-formlycytosine	 (5fC)	and	5-
carboxylcytosine	(5caC)	[63].	While	5hmC	is	found	in	relatively	high	abundance,	5fC	





Figure 1.9. The chemical structure of cytosine and cytosine modifications 
The	 addition	 of	 a	 methyl	 group	 to	 cytosine	 (C)	 (left)	 leads	 to	 5-methylcytosine	 (5mC)	
(middle).	This	can	then	be	oxidised	to	form	5-hydroxymethylcytosine	(5hmC)	(right).		
 
1.4.1.  TET enzymes 
A	 family	of	Fe	 (II)	and	α-ketoglutarate	 (α-KG)	 -dependent	dioxygenases	called	Ten-
Eleven	Translocation	(TETs)	catalyse	the	oxidation	of	5mC	into	5hmC	[81].	There	are	
three	TET	 genes	 (TET1,	 TET2	 and	TET3)	 in	mammalian	DNA	 [64].	 	 Structurally,	 the	
enzymes	 are	 composed	 of	 a	 double-stranded	 beta-helix	 fold	 that	 contain	 metal	
binding	residues	and	TET1	and	TET3	contain	a	CxxC	domain	the	recognises	CpG-rich	











and	 unmodified	 CpGs	 [68,	 69].	 	 Knockdown	 of	 each	 TET	 enzyme	 in	 an	 embryonic	
carcinoma	cell	 line	determined	differential	effects	of	the	three	proteins	[61].	While	
there	was	some	overlap	between	knockdowns,	TET1	depletion	led	to	a	60%	loss	of	




where	 it	 is	 thought	 to	 be	 responsible	 for	 epigenetic	 reprogramming	 during	
mammalian	development	 [61,	64].	TET1	associates	with	CGI	promoters,	potentially	
acting	as	a	control	mechanism	against	aberrant	de	novo	methylation	of	active	genes	
[27].	 In	 cultured	 cells,	TET1	 overexpression	 correlates	with	 a	decrease	 in	5mC	and	
only	 a	 small	 increase	 in	 unmodified	 C;	 perhaps	 indicating	 its	 primary	 role	 in	 the	
conversion	of	5mC	to	5hmC	while	TET2	and	TET3	further	convert	5hmC	into	5fC	and	
5caC	[61,	64].		
1.4.2.  5hmC function as opposed to 5mC 
The	 most	 widely	 accepted	 function	 of	 5hmC	 is	 as	 an	 intermediate	 in	 the	 DNA	
demethylation	pathway.	However,	the	 levels	of	5hmC	are	considerably	higher	than	
that	of	5fC	or	5caC	and	5hmC	has	a	distribution	distinct	 from	5mC,	 suggesting	 the	
base	may	additionally	function	as	an	epigenetic	modification	[63,	70].		As	discussed	
in	 section	 1.3,	 the	 majority	 of	 5mC	 is	 found	 outside	 of	 genes,	 associated	 with	
heterochromatin	marks	such	as	H3K9me3	[38,	47,	71].	However,	5hmC	tends	to	be	










CpG	within	 a	 cAMP	 response	 element	 (CRE)	was	 enough	 to	 reduce	 binding	 of	 the	
transcriptional	 activator,	 CRE	 binding	 protein	 (CREB),	 and	 cause	 a	 corresponding	
decrease	in	reporter	gene	expression.	Therefore,	a	single	5hmC	in	the	critical	CpG	is	




may	 prevent	 gene	 expression	 by	 inhibiting	 transcription	 factor	 binding;	 however,	
unlike	 5mC,	 5hmC	 does	 not	 colocalise	 with	 heterochromatin.	 Conversely,	 the	
presence	of	5hmC	 in	gene	bodies	and	enhancers	has	been	 found	to	correlate	with	
gene	expression	 [4,	9,	21,	22].	TET2	knockdown	correlates	with	 loss	of	5hmC	 from	










Figure 1.10. 5hmC genomic distribution	
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The	 results	 of	 TET1	 knockdown	 support	 this	 theory	 as	 while	 numerous	 genes	 are	
downregulated,	 a	 surprisingly	 large	 number	 are	 activated	 [64].	 In	 ESCs	 these	
derepressed	 genes	 frequently	 correspond	with	 sites	 of	 bivalent	 chromatin,	 where	
both	 activating	 (H3K4me3)	 and	 repressive	 (H3K27me3)	 marks	 are	 present	 [64].	
Bivalent	 chromatin	 has	 been	 associated	with	 a	 ‘poised’	 chromatin	 state,	 generally	
associated	with	developmental	genes	that	are	primed	to	be	activated	or	repressed	












Figure 1.11. 5hmC and gene expression 
Top:	H3K9me3	and	5mC	maintain	heterochromatin.	Middle:	H3K4me3,	H3	lysine	acetylation	
and	an	absence	of	5mC,	mark	active	CpG	 islands.	Bottom:	5hmC	 is	 found	at	poised	genes,	
associated	 with	 the	 active	 histone	 mark	 H3K4me3	 and	 the	 repressive	 histone	 mark	
H3K27me3.	5hmC	inhibits	the	binding	of	both	methyl-binding	proteins	(MBP)	that	associate	
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1.4.3.  DNA demethylation 
DNA	methylation	 can	 be	 lost	 from	DNA	 passively	 via	 replication	 if	 DNMT1	 fails	 to	
copy	 the	methyl	mark	 onto	 the	 daughter	 strand.	 This	 can	 happen	when	 levels	 of	
DNMT1	 are	 low	 and	 when	 5mC	 has	 been	 oxidised	 to	 5hmC,	 as	 DNMT1	 poorly	
recognises	 5hmC	 [54,	 75].	DNA	demethylation	 is	 also	 known	 to	occur	 as	 an	 active	




steps	 in	 this	 pathway	 (Figure	 1.12)	 [42].	 The	 DNA	 repair	 protein	 thymine	 DNA	
glycosylase	 (TDG)	excises	5fC	and	5caC	 from	the	DNA	and	 the	base	excision	 repair	













Figure 1.12. DNA demethylation 
DNMT	 enzymes	 catalyse	 the	 addition	 of	 a	 methyl	 group	 to	 DNA,	 generating	 5-
methylcytosine	 (5mC).	 This	 can	 be	 oxidised	 by	 the	 TET	 enzymes	 to	 form	 5-
hydroxymethylcytosine	 (5hmC).	 5hmC	 can	be	 further	 oxidised	by	 the	 TET	 enzymes	 into	 5-
formylcytosine	 (5fC)	 and	 5-carboxylcytosine	 (5caC).	 5mC,	 5hmC,	 5fC	 and	 5caC	 can	 be	 lost	
passively	via	dilution	during	DNA	replication.	5fC	and	5caC	are	also	subject	to	active	removal	
























1.5. Transposable elements  
Repetitive	DNA,	composed	of	tandem	repeats	and	transposable	elements,	accounts	
for	50-70%	of	the	human	genome	(Figure	1.13)	[48,	49].	Tandem	repeats	are	short	
non-coding	 sequences	 that	 are	 repeated	 head	 to	 tail	 [48].	 They	 help	 maintain	
genome	stability;	at	 telomeres	they	protect	chromosome	ends	and	at	centromeres	
they	facilitate	sister	chromatid	cohesion	[48].	Transposable	elements	 (transposons)	
are	mobile	DNA	 that	have	 replicated	and	 reinserted	 themselves	across	 the	human	
genome.	 Transposons	 have	 significantly	 contributed	 to	 human	 evolution,	 however	
the	 rate	of	 transposition	has	been	 in	 steady	decline	 in	hominids	 since	mammalian	
radiation	[78,	79].	 
1.5.1. Transposable element families 
Two	 classes	 of	 transposons	 exist:	 Class	 I,	 retrotransposons,	 that	 use	 an	 RNA	
intermediate	to	move	about	the	genome	and	class	II,	DNA	transposons,	that	excise	
and	reintegrate	themselves	from	one	position	to	another	[48].	
Figure 1.13. Repetitive DNA in the 
human genome sequence 
The	 proportion	 of	 the	 human	 genome	
occupied	by	repetitive	DNA	classes.	SINE=	
short	 interspersed	 repetitive	 element;	
LINE=	 long	 interspersed	 repetitive	





















Long interspersed nuclear elements (LINEs) 
LINEs	are	autonomous,	class	I	retrotransposons,	typically	around	6kb	long	[79].	LINEs	
have	 an	RNA	polymerase	 II	 promoter	 and	encode	proteins	ORF1	 and	ORF2,	which	
facilitate	 their	 retrotransposition	 (Figure	 1.14)	 [79,	 80].	 In	 humans	 the	 most	
prevalent	LINE	family	is	LINE-1,	which	accounts	for	~17%	of	the	human	genome,	only	
L1Hs	remains	active	(Figure	1.14)[79].	 
Short interspersed nuclear elements (SINEs) 
SINEs	are	non-autonomous	retrotransposons	of	100-400bp	in	length	[79].	SINEs	are	
transcribed	via	RNA	polymerase	III	and	rely	on	LINE	proteins	to	transpose	[80].	The	















Figure 1.14. Human retrotransposons	
The	 structure	 (left)	 and	 age	 (right)	 of	 human	 retrotransposons	 are	 represented	 as	 a	
schematic.	Top:	ERVs	are	LTR	transposons,	encoding	the	gag,	pol	and	env	genes	required	for	
their	 retrotransposition.	 The	 transposon	 is	 flanked	 by	 long	 terminal	 repeats	 (LTRs)	 [80].	
Middle:	LINE-1	 is	 the	most	common	LINE	element	 in	modern	humans.	ORF1	and	ORF2	are	
the	 proteins	 required	 to	 facilitate	 retrotransposition.	 Bottom:	 the	 primate-speficic	 Alu	
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that	 epigenetic	 silencing	 evolved	 as	 means	 of	 repressing	 the	 expression	 of	
transposons	 [82].	 Indeed,	 many	 transposons	 are	 enriched	 in	 5mC	 and	 repressive	
histone	modifications	[82].		
Alu	elements	contain	25%	of	all	CpG	dinucleotides	 in	 the	human	genome	 [81,	84].	
This	 is	 distinct	 from	other	 repeat	 sequences;	 LINEs	 are	 preferentially	 found	within	
AT-rich	regions	and	the	proportion	of	CpGs	found	within	LTRs	correlates	with	their	
genomic	 coverage	 [84].	 The	 CpGs	 within	 Alu	 elements	 are	 generally	 methylated.	
Primate-specific	 transposons	 show	 higher,	 more	 consistent	 levels	 of	 DNA	
methylation	across	tissues	and	between	individuals	[85,	86].	This	may	reflect	the	fact	
that	 these	 transposons	 are	 more	 likely	 to	 be	 active	 and	 therefore	 the	 need	 for	
silencing	 by	 repressive	 chromatin	 is	 greater	 [86].	 Accordingly,	 the	 most	 recently	















Figure 1.15. The mutagenic potential of retrotransposons 
The	 insertion	 of	 retrotransposons	 into	 non-coding	 DNA	 can	 disrupt	 regulatory	 sequences	
such	as	enhancers	or	 insulators,	or	can	form	new	enhancers/	promoters;	Alu	elements	can	
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1.6. Epigenetic alterations in cancer 
Epigenetic	mechanisms	tightly	control	gene	expression	to	maintain	differentiation	of	
somatic	cells.	Disruptions	to	this	control	are	a	major	contributor	to	cancer	initiation	
and	 progression	 [88,	 89].	 Alterations	 to	 the	 pattern	 of	 5mC	 are	 the	 most	 widely	
studied	 example	 of	 this	 [89].	 Cancer	 cells	 exhibit	 both	 genome	 wide	
hypomethylation	 leading	 to	 genomic	 instability	 and	hypermethylation	of	 promoter	
CGIs	leading	to	silencing	of	tumour	suppressor	genes	(Figure	1.16)	[34].	These	5mC	
changes	 are	 accompanied	 by	 changes	 in	 histone	 modifications	 and	 chromatin	
structure:	 global	 hypomethylation	 is	 accompanied	 by	 abnormal	 lysine	 acetylation	
and	an	open	chromatin	 structure;	while	hypermethylated	CGIs	are	associated	with	
repressive	 histone	 marks	 and	 stable	 nucleosome	 positioning	 [90].	 Furthermore,	
5hmC	is	consistently	reduced	in	many	forms	of	cancer	[91].	Epigenetic	changes,	such	
















Figure 1.16. Epigenetic alterations in cancer 
During	 cancer	 the	 pattern	 of	 5mC,	 5hmC	 and	 histone	 modifications	 are	 disrupted.	 Top	
panel:	 in	healthy	cells	5mC	is	found	genome	wide	and	across	repeat	sequences	where	it	 is	
associated	with	H3K9me3.	CGIs	 are	 free	of	 5mC	and	associated	with	 active	histone	marks	
such	as	acetylation	of	lysine	residues.	5hmC	is	found	at	gene	bodies	and	enhancers.	Bottom	







1.6.1. Genome wide hypomethylation  
Global	 loss	of	5mC	has	been	 linked	to	cancer	progression	and	metastasis	 [34].	This	
loss	primarily	occurs	at	CpG	poor	regions	such	as	repetitive	DNA,	 introns	and	gene	
deserts	 [2].	 It	 increases	genomic	 instability	by	 loosening	 the	chromatin	around	 the	
bulk	 of	 the	 genome	 and	 allowing	 transcription	 of	 transposable	 elements	 [2].	 In	 a	




a	 marker	 for	 malignant	 transformation	 [93].	 Hypomethylation	 of	 LINE1	 repetitive	
elements	 have	 been	 identified	 as	 a	 putative	 marker	 for	 OSCC	 [2].	 While	
hypomethylation	primarily	 targets	 intergenic	and	 intronic	DNA,	 loss	of	methylation	
at	genes	usually	silenced	in	the	given	tissue	have	also	been	described	in	HNSCC	cells,	
including	PI3,	AIM2,	SPP1	and	ADGRES	[2,	94].		






prostate,	 breast	 and	 liver	 suggesting	 a	 potential	 mechanism	 for	 the	
hypermethylation	observed	[39].	In	a	‘two	hit’	model	of	cancer	initiation,	silencing	by	







which	are	rarely	mutated	 [92].	 Interestingly,	CGI	methylation	changes	 in	cancer	do	
not	 always	 correspond	with	 gene	 expression	 changes.	 Instead,	many	 of	 the	 genes	
methylated	 in	 cancer	 were	 already	 silenced	 in	 the	 normal	 tissue	 [95].	 In	 these	
situations,	the	addition	of	the	methyl	group	may	act	by	stabilising	the	gene	silencing	
and	 therefore	 preventing	 differentiation	 or	 reactivation	 of	 the	 gene	 in	 the	 later	
stages	of	tumour	progression	[95].	
Epigenetic	 silencing	 of	 tumour	 suppressor	 genes	 can	 occur	 at	 any	 point	 during	
carcinogenesis,	however	 it	 commonly	occurs	during	 the	very	early	 stages	and	may	
predispose	cells	 to	genetic	abnormalities	 that	advance	 the	neoplastic	process	 [88].	
For	example	silencing	of	the	cell	cycle	regulator	CDKN2A	could	allow	cells	to	evade	
apoptosis	and	silencing	of	 the	DNA	repair	gene	MGMT	may	promote	DNA	damage	
[2,	 88,	 96].	 The	 chemical	 structure	 of	 5mC	 can	 also	 increase	mutation	 rates.	 The	
mark	is	more	sensitive	to	UV	radiation	and	as	described	in	section	1.3.1,	transition	of	
5mCà	 T	 often	eludes	DNA	 repair	machinery.	Nearly	 50%	of	 the	 inactivating	point	
mutations	 in	 the	 tumour	 suppressor	 gene	 TP53	 occur	 at	 5mC	 sites	 [90,	 92,	 96].	
Therefore,	 hypermethylation	 of	 CGIs	 in	 premalignant	 cells	 can	 promote	 cancer	







1.6.3. CpG island hypermethylation in HNSCC 
Hypermethylated	CGIs	have	been	proposed	as	potential	biomarkers	of	HNSCC	[97].		
Panels	 of	 several	 tumour	 suppressor	 genes	 were	 found	 to	 be	 more	 sensitive	 as	
diagnostic	 markers	 than	 single	 gene	 tests	 [97].	 For	 example,	 in	 an	 analysis	 of	 95	
HNSCC	patients	55%	showed	CGI	hypermethylation	in	the	promoter	of	at	 least	one	
of	CDKN2A,	MGMT,	GSTP1	and	 DAPK1	 [98].	 Another	 panel,	 consisting	 of	CDKN2A,	
DAP-Kinase,	CDH1	and	RASSF1,	was	able	to	identify	60%	of	HNSCC	cases,	with	5mC	
at	 CGIs	 increasing	 with	 tumour	 size	 [99].	 The	 use	 of	 a	 larger	 panel	 of	 16	 tumour	
suppressor	genes	found	that	5mC	of	CGIs	was	high	in	poorly	differentiated	tumours	
and	 increased	 in	 advanced	 tumours	 [100].	 These	 results,	 and	 others,	 suggest	 that	
hypermethylation	of	CGIs	may	provide	some	diagnostic	power	for	HNSCC,	but	that	a	
well-defined	panel	of	tumour	suppressor	genes	must	first	be	decided	upon	[97-102].		




of	 the	MLL	protein	 in	 rare	 cases	of	AML,	 and	 is	 frequently	downregulated	 in	 solid	
tumours	 [54,	 104,	 105].	 TET2	 is	 inactive	 in	 about	 15%	 of	 all	 myeloid	 cancers;	
including	 22%	 of	 AML	 [91].	 In	 pre-leukemic	 haematopoietic	 cells	 TET2	 loss	
contributes	 to	 leukemic	 transformation	 by	 deregulating	 a	 large	 number	 of	 genes	
involved	in	tumourigenesis	[106].	Furthermore,	overexpression	of	TET2	in	melanoma	









cancers,	 this	produces	α-hydroxyglutarate	 (α-HG)	 in	place	of	α-KG	 [91].	α-HG	 is	an	
oncometabolite	that	 is	structurally	similar	 to	α-KG	and	can	bind	and	 inactivate	TET	
proteins	 in	place	of	α-KG	 (Figure	1.17)	 [62,	 108,	 109].	 IDH	mutations	 are	mutually	
exclusive	with	those	of	TET2	loss	[109]. 	
1.6.5. 5hmC depletion and diagnostic potential 
In	 a	meta-analysis	 of	 published	 papers	 examining	 the	 relationship	 between	 5hmC	
and	cancer,	Chen	and	colleagues	determined	a	significant	association	between	5hmC	
loss	 and	 cancer	 progression	 [55].	 The	 study	 included	 1736	 patients	 with	 different	
cancer	 types	 and	 determined	 that	 low	 to	 non-existent	 5hmC	 levels	 significantly	
correlated	with	lymph	node	metastasis,	advanced	TNM	stage	and	a	poor	prognosis,	
suggesting	 that	 5hmC	 levels	 may	 function	 as	 a	 diagnostic	 and	 prognostic	 marker	
[55].	Of	particular	 interest	 to	 this	project	 is	 the	 inverse	correlation	between	5hmC	
and	oral	 squamous	 cell	 carcinoma	 (OSCC)	 [57,	 110].	 Contrary	 to	 the	metaanalysis,	
high	 5hmC	 levels	 in	 OSCC	 are	 associated	with	 aggressive	 tumour	 features	 and	 an	
unfavourable	 prognosis	 [55,	 110].	 This	 could	 be	 accounted	 for	 by	 differences	 in	












Figure 1.17. 5hmC and cancer 
Top:	In	healthy	cells	IDH	produces	α-KG	from	isocitrate.	TET	proteins	use	α-KG	and	Fe(II)	as	
cofactors	 to	 convert	 5mC	 into	 5hmC.	 Bottom	 two	 panels:	 5hmC	 is	 reduced	 in	 cancer.	



































[113].	 Similar	 correlations	 have	 been	 found	 in	 other	 cancers	 including	
mucoepidermoid	carcinoma,	colorectal	and	prostate	cancers	[87,	111,	114,	115].	 In	
HNSCC,	 primate	 specific	 repeats	 that	 are	 highly	 methylated	 in	 normal	 tissues	 are	
subject	to	a	more	substantial	reduction	in	methylation	than	older	families	[86].	This	
may	be	selected	for	during	cancer	progression	due	to	the	higher	mutagenic	potential	
of	 these	 active	 elements	 [86].	 Furthermore,	 overexpression	 of	 the	 LINE-1	 protein,	


















Figure 1.18. Mechanisms of epigenetic gene silencing and the potential for 
intervention 
In	 normal	 and	 cancer	 cells	 the	 relationship	 between	 5mC,	 histone	 modifications	 and	






















5-Aza-2’-deoxycytidine	 (Decitabine	 or	 DAC)	 and	 5-azacytidine	 (AZA)	 are	 cytosine	
analogues	that	act	as	DNMTis	and	DNA	demethylating	agents	by	incorporating	into	
DNA	in	place	of	cytosine	[117].	In	preclinical	models	DAC	is	estimated	to	be	10	times	
more	 potent	 than	 AZA	 [118].	 This	 is	 because	 DAC	 has	 a	 deoxyribonucleoside	
structure,	 while	 AZA	 has	 a	 ribonucleoside	 structure	 and	 80-90%	 of	 AZA	 is	
incorporated	 into	 RNA	 instead	 of	 DNA	 [75,	 118].	 Elevated	 levels	 of	 the	 DNMT	
enzymes	have	been	found	in	many	cancers,	therefore	inhibition	of	DNMTs	by	DAC	or	









1.7.2 Current usage and limitations of 5-aza-2’-deoxycytidine (DAC) 
As	a	single	agent	the	response	rate	to	DAC	 in	the	treatment	of	AML	 is	reported	as	
being	 between	 33-89%,	 with	 hypomethylation	 correlating	 with	 patient	 response	
[124,	 125].	 Myelosuppression	 is	 the	 most	 widely	 recognised	 side	 effect	 to	 DAC	




patients	 [118,	 122,	 126].	 High	 doses	 of	 DAC	 induce	 DNA	 damage	 and	 cytotoxicity	
[71].	However,	 it	has	been	observed	that	 low	dose	treatments	are	 just	as	effective	
[90,	 122,	 127].	 In	 vitro	 work	 by	 Tsai	 et	 al.,	 demonstrated	 that	 low	 dose	 DAC	
treatment	 resulted	 in	 decreased	 promoter	 methylation,	 subsequent	 gene	 re-
expression	 and	 the	 inhibition	 of	 subpopulations	 of	 both	 primary	 leukaemia	 and	
cultured	breast	cancer	cells	[117].	
1.7.3 Potential efficacy of DAC in solid tumours 
Epigenetic	 therapies	 only	 have	 FDA	 and	 EMA	 approval	 for	 the	 treatment	 of	
haematological	 malignancies	 [120].	 However,	 preclinical	 studies	 suggest	 that	 DAC	
and	AZA	treatment	may	be	transferable	to	solid	 tumours	 [117,	120,	121].	Cultured	
and	 primary	 breast	 tumour	 epithelial	 cells	 were	 subject	 to	 transient,	 clinically	
relevant,	nanomolar	doses	of	DAC	and	AZA	and	an	anti-tumour	‘memory’	response	
was	 observed.	 This	 included	 widespread	 gene	 expression	 changes,	 inhibition	 of	
subpopulations	 of	 cancer	 stem-like	 cells	 and	 significantly	 reduced	 xenograft	
formation	when	injected	into	NOD/SCID	mice	[117].		
In	 a	 review	of	published	 records	of	 clinical	 activity,	DAC	was	 found	 to	exhibit	 35%	
response	rate	in	breast	cancer,	34%	in	colorectal,	36%	in	pancreatic	and	only	9%	in	
HNSCC	 [125].	However,	HNSCC	patients	make	up	 a	 very	 small	 proportion	 (only	 29	
cases)	of	all	patients	treated	with	DAC	[125].	Indeed,	the	only	clinical	trial	involving	
DAC	treatment	in	HNSCC	was	a	phase	II	study	in	1987	for	a	variety	of	solid	tumours	









more	 promise	 [120,	 121].	 In	 HNSCC	 cell	 lines	 treatment	with	 DAC	 plus	 the	HDACi	










or	 other	 epigenetic	 agents,	 patient	 outcomes	 may	 improve	 [120,	 121].	 A	 huge	
variation	 exists	 in	 the	 dosing	 regime	 employed	 by	 different	 studies;	 this	 must	 be	






Table 1.1. DAC therapeutic application in solid tumours  
Clinical	trials	investigating	the	use	of	DAC	in	the	treatment	of	cancer:	either	as	a	single	agent	
(top),	or	combined	with	epigenetic	(middle)	or	chemotherapeutic	(bottom)	drugs	[120,	121].	





















DAC: 75 mg/m2 1h IV infusion 
on day 1 with intervals of 7h 







lung cancer II 15 
DAC: single 8h IV infusion of 












DAC:10 mg/m2/day on days 1 
to 5 and Vorinostat: 200 mg 
twice a day on days 6 to 12  
Anti-tumour activity 







DAC: 5–15 mg/m2/day for 10 
days. 
VPA: 10–20 mg/kg/day for 
days 5–21 q 28 days  
Neurological toxicity 
Increase in foetal Hb 









DAC: 45- 120 mg/m2 
Cisplatin: 33 mg/m2 for 3 
consecutive days every 21 days  
Insignificant anti-








DAC: 50 mg/m2 Cisplatin: 40 
mg/m2 for 3 consecutive days 








Cancer  17 
DAC: 10 mg/m2/day for 5 days  
Carboplatin: 5 day   







Melanoma I-II 35 
DAC: 0.15 mg/kg IV daily × 5 
days/wk for 2wks  
Temozolomide 
orally 75 mg/m2 daily for wks 






[140] Ovarian 1 10 
DAC: 10–20 mg/m2/day days 









Ovarian  15 
DAC: IV 45 mg/m2  
day 1 
Carboplatin 6 day  
DAC appears to 
reduce the efficacy 





1.8. Drug Repurposing  
The	costs	and	 time	demands	of	drug	discovery	are	considerable,	with	only	a	 small	
percentage	 of	 discovered	 drugs	 ever	 making	 it	 to	 the	 market	 [142,	 143].	
Furthermore,	 the	 costs	 are	 increasing;	 a	 study	 in	2003	estimated	 that	 the	average	
research	and	development	cost	per	drug	was	$802	million;	$484	million	higher	than	
a	similar	study	in	1999	[144].	Concurrently,	the	number	of	newly	approved	drugs	is	
in	 decline,	 both	 in	 Europe	 and	 America	 [145-147].	 	 Therefore,	 a	 novel	 strategy	 of	
drug	development	is	required.		
Drug	 repurposing	 (repositioning,	 reprofiling,	 redeployment)	 is	 the	 use	 of	 drugs	
(licensed	 or	 not)	 for	 indications	 that	 are	 different	 to	 their	 original	 indication	 or	
therapeutic	purpose	[147].	The	risks	associated	with	drug	development	are	reduced	
as	repurposed	drugs	have	often	been	through	several	stages	of	clinical	and	technical	
development,	 providing	 information	on	 the	 safety	 and	pharmacokinetic	 profiles	 of	
the	drug,	as	well	as	on	issues	such	as	bulk	manufacturing	and	environmental	toxicity	
[147].	While	this	does	not	always	result	 in	avoiding	Phase	I	trials,	 it	 informs	on	the	
dosing	structure	and	schedule	and	tends	to	result	in	a	shorter	development	time	for	
repurposed	 drugs	 (3-12	 years)	 compared	 with	 de	 novo	 drugs	 (10-17	 years)	 [148,	
149].	 Furthermore,	 repurposed	 drugs	 have	 a	 higher	 success	 rate	 in	 clinical	 trials	
[142].	 Many	 repurposed	 drugs	 were	 found	 serendipitously	 [145,	 146].	 Examples	
include	viagra,	 initially	developed	to	treat	hypertension	and	angina,	but	discovered	
to	 be	 effective	 against	 erectile	 dysfunction;	 buproprion,	 designed	 to	 treat	
depression,	 but	 found	 to	 aid	 in	 the	 cessation	of	 smoking;	 and	 the	 type	2	diabetes	




majority	 of	 available	 drugs	 are	 thought	 to	 possess	 secondary	 indications,	 either	
through	off-target	effects	of	the	drug,	or	due	distinct	diseases	originating	from	the	
same	 disrupted	 pathways	 [142,	 150].	 Nowadays	 the	 wealth	 of	 knowledge	 on	 the	
structure	of	drugs	and	drug	 targets	allows	 for	potential	 repurposing	projects	 to	be	
determined	 in	silico,	 further	reducing	the	failure	rate	of	the	repurposed	compound	
[145].		
A	key	 issue	with	drug	repurposing	 is	 the	difference	 in	patient	compliance	between	
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1.9. Aims and Objectives 
The	 primary	 aim	 of	 this	 thesis	 was	 to	 investigate	 the	 relationship	 between	 DNA	
modifications	 and	 HNSCC	 and	 to	 examine	 the	 efficacy	 of	 the	 DNA	 demethylating	
agent,	DAC,	in	HNSCC	treatment.	This	can	be	split	into	five	objectives:	
• Examine	the	potential	efficacy	of	DAC	treatment	on	HNSCC	cell	lines	











Chapter 2. Methods 
2.1. Cell lines and culture 
2.1.1. Cell lines 
Three	 human	 HPV	 negative	 HNSCC	 cell	 lines	 (VU40T,	 SCC040,	 HN12);	 one	 human	
HPV	positive	HNSCC	 cell	 line	 (UDSCC2);	 and	primary	human	oral	 keratinocyte	 cells	
(HOK)	were	used	in	this	work.	Details	are	provided	in	Table	2.1.	SCC040	and	VU40T	
cell	lines	were	a	gift	from	our	collaborator	Dr	S.	Roberts	(School	of	Cancer	Sciences;	
University	 of	 Birmingham):	 who	 obtained	 SCC040	 cells	 from	 the	 German	 Culture	
Collection,	DSMZ	(#ACC660)	and	VU40T	from	Prof	H.	Joenje	(VU	University	Medical	
Centre,	Amsterdam).	HN12	 and	UDSCC2	 cells	were	obtained	 from	Dr	 J.	 S.	Gutkind	
(NIDCR,	NIH,	Bethesda).	Primary	human	oral	keratinocyte	(HOK)	cells,	isolated	from	
fetal	oral	mucosa	were	purchased	from	Caltag	Medsystems.	
Table 2.1. Details of the cell types used in the studies 
Cell Line Site of Origin Gender Age Stage Smoking /Alcohol 
HPV 
Status Reference 
VU40T Tongue Female 65 T3N0 -/ - - [151] 
SCC040 Tongue Male 50 T2N2 -/+ - [152] 
UDSCC2 Hypopharynx Male 58 T1N2 N/A + [153] 
HN12 
Metastasized 
from base of 
tongue to lymph 
node 
Female N/A T4N1 N/A - [154] 







2.1.2. Cell maintenance 
HNSCC	 cultures	 were	 maintained	 in	 Dulbecco’s	 Modified	 Eagles	 Medium	 (Sigma-	
Aldrich)	supplemented	with	10%	fetal	bovine	serum	(FBS)	(Sigma-Aldrich),	100U/ml	
penicillin-streptomycin	 (Life	 Technologies),	 4mM	 L-glutamine,	 1X	 non-essential	
amino	acids	(Life	Technologies)	and	1mM	sodium	pyruvate	(Life	Technologies).		
HOKs	 were	 cultured	 in complete	 oral	 keratinocyte	 medium	 (SC-2611),	 containing	
amino	 acids,	 vitamins,	 hormones	 and	 growth	 factors,	 optimised	 for	 the	 growth	 of	
normal	 human	 keratinocytes	 and	 supplemented	 with	 1%	 penicillin-streptomycin	
solution	 and	 1%	 oral	 keratinocyte	 growth	 supplement	 (all	 purchased	 from	
ScienceCell).		 
All	 cell	 lines	 and	 treatments	 were	 maintained	 at	 37°C	 in	 a	 humidified	 5%	 CO2	
incubator	(Sanyo).	
To	split	HNSCC	cell	lines	for	maintenance	or	subculture	the	media	were	removed	and	
cells	 washed	 once	 in	 phosphate	 buffered	 saline	 solution	 (PBS)	 (Sigma-Aldrich).	
Following	this,	cells	were	 incubated	with	0.25%	Trypsin	(Sigma-Aldrich)	for	5min	or	
until	 the	 cells	 begin	 to	 round	 up	 and	 detach	 as	 determined	 by	 inverted	 light	
microscope.	The	trypsin	was	inactivated	with	an	equal	volume	of	complete	media.		
2.2. Drug Treatments 
2.2.1. 5-Aza-2’-deoxycytidine treatments 
5-Aza-2’-deoxycytidine	 (DAC)	 was	 purchased	 from	 Sigma-Aldrich	 and	 dissolved	 in	




treated	 with	 a	 range	 of	 concentrations	 of	 DAC	 or	 an	 equivalent	 volume	 of	 the	
vehicle,	 50%	 acetic	 acid.	 Unless	 otherwise	 stated,	 treatments	 were	 96h	 with	 a	
change	of	treatments	and	media	after	48h.		
2.2.2. CellTiter Blue Cell Viability assay 
Cell	viability	experiments	were	performed	 in	a	96-well	 format.	Cells	were	grown	 in	
200μl	media	 and	 viability	was	determined	by	 incubation	with	20μl	 of	 the	CellTiter	







signal	 from	 the	 media.	 Triplicate	 wells	 were	 used	 and	 all	 treated	 wells	 were	
normalised	to	the	vehicle	only	control.				
2.2.3. Dose response curves 
Sigma	 plot	 software	 (Systat	 Software	 Inc.)	 was	 used	 to	 generate	 sigmoidal,	 4-
parameter	dose	response	curves	after	drug	titrations.		
2.2.4. DAC sensitising assay 
A	 panel	 of	 100	 drugs	 (FMC1),	 dissolved	 in	 100%	 DMSO,	 ethanol	 or	 water	






blind	 with	 controls	 hidden	 within	 the	 panel.	 HNSCC	 cells	 were	 subject	 to	 96h	
treatment	with	 each	 drug	 either	 in	 the	 presence	 of	 500nM	DAC	 or	 an	 equivalent	




The	 assay	 was	 performed	 in	 triplicate	 and	 SPSS	 software	 (IBM	 Analytics)	 used	 to	
perform	a	paired	t-test	analysis	with	Bonferroni	correction	for	each	of	the	‘DAC	plus	
drug’	samples	relative	to	the	‘drug	only’	and	the	‘DAC	only’	samples.		
2.2.5. Drug treatments 
Paracetamol,	 zinc	 acetate,	 valdecoxib	 and	 disulfiram	were	 purchased	 from	 Sigma-
Aldrich.		These	were	dissolved	in	100%	DMSO	at	5000X	the	working	concentrations,	
aliquoted	and	stored	at	-20°C.		




4μM);	 one	 with	 titrations	 of	 132.3µM	 paracetamol	 (16.5μM,	 33.1μM,	 66.15μM,	
132.3μM,	264.6μM,	529.2μM,	1058.4μM)	 and	one	with	matched	 titrations	of	DAC	





Inc.)	was	 used	 to	 calculate	 combination	 index	 (CI)	 and	 dose	 reduction	 index	 (DRI)	
values	from	this	data	[156].		
2.3. DNA extraction and dot blotting of DNA 
2.3.1. DNA extraction 
DNA	 was	 extracted	 using	 the	 DNeasy	 blood	 and	 tissue	 kit	 (Qiagen)	 as	 per	 the	




column	 and	 centrifuged	 at	 14,000xg	 for	 1min	 to	 bind	 the	DNA	 to	 the	 silica-based	
membrane.	This	was	washed	with	buffers	AW1	and	AW2	and	the	DNA	eluted	with	
50-200µl	 of	 AE	 buffer.	 DNA	 concentration	 was	 determined	 using	 a	 Nanodrop	
spectrophotometer	(Thermo	Fisher	Scientific).		
2.3.2. Dot blotting 
Dot	 blotting	 of	 DNA	 was	 performed	 as	 described	 in	 the	 Current	 Protocols	 in	
Molecular	 Biology	 using	 the	 buffers	 outlined	 below	 (Table	 2.2)	 [157].	 DNA	 (1μg,	
0.5μg,	0.25μg	or	0.125μg)	was	combined	with	0.4M	NaOH	and	10mM	EDTA	in	a	total	
volume	of	50μl.	This	mixture	was	heated	at	100°C	 for	10min	 to	denature	 the	DNA	
then	 quenched	 on	 ice	 for	 5min.	 Nytran	 Supercharge	 Positively	 Charged	 Nylon	
membrane	(Fisher	Scientific)	and	Whatman	filter	paper	were	soaked	in	dH2O	prior	to	
use.	The	96-well	dot	blotting	apparatus	(BioRad)	was	assembled	with	the	membrane	





vacuum-drain,	 followed	 by	 a	 wash	 with	 100μl	 0.4M	 NaOH.	 The	 membrane	 was	
briefly	soaked	in	2X	SSC	buffer	and	allowed	to	dry,	suspended,	at	room	temperature	
(RT)	for	2h.		
2.3.3. Antibody incubation 
Dried	membranes	were	blocked	in	5%	low-fat	milk	(Marvel)	in	PBS	at	RT	for	1h	and	
incubated	 with	 primary	 antibodies	 (5mC:	 Cell	 Signalling	 (28692S),	 1:750;	 5hmC:	
Active	Motif	1:5000)	in	1%	bovine	serum	albumin	(BSA)	at	4°C	overnight.		
The	 following	 day	 membranes	 were	 washed	 in	 low	 fat	 milk	 and	 incubated	 with	
secondary	antibodies	(anti-rabbit-IgG-HRP	(Santa	Cruz	sc-2004),	1:5000	dilution)	for	
2h	 at	 4°C.	 Membranes	 were	 then	 washed	 in	 PBS	 and	 treated	 with	 a	 1:1	 ratio	 of	
Amersham	 ECL	 Western	 Blotting	 Reagent	 (GE	 Healthcare)	 and	 Supersignal	 West	
Femto	 reagent	 (Thermo	 Scientific)	 for	 2min	 and	 placed	 in	 an	 autoradiography	
cassette.	 In	 a	 dark	 room	 the	 membrane	 was	 exposed	 to	 Amersham	 ECL	
chemiluminescence	 film	 (GE	 Healthcare)	 and	 the	 film	 developed	 on	 a	 photon	
imaging	system	(PROTEC).	To	stain	for	total	DNA,	the	blots	were	incubated	in	0.04%	




the	 dot	 blots.	 Lanes	 were	 selected	 using	 the	 ‘gels’	 sections	 within	 the	 ‘analyse’	







Table 2.2: Buffers used for dot blotting of DNA 
Buffer Component Company 
20X SCC Buffer 
0.3M trisodium citrate Sigma-Aldrich 
3M sodium chloride Sigma-Aldrich 
dH2O  
1% BSA 
1% Bovine serum albumin Sigma-Aldrich 
PBS Sigma-Aldrich 
0.04% Methylene Blue 
0.04% Methylene blue Sigma-Aldrich 
0.05M Sodium acetate Sigma-Aldrich 
	
2.4. Protein extraction and Western blotting 
The	buffers	used	for	this	protocol	are	outlined	in	Table	2.3.	
2.4.1. Protein extraction 
HNSCC	 cells	 were	 washed	 twice	 in	 cold	 PBS	 and	 incubated	 with	 RIPA	 buffer	
containing	1X	 cOmplete	EDTA-free	protease	 inhibitors	 (Roche)	 for	45min	at	4°C	 to	






2.4.2. SDS-PAGE  
Prior	 to	 gel	 electrophoresis,	 20μl	 of	 protein	was	 combined	with	 4X	 loading	 buffer	
and	denatured	by	incubation	at	95°C	for	5min.	






20µl	 of	 sample	 or	 5µl	 of	 PageRuler	 Prestained	 Protein	 ladder	 (Thermo	 Fisher	
Scientific)	were	 loaded	to	each	well	and	the	gel	electrophoresed	 for	1h	at	200V	at	
RT.	
2.4.3. Transfer of proteins from gel to membrane 
Filter	 paper	 and	 sponges	were	 soaked	 in	 transfer	 buffer	 for	 10min.	 Nitrocellulose	
membrane	was	 soaked	 briefly	 in	 100%	methanol	 (Sigma-Aldrich),	washed	 in	 dH2O	
and	soaked	in	transfer	buffer	for	10min.		
When	electrophoresis	was	complete	the	gel	was	removed	from	the	glass	casing	and	
the	 transfer	 apparatus	 assembled	 (BioRad).	 The	 gel	 and	 membrane	 were	 placed	
side-by-side	 encased	 in	 soaked	 filter	 paper	 and	 sponge	 and	 held	 together	 in	 the	
transfer	cassette.	This	assembly	was	transferred	to	a	transfer	tank	filled	with	transfer	





Once	 the	 transfer	was	complete	 the	gel	was	washed	briefly	 in	1X	PBST	 (Table	2.3)	











Following	 primary	 antibody	 incubation	membranes	were	washed	 3X	 5min	 in	 PBST	
and	 incubated	 with	 the	 secondary	 antibody	 (anti-rabbit-IgG-HRP	 (Santa	 Cruz	 sc-
2004),	 1:5000	 dilution)	 for	 2h	 at	 RT.	 The	 membranes	 were	 washed	 3X	 15min	 in	
PBST.	 The	 EZ-ECL	 Chemiluminescence	 Detection	 Kit	 for	 HRP	 (Biological	 Industries)	
was	prepared	as	described	by	the	manufacturer	and	incubated	with	the	membrane	
for	1min	prior	to	placing	the	membrane	into	an	autoradiography	cassette.	In	a	dark	






Each	 membrane	 was	 subject	 to	 three	 antibodies:	 CYP2E1,	 COX-2	 and	 the	 control	
Lamin	A/C.	After	one	antibody	was	developed	the	membranes	were	washed	briefly	
in	1X	PBST,	then	washed	with	stripping	buffer	(Table	2.3)	for	2	x	7.5min.	Membranes	
were	 washed	 briefly	 in	 1X	 PBST	 and	 the	 antibody	 incubation	 step	 repeated	 as	
described	above.		
2.4.5. ImageJ Analysis 







Table 2.3: Buffers used for Western blotting 
Buffer Components Supplier 
RIPA Buffer 
150mM sodium chloride Sigma-Aldrich 
0.5% Sodium deoxycholate Sigma-Aldrich 
0.1% Sodium dodecyl sulfate Sigma-Aldrich 
50mM Tris Sigma-Aldrich 
4X Loading Buffer 
4% SDS,  









10% resolving gel 
37.5:1 acylamide:bisacrylamide Protogel 
375mM Tris-HCl pH 8.8 Sigma-Aldrich 
0.1% w/v SDS Sigma-Aldrich 
0.1% w/v N,N,N’,N’- 
tetramethylethylenediamine (TEMED) 
Sigma-Aldrich 
0.1% w/v ammonium persulphate (APS) Sigma-Aldrich 
Stacking gel 
37.5:1 acylamide:bisacrylamide Protogel 
375 mM Tris-HCl pH 6.8 Sigma-Aldrich 
0.1% w/v SDS Sigma-Aldrich 
0.1% w/v TEMED Sigma-Aldrich 
0.1% w/v APS Sigma-Aldrich 
Running Buffer 
25 mM Tris-HCl pH 7.5 Sigma-Aldrich 
2 mM glycine Thermo Fisher Scientific 
10% SDS Sigma-Aldrich 
1X PBST 
1X Phosphate Buffered Saline Sigma-Aldrich 
0.1% Tween-20 Sigma-Aldrich 
Transfer Buffer 
 
100 mM Tris-HCl pH 7.2 Sigma-Aldrich 
200 mM glycine Sigma-Aldrich 
0.05% SDS Sigma-Aldrich 
20% methanol Sigma-Aldrich 
Stripping Buffer 
1.5% w/v glycine Sigma-Aldrich 
0.1% SDS Sigma-Aldrich 
1% Tween20 Sigma-Aldrich 
Adjust to pH2.2 with HCL  
  
Coomassie Destain 
30% Methanol VWR 





2.5. Giemsa and Jenner Staining 
2.5.1. Cell plating and fixation 
Glass	 coverslips	 were	 incubated	 in	 methanol	 (Sigma-Aldrich)	 for	 at	 least	 24h;	





2.5.2. Giemsa-Jenner staining 
The	 protocol	 was	 performed	 as	 described	 previously	 [155].	 Fixed	 cells	 were	
incubated	 with	 Jenner	 stain	 (VWR)	 diluted	 1:3	 in	 1mM	 sodium	 phosphate	 buffer	
pH5.6	 for	5min	at	RT	 followed	by	 repeated	washing	 in	dH2O	 to	 remove	stain	 from	
the	wells.	 The	 cells	were	 then	 incubated	with	Giemsa	 stain	 (VWR),	 diluted	1:20	 in	




2.6.1. Cell fixation 
Immunofluorescence	was	performed	as	described	in	Roulois	et	al.,	2015	[158].	Cells	
were	grown	on	methanol-sterilised	coverslips,	washed	twice	in	cold	PBS,	blotted	on	




20°C.	 The	 methanol	 was	 removed	 by	 aspiration	 and	 replaced	 with	 excess	 100%	
acetate	for	1min	at	-20°C	to	permeabilise	the	nuclei.	The	acetate	was	removed	and	
the	coverslips	allowed	to	dry	briefly	at	-20°C.		
2.6.2. Antibody incubation 
Coverslips	were	washed	three	times	in	cold	PBS	and	blocked	with	saturation	buffer	
(1%	 BSA	 in	 PBS)	 for	 1h	 at	 4°C.	 Coverslips	 were	 incubated	 overnight	 at	 4°C	 with	
primary	 antibodies	 (dsRNA	 (Scicons:	 J2)	 diluted	 1:1000;	 Ki67	 (Abcam:	 ab15580)	
1:1000;	 γH2AX	 (Abcam)	 1:1000)	 diluted	 in	 1%	 BSA	 in	 PBS.	Wells	 were	washed	 3X	
5min	 in	 PBS	 and	 incubated	with	 the	 corresponding	 secondary	 antibody	 (goat	 anti-
mouse	Alexa	Fluor	488	at	1:2000	dilution	for	J2;	donkey	anti-rabbit	Alexa	Fluor	488	
at	 1:250	 for	 Ki67	 and	 γH2AX)	 for	 1h	 at	 room	 temperature,	 protected	 from	 light.	
Wells	were	washed	 3X	 5min	 in	 PBS.	 Coverslips	were	 allowed	 to	 dry	 and	mounted	
onto	 slides	 using	 ProLong	 Gold	 Antifade	 Mountant	 with	 DAPI	 (4',6-diamidino-2-
phenylindole)		(Fisher	Scientific).	The	slides	were	stored	in	the	dark	at	4°C	for	at	least	
72h.	
2.6.3. Confocal microscopy 
Immunofluorescence	 slides	were	 imaged	 on	 a	 Zeiss	 780	 Zen	 confocal	microscope.	
The	 microscope	 settings	 were	 adjusted	 for	 each	 antibody	 and	 then	 maintained	













To	 determine	 the	 number	 of	 Ki67	 positive	 nuclei	 in	 each	 image	 first	 the	 colour	






2.7. Apoptosis and Necrosis detection 
2.7.1. Annexin V and Propidium Iodide staining 
The	Annexin	V	Apoptosis	Detection	APC	Kit	 (eBioscience)	was	used	to	stain	HNSCC	
cells	with	annexin	and	propidium	iodide	prior	to	Fluorescence-activated	cell	sorting	
(FACS).	 HNSCC	 cells	 were	 washed	 in	 PBS,	 trypsinised	 and	 counted.	 Cells	 were	
resuspended	 in	1X	Binding	Buffer	at	a	concentration	of	5x106	cells/ml.	The	kit	was	






Buffer	 plus	 5μL	 of	 Propidium	 Iodide	 (PI)	 Staining	 Solution	 and	 analysed	 by	
immediately	on	a	Cyan	B	FACS	analyser	(Beckman	Coulter).		
2.7.2. Fluorescence-activated cell sorting (FACS) 






2.8. Cell cycle analysis 
VU40T	cells	were	harvested,	washed	and	centrifuged	to	form	a	pellet,	then	fixed	by	
adding	 ice-cold	 70%	 ethanol	 drop-wise	 whilst	 vortexing,	 followed	 by	 a	 30min	
incubation	at	4°C.	The	pellet	was	washed	twice	in	PBS,	treated	with	RNase	(Roche)	to	
remove	 RNA,	 resuspended	 in	 50μg/μl	 propidium	 iodide	 (PI)	 (Invitrogen)	 and	
analysed	on	a	Cyan	B	FACS	analyser	(Beckman	Coulter).		
Doublets	 and	 debris	 were	 removed	 as	 described	 in	 section	 2.7.2.	 PI	 emission	 is	












Buffer	 and	 50µl	 PGE2-AP	 conjugate,	 then	 50µl	 Anti-PGE2	 antibody.	 The	 plate	 was	
incubated	for	2h	at	RT	and	washed	3	times	 in	1X	Wash	Buffer.	The	plate	was	then	




pNpp	 substrate	 solution;	 total	 activity	 wells	 containing	 pure,	 unwashed	 PGE2-AP	
conjugate;	 and	 non-specific	 binding	 wells	 containing	 no	 sample	 or	 standard.	 The	
absorbance	values	of	the	standards	of	known	concentration	were	used	to	calculate	
the	concentrations	of	the	sample	wells.		




only	 control	 for	96h.	As	 a	 control,	 1mM	paracetamol	was	 included.	All	 treatments	
were	performed	in	triplicate.	Following	treatment	the	media	was	removed	from	the	




Glutathione	 S-transferase	 and	 GSH-Glo	 reaction	 buffer	 at	 a	 ratio	 of	 1:1:10.	 Wells	
were	 incubated	 with	 100µl	 of	 this	 mixture	 for	 30min	 at	 RT.	 In	 the	 presence	 of	
glutathione	 the	 Glutathione	 S-Transferase	 can	 convert	 Luciferin-NT	 into	 Luciferin.	
Wells	were	incubated	with	100µl	of	reconstituted	Luciferin	Detection	Reagent	at	RT	






2.11. Quantitative Reverse Transcriptase Polymerase Chain 
Reaction (qRT-PCR) Analysis 
2.11.1. RNA extraction 
RNA	 was	 extracted	 using	 the	 RNeasy	 Mini	 Kit	 (Qiagen)	 as	 the	 manufacturer	











2.11.2. cDNA synthesis 
RNA	 was	 converted	 into	 cDNA	 using	 the	 iScript	 cDNA	 Synthesis	 kit	 (Bio-Rad)	 as	
described	 in	 the	 protocol.	 The	 reaction	mix	 of	 1µg	RNA,	 5X	 iScript	 reaction	 buffer	
and	 iScript	 reverse	 transcriptase,	 adjusted	 to	a	 total	 volume	of	20μl	with	nuclease	
free	water,	was	incubated	at	25°C	for	5min,	46°C	for	20min	and	finally	95°C	for	1min.	
The	cDNA	was	purified	using	QiaQuick	PCR	purification	kit	(Qiagen).		
2.11.3. cDNA quantification 
The	 concentration	 of	 cDNA	 was	 determined	 using	 Qubit	 dsDNA	 High	 Sensitivity	
Assay	 kit	 (Thermo	 Fisher	 Scientific).	Qubit	 dsDNA	HS	 reagent	was	 diluted	 1:200	 in	
Qubit	 dsDNA	HS	 buffer.	 In	 Qubit	microtubes,	 199µl	 of	 the	 reagent	was	 combined	
with	1µl	of	DNA	sample,	or	190µl	with	10µl	of	the	standards	provided.	These	were	
incubated	for	2min	at	RT	to	allow	the	fluorescent	dye	to	bind	the	DNA.	The	dye	only	
emits	 a	 signal	 when	 bound	 to	 DNA.	 A	 Qubit	 3.0	 Fluorometer	 (Thermo	 Fisher	
Scientific)	was	used	to	record	this	and	the	signals	of	the	standards	used	to	quantify	
the	DNA	in	each	sample.		
2.11.4. Quantitative reverse transcriptase PCR (qRT-PCR) 
qRT-PCR	 was	 performed	 on	 the	 Roche	 LightCycler	 480	 II	 using	 the	 programme	
outlined	 in	 Table	 2.4.	 The	 reaction	mix	 comprised	 1μl	 of	 cDNA,	 0.075μl	 of	 100μM	
forward	 and	 reverse	 primers,	 6μl	 LightCycler	 480	 SYBR	 Green	 Master	 Mix	 and	













Table 2.4: Programme used for quantification RNA by qPCR 
Cycle Step Temperature (°C) Time (Seconds) 















Cooling 40 30 
 
2.11.5. Primer design 
Primers	for	qRT-PCR	were	designed	using	the	Primer3	software	with	RNA	sequences	
downloaded	 from	 the	 UCSC	 genome	 browser	 [159].	 Primers	 were	 designed	 to	






Table 2.5: Primers used for qRT-PCR 
GENE SYMBOL FORWARD (5’-3’) REVERSE (5’-3’) 
Product 
size 
TET1 TCATGGGTGTCCAATTGCTA GATGAGCACCACCATCACAG 121 
TET2 GGACATGATCCAGGAAGAGC CCCTCAACATGGTTGGTTCT 118 
GAPDH CCTGGCCAAGGTCATCCAT AGGGGCCA TCCACAGTCTT 98 
DNMT1 GAGCCACAGATGCTGACAAA GACACAGGTGACCGTGCTTA 133 
DNMT3A AAGGAGGAGCGCCAAGAG GGATGGGGACTTGGAGATCA 129 
DNMT3B GGGAGGTGTCCAGTCTGCTA GGCTTTCTGAACGAGTCCTG 129 
PTGS1 (COX-1) CGTCCCGCACCCCAGCAG CTGGGTCCGCGAGCAGGA 104 
PTGS2 (COX-2) TCATCATCAGCGCCCTCAA GCTCGTTCACAGCCTTCATG 93 
PTGS1 (COX-3) CGTCCCGCACCCCAGCAG GCTGAGCCTGGCATTCAAGG 104 
PTGER1 (EP-1) GCCAGCTTGTCGGTATCATG CTGCAGGGAGGTAGAGCTC 101 
PTGER2 (EP-2) AAGCTGTGGTCAAGGCTACA GCCAAGTACCATGCTCACTG 97 
PTGER3 (EP-3) GGATCATGTGCGTGCTGTC TGTGTCTTGCAGTGCTCAAC 97 
PTGER4 (EP-4) TGCTCATCTGCTCCATCCC ATTCGGATGGCCTGCAAATC 107 
FAAH CTGCTCTGGACTTGAATGCC CCCCAAAGTAGCCCCTGTAA 108 
TRPV1 TATCACCATCCAGAGGCCAG ACTCCTGCGATCATAGAGCC 109 
CYP2E1 CGGAACTATGGGATGGGGAA CGGAAGAGGATGTCGGCTAT 158 
IFNβ1 TCACTGTGCCTGGACCATAG AGCAATTGTCCAGTCCCAGA 124 
IRF7 GGAGGCCCAAGGAGAAGAG TATCCAGGGAAGACACACCC 102 
TLR3 ACAGCATCAAAAGAAGCAGAAA AGCTTGTTGAACTGCATGATGT 104 
IFIH1 (MDA5) GTTGGACTCGGGAATTCGTG CAAACGATGGAGAGGGCAAG 102 





2.12. RNA sequencing and analysis 
RNA	was	extracted	 from	VU40T	 cells	 as	described	 in	 section	2.11.1	and	quantified	
using	a	Nanodrop.	For	each	cell	type	of	condition	three	RNA	samples	were	pooled	in	
equal	 amounts	 and	 a	 single	 library	 was	 made	 using	 the	 TruSeq	 Stranded	 mRNA	
Library	Prep	kit.	Qubit	fluorometric	quantitation	(Thermo	fisher	scientific)	was	used	
to	quantify	the	pool	and	the	integrity	of	the	RNA	(RIN	number)	was	determined	by	
Tape	 station	 (Agilent).	 All	 samples	 included	 in	 this	work	 had	 a	 RIN	 number	 of	 10.	







expression	 was	 quantified	 using	 StringTie	 (Galaxy	 version1.3.3),	 specifying	 a	
minimum	transcript	length	of	200	nucleotides,	with	GENCODE	v19	as	the	reference	
genome	[161,	162].		
Comparison	 between	 treatment	 groups	 was	 performed	 using	 DeSeq2	 (Galaxy	
version	2.11.39)	[163].	Prior	to	this	HiSAT	bam	files	were	converted	into	a	count	file	
using	htseq-counts	(Galaxy	Version	0.6.1)	using	Gencode	v19	as	the	reference.	Those	






Cuffcompare	 (Galaxy	 version	 2.2.1.0)	 was	 used	 to	 determine	 expression	 of	
transposable	 element	 using	 a	 transposable	 element	 reference	 sequence	 (rmsk,	
downloaded	from	UCSC,	created	using	RepeatMasker	programme)	for	comparison.		
Genes	 or	 transposons	with	 an	 FPKM	more	 than	 1	were	 considered	 expressed	 and	





2.13. Methylated and hydroxymethylated DNA 
Immunoprecipitation (MeDIP and hMeDIP) 
2.13.1. Cell treatment 
VU40T	cells	were	treated	with	100nM	or	1μM	DAC	or	an	equivalent	volume	of	50%	
acetic	 acid	 for	 96h	 in	 media	 containing	 charcoal	 stripped	 FBS	 (Gibco	 by	 Life	
Technologies)	 in	place	normal	the	FBS	described	 in	section	2.1.2.	Charcoal	stripped	
serum	 has	 reduced	 levels	 of	 lipid-based	 materials	 such	 as	 some	 hormones	 and	
growth	 factors.	 This	 provides	 a	 more	 defined	 background	 to	 test	 the	 molecular	
effects	of	drug	 treatment.	Previous	observations	 from	the	 lab	have	suggested	 that	
charcoal	 stripped	 serum	 does	 not	 alter	 the	 growth	 of	 HNSCC	 cell	 lines	 and	 can	
amplify	 the	 effect	 of	 DAC	 treatment	 on	 gene	 expression.	 The	media	was	 changed	
daily	and	experiments	performed	in	duplicate.	
2.13.2. DNA extraction 
MeDIP	was	performed	as	described	previously	and	is	summarised	in	Figure	2.1	using	
the	buffers	described	in	Table	2.6	[168].	Briefly,	cells	were	harvested	by	cell	scraping,	
homogenized	 with	 a	 1.1x	 40mm	 needle	 and	 syringe	 (Neolus)	 and	 centrifuged	 at	
400xg	 for	 10min.	 The	 cell	 pellet	 was	 resuspended	 in	 300µl	 lysis	 buffer	 with	 10µl	
20mg/ml	 Proteinase	 K	 solution	 (Thermo	 Fisher	 Scientific)	 for	 6h	 at	 55°C.	 An	 equal	
volume	 of	 Phenol:Chloroform:Isoamyl	 alcohol	 25:24:1	 (PCIA)	 (Sigma-Aldrich)	 was	
added	 to	 the	 sample,	mixed	 and	 centrifuged	 for	 5min	 at	 14,000xg.	 The	 top	phase	
was	collected,	mixed	with	an	equal	volume	of	PCIA	and	centrifuged	at	14,000xg	for	










80%	 amplitude	 for	 10	 cycles	 of	 30s	 ‘on’,	 30s	 ‘off’	 to	 generate	 fragments	 of	 300-
1000bp.	 For	 each	 immunoprecipitation	 5-10μg	 of	 sonicated	 DNA	 was	 used,	 the	
amount	was	kept	constant	within	each	set	of	experiments.	An	input	of	10µl	of	each	
sample	was	retained.	A	“no	antibody”	control	sample	was	compiled	from	a	mixture	
of	 all	 samples.	 The	 DNA	 was	 diluted	 in	 1X	 TE	 buffer	 and	 denatured	 at	 100°C	 for	
10min	 then	 immediately	quenched	on	 ice.	 10X	 IP	buffer	was	added	 to	 give	a	 final	
concentration	 of	 1X.	 Prior	 to	 immunoprecipitation	 (IP)	 sheep	 anti-mouse	 IgG	
Dynabeads	(M-280	Invitrogen)	were	washed	three	times	in	0.1%	BSA	(Sigma-Aldrich)	
in	PBS	using	a	magnetic	 rack.	To	 reduce	nonspecific	binding	each	 sample	was	pre-
cleared	 by	 incubation	 with	 60μl	 of	 beads	 for	 1h,	 rotating	 at	 4°C,	 after	 which	 the	
sample	 was	 retained	 and	 the	 Dynabeads	 discarded.	 The	 samples	 were	 then	
incubated	 with	 5μl	 of	 anti-5mC	 antibody	 (Eurogentec)	 for	 2h,	 rotating	 at	 4°C.	 To	







2.13.4. Recovery of 5mC enriched DNA 
The	Dynabeads,	now	bound	to	5mC	enriched	DNA,	were	washed	three	times	in	1X	IP	
buffer	and	 incubated	at	50°C	overnight,	 shaking,	 in	proteinase	K	digestion	buffer	+	
7µg	proteinase	K	(Ambion)	to	detach	the	DNA	from	the	beads.	A	magnetic	rack	was	
used	 to	 collect	 the	 Dynabeads	 that	 were	 discarded	 and	 the	 supernatant,	 now	
containing	the	5mC	enriched	DNA	was	retained.	The	DNA	was	extracted	using	PCIA	
extraction	as	described	in	section	2.13.2	and	precipitated	in	100%	ethanol,	400mM	
NaCl	 and	 2μl	 4mg/ml	 glycogen	 (Thermo	 Fisher	 Scientific).	 The	 final	 5mC	 enriched	
DNA	pellet	was	resuspended	in	30µl	1X	TE.		
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Figure 2.1: Steps involved in the Methylated DNA immunoprecipitation (MeDIP)  
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binds to magnetic beads 
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2.13.5. Hydroxymethylated DNA Immunoprecipitation (hMeDIP) 
To	 determine	 the	 distribution	 of	 5hmC	 in	 VU40T	 cells	 hMeDIP	 experiments	 were	




To	determine	 the	efficacy	of	 the	MeDIP	and	hMeDIP	 immunoprecipitation,	a	qPCR	
was	performed.	Primers	against	RARβ	promoter	 (methylated,	positive	control)	and	
KRT6A	(unmethylated,	negative	control)	were	used	to	test	the	MeDIP	efficacy	(Table	
2.7).	 Previous	hMeDIP	 sequencing	 results	were	used	 to	design	primers	 for	 regions	




























































2.14. Illumina Library Preparation and Sequencing of (h)MeDIP 
samples 
2.14.1. NEBNext ChIP-Seq Library prep Master Mix Set 
VU40T	 (h)MeDIP	 libraries	were	prepared	using	 the	NEBNext	ChIP-Seq	 Library	prep	
Master	 Mix	 Set	 for	 Illumina	 using	 Multiplex	 oligonucleotides	 for	 Illumina	 (New	
England	 Biolabs).	 The	 total	 volume	 of	 hMeDIP	 or	 50ng	 of	 MeDIP	 were	 used	 for	
library	preparation.	
2.14.1.1. End repair of sonicated DNA fragments 
The	DNA	was	incubated	with	NEBNext	End	Repair	Enzyme	Mix	and	Buffer	for	30min	
at	20°C	to	repair	the	ends	of	the	sonicated	DNA	fragments.		







2.14.1.3. dA-tailing and adapter ligation 
To	add	dA	tails	to	the	end-repaired	DNA,	Klenow	fragment	plus	dA-tailing	Reaction	
Buffer	 were	 added	 to	 the	 sample	 and	 incubated	 at	 37°C	 for	 30min.	 The	 samples	









2.14.1.4. Dual-SPRI size selection 
Dual-SPRI	 size	 selection	was	 performed	 to	 select	 for	 smaller	 fragments	 of	 adapter	
ligated	 DNA	 (~300bp)	 which	 are	 suitable	 for	 Illumina	 sequencing.	 The	 library	 was	
incubated	with	0.9X	AMPure	XP	beads	at	RT	for	5min.	AMPure	XP	beads,	bound	to	
fragments	 over	 300bp,	 were	 captured	 with	 a	 magnetic	 rack	 and	 discarded.	 The	
supernatant,	 containing	 smaller	 fragments,	 was	 transferred	 to	 a	 new	 tube	 and	
incubated	with	0.2X	AMPure	XP	beads	 for	5min.	This	 captured	DNA	of	 the	 correct	
size	on	the	beads,	which	were	retained,	while	the	supernatant	was	discarded.	Beads	
were	washed	twice	in	80%	ethanol	and	DNA	eluted	into	0.1X	TE	buffer.	




to	 the	 samples.	 This	 contained	 NEBNext	 High-Fidelity	 Master	 Mix,	 Universal	 PCR	









Table 2.8: NEBNext library preparation PCR programme 
 Temperature Time (Seconds) 
Initial denaturation 98 30 
Denaturation 98 10 
X15 Annealing 65 30 





2.14.2. Kapa Hyper Library Preparation 
The	 Kapa	 Hyper	 library	 preparation	 kit	 (KapaBiosystems)	 was	 used	 to	 generate	
Illumina	 libraries	 from	 HOK	 (h)MeDIP	 experiments.	 This	 kit	 claims	 a	 greater	 yield	
from	 lesser	 quantities	 of	 DNA	 and	 therefore	 was	 better	 suited	 for	 experiments	
involving	 primary	 cells.	 The	 protocol	 is	 similar	 to	 the	 one	 described	 in	 2.14.1,	
however	 the	 adapter	 ligation	 and	 indexing	 are	 applied	 in	 a	 single	 step,	 and	 fewer	
SPRI	 clean	 up	 steps	 are	 applied,	 therefore	 the	 loss	 of	 material	 during	 library	
preparation	is	reduced.		
2.14.2.1. End repair, dA-tailing and adapter ligation 
The	 library	 preparation	 was	 performed	 as	 the	 manufacturer	 recommends.	




fragmented	 DNA	 was	 end	 repaired	 and	 A-tailed	 by	 incubating	 the	 DNA	 with	 End	
Repair	and	A-tailing	Buffer	and	Enzyme	Mix	at	20°C	for	30min	then	65°C	for	30min.	
Illumina-indexed	adapters	were	 then	 ligated	 to	 the	 fragmented	DNA	by	 incubating	
the	 A-tailed	 DNA	 fragments	with	 DNA	 Ligase,	 Ligation	 Buffer	 and	 distinct	 indexed	
adapters	for	1h	at	20°C.	
The	 ligated	product	was	cleaned	up	by	SPRI	as	described	 in	 section	2.14.1.2.	After	
adapter	ligation	this	was	performed	twice	to	remove	adapter	dimers.	
2.14.2.2. Library amplification 




Table 2.9: KAPA Hyper Library preparation PCR programme 
	
	 	
 Temperature Time (Seconds) 
Initial denaturation 98 45 
Denaturation 98 15 
X14 Annealing 60 30 







2.14.2.3. Dual-SPRI size selection 
To	 select	 for	 adapter	 ligated	 DNA	 fragments	 of	 250-450bp	 in	 size,	 dual-SPRI	 size	
selection	was	performed.	 The	 library	was	 incubated	with	0.6X	AMPure	XP	 reagent	
for	10min	at	RT.	The	magnetic	beads	containing	the	larger	fragments	were	captured	
and	discarded	 and	 the	 supernatant	 retained.	 The	 supernatant	was	 then	 incubated	




2.14.3. Library Fragment Size Determination 





 2.14.3.1 Preparing the gel mix 
The	 gel	 mix	 was	 prepared	 prior	 to	 use	 by	 adding	 15µl	 High	 Sensitivity	 DNA	 dye	
concentrate	to	one	vial	of	High	Sensitivity	DNA	gel	matrix.	This	was	vortexed	to	mix,	
transferred	to	a	spin	filter	(provided)	and	centrifuged	at	2240xg	for	10min.		
 2.14.3.2 Set up chip priming station 
To	 set	 up	 the	 chip	 priming	 station	 a	 1ml	 syringe	 was	 inserted	 into	 the	 luer	 lock	







 2.14.3.3 Loading the gel-dye mix and samples 
9µl	of	gel-dye	mix	was	loaded	into	the	well	indicated	by	the	protocol.	Following	this	










2.14.4. Library DNA Quantification 
The	SYBR	FAST	LightCycler	480	qPCR	Kit	(KAPA)	was	used	as	per	the	manufacturer’s	
instructions	 to	 quantify	 the	 total	 amount	 of	 adapter-ligated	 DNA	 in	 each	 library.	
Libraries	were	first	diluted	to	1:1000	and	1:5000.	For	each	reaction	6µl	KAPA	SYBR	







libraries	 was	 determined	 from	 this.	 The	 size-adjusted	 concentration	 can	 be	
calculated	by	multiplying	the	concentration	by	(452	(average	fragment	length	of	the	
standards)/	(average	fragment	length	of	a	sample).		
Table 2.10: KAPA Library Quantification thermal cycling conditions 
Step Temperature (oC) Time 
Initial activation/denaturation 95 5 min 
Denaturation 95 30 sec 
35 cycles 
Annealing/extension/data acquisition 60 45 sec 
	
	
2.14.5. Illumina Sequencing  
(h)MeDIP	 Libraries	 to	 be	 analysed	 on	 one	 flow	 cell	 were	 pooled	 in	 equimolar	
quantities	to	a	total	concentration	of	2nM	and	sequenced	on	a	HiSeq	2500,	using	V3	
SBS	Chemistry	(1x51	cycles).		
2.14.6. (h)MeDIP Sequencing Data Analysis. 
2.14.6.1. MeDIP and hMeDIP alignment 
MeDIP	 and	 hMeDIP	 sequencing	 data	 were	 aligned	 to	 the	 human	 genome	 (build	
hg19)	 using	 Bowtie2	 (v2-2.2.6),	 and	 with	 ‘very-sensitive-local’	 alignment	 option	
(example	command	line:	bowtie2-2.2.6/bowtie2-align-s	--wrapper	basic-0	-p	2	--very-
sensitive-local	 -x	 ucsc.hg19.fa	 –reads	 sample.fastq.gz).	 Reads	 overlapping	 the	
Encode	 blacklisted	 regions	 were	 removed	 using	 bedtools	 (v2.22.0).	 MeDIP	 and	




Regional	 Genetics	 Laboratory,	 Birmingham	 Women’s	 Hospital,	 UK).	 The	 resulting	
sequenced	and	aligned	reads	are	outlined	in	Supplementary	data	3.		
2.14.6.2. MeDIP peak calling and annotation 
For	 each	 sample	 peaks	 were	 called	 from	MeDIP	 aligned	 reads	 using	MACS	 v2.1.1	
[169].	 To	 increase	 peak-calling	 specificity	 and	 better	 eliminate	 background	 bias,	 a	




list	 of	 all	 identified	 peaks.	 Upon	merging,	 peaks	within	 150bp	 are	 counted	 as	 the	
same	peak	and	the	midpoint	taken	as	the	peak	summit.	For	each	individual	sample,	
HOMER	v4.8	 [170]	was	used	 to	 annotate	peaks	 and	 calculate	 the	normalized	 read	
density	 (RPM)	averaged	over	a	400bp	window	centred	on	 the	peak	summits	 taken	
from	the	aggregated	peaks	list.	MeDIP	peak	calling	and	annotation	is	attributed	to	Dr	
W.	Croft	(University	of	Birmingham,	UK).	
2.14.6.3. hMeDIP peak calling and annotation 
For	hMeDIP	analysis	the	Homer	suite	(v4.8)	[170]	was	used	to	call	peaks	and	perform	
annotation	 of	 the	 peaks	 using	 default	 settings.	 The	 command	 ‘makeTagDirectory	
VU40T-Aza-unique-tbp1-frag350	 hMeDIP.merged.hg19.brm.bam	 -checkGC	 -tbp	 1	 -
fragLength	350	-genome	hg19	-i	 input.hg19.brm.bam’	was	used	to	ensure	uniquely	
mapped	 reads	 are	 retained,	 the	 background	 signal	 is	 removed	 (to	 improve	




Homer	 was	 used	 to	 count	 only	 unique	 alignments.	 Peaks	 from	 different	
experimental	conditions	were	merged	using	the	‘mergePeaks’	program	from	Homer.	
It	 produced	 a	 list	 of	 peaks	 occurring	 in	 at	 least	 one	of	 the	 conditions	 as	well	 as	 a	
summary	statistics	of	the	intersect	between	different	input	lists.	
Peaks	were	annotated	with	counts,	CpG	and	CG%,	detailed	annotations,	distance	to	
TSS	 and	 closest	 gene	 determined	 using	 the	 following	 command	 from	 Homer:	
‘annotatePeaks.pl	 merged-peaks.txt	 hg19	 -size	 350	 -CpG	 -go	 output-go-results	 -
annStats	 annotation-stats.txt	 -d	 /sample1	 /sample2	 /etc	 >	 annotation-results.txt’.	
hMeDIP	peak	calling	and	annotation	was	performed	by	Dr	S.	Clokie.		
MeDIP	 and	 hMeDIP	 peaks	 were	 annotated	 independently	 for	 each	 replicate	 and	
sample.	In	the	case	of	the	VU40T	samples,	where	replicates	were	available,	analysis	
was	 performed	 on	 each	 replicate	 and	 the	 mean	 calculated.	 When	 comparisons	
between	treatments	or	cell	lines	were	performed	(i.e.	when	using	the	merged	file)	all	
peaks	from	all	replicates	were	considered.		
2.14.6.4. Comparison of hMeDIP peaks with published datasets 
The	 UCSC	 table	 browser	 [171]	 was	 used	 to	 transfer	 ENCODE	 datasets	 for	 histone	
modification,	 transcription	 factor	 binding	 sites,	 DNase	 hypersensitive	 sites	 and	
chromatin	states		for	primary	Normal	Human	Epidermal	Keratinocytes	(NHEK)	[172,	
173]	and	CpG	islands	to	Galaxy	[160].		














Gene Ontology  
The	online	software	GREAT	[177]	was	used	to	assign	genes	to	genomic	co-ordinates	
and	perform	gene	ontology	on	these.		
Enrichment of 5hmC at Alu element subfamilies 
The	 repeatmasker	bed	 file	 that	 contains	 annotated	Alu	elements	was	downloaded	
from	UCSC.	HOK	hMeDIP	 reads	were	 counted	 and	 the	 read	 density	 over	 each	Alu	











Figure 2.2. Overview of the steps of MeDIP and hMeDIP sequencing and analysis 
Quality	 control	 steps	 are	 shown	 in	 red	and	anything	 removed	 from	 the	 samples	 shown	 in	
blue.	
DNA Extraction 
PCIA extract DNA from VU40T and HOK cells  
Sequence 
Illumina sequenced on a HiSeq 2500  
Align 
Align to human genome sequence hg19 using 
Bowtie2  
Peak Call 
MeDIP à MACS v2.1.1 
hMeDIP à Homer 
Compare samples 
Compare the genomic locations of 5hmC and 
5mC enriched regions between samples 
Sonication 
Shear DNA to around 500bp 
Immunoprecipitation 
Enrich for DNA marked by 5hmC or 5mC 
using antibody-bound beads 
DNA recovery 
Recover 5hmC or 5mC enriched DNA 
Library preparation 
VU40T à NEBNext library prep kit.  
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Chapter 3. DAC as a potential 




However,	 it	 has	 been	 observed	 that	 low	 dose	 treatments	 are	 effective	 and	 that	
efficacy	might	 be	 transferable	 to	 solid	 tumours	 [90,	 122,	 127].	 Like	 other	 cancers,	
HNSCC	 is	 characterised	 by	 promoter	 methylation	 of	 tumour	 suppressor	 genes,	
therefore,	this	chapter	aims	to	examine	the	potential	efficacy	of	DAC,	either	alone,	
or	combined	with	other	drugs,	in	the	treatment	of	HNSCC	[97].	
3.1. Mechanism of action of DAC 
3.1.1. DNA demethylation 
DAC	 is	a	cytosine	analogue	that	 is	 recognised	by	the	DNA	replication	machinery	as	
the	 equivalent	 to	 cytosine	 and	 incorporated	 into	 DNA	 in	 its	 place	 [75].	 One	
mechanism	by	which	DAC	decreases	5mC	 levels	 is	 via	 this	 incorporation,	 as	 unlike	
cytosine,	 DAC	 cannot	 be	 methylated	 and	 so	 the	 mark	 is	 diluted	 out	 of	 the	 DNA	
through	subsequent	rounds	of	replication.		Similar	mechanisms	have	been	proposed	
for	 AZA	 and	 other	 nucleoside	 analogues	 [75,	 178].	 However,	 the	 degree	 of	




of	 analogues	 found	 in	 the	 DNA	 [178].	 Furthermore,	 DNMT1	 was	 co-purified	 with	
DNA	in	cells	treated	with	DAC	[179].	Once	DAC	is	incorporated	into	the	DNA,	DNMT1	
recognises	and	binds	to	DAC	as	it	would	to	cytosine	[75].	This	involves	covalent	bond	
formation	 between	 the	 DNMT	 enzyme	 and	 the	 carbon-6	 atom	 on	 the	 pyrimidine	
ring.	When	bound	to	cytosine	this	bond	is	resolved	by	beta-elimination	through	the	
carbon-5	 atom.	 However,	 DAC	 has	 a	 nitrogen	 atom	 at	 this	 position	 and	 so	 the	
covalent	 bond	 cannot	 be	 resolved	 [75].	 DNMT	 becomes	 trapped	 on	 the	 DNA,	
preventing	 it	 from	 functioning	 as	 a	 methyltransferase.	 Furthermore,	 the	 adducts	
formed	from	this	 trapping	trigger	DNA	damage	signalling	pathways	resulting	 in	the	
eventual	 degradation	 of	 DNMT	 [75].	 The	 5mC	 mark	 is	 then	 diluted	 out	 through	
subsequent	rounds	of	replication	(Figure	3.1).	
Demethylation	 by	 DNMTi	 treatment	 can	 reactivate	 epigenetically	 silenced	 tumour	
suppressor	genes.	Additionally,	at	low	doses,	DAC	and	AZA	demethylate	endogenous	
retroviruses	(ERVs),	allowing	them	to	be	expressed	as	double-stranded	RNA	(dsRNA)	
[158,	 180].	 The	 ERV	 dsRNA	 activates	 the	 immune	 system	 to	 produce	 an	 antiviral	
response,	 eventually	 leading	 to	 apoptosis	 [158,	 180].	 This	mechanism	of	 action	 of	
low	 dose	 DNMTi	 is	 referred	 to	 as	 viral	mimicry	 and	 is	 discussed	 in	more	 detail	 in	
(Chapter	6)	[158,	180].		
3.1.2. DNA damage  














Figure 3.1. The mechanism of action of DAC 
DAC	 is	 incorporated	 into	 DNA	 in	 place	 of	 cytosine.	 It	 then	 covalently	 traps	 the	 DNMT	
enzyme.	This	causes	adducts	 in	the	DNA	that	 lead	to	DNA	damage.	Additionally	the	DNMT	
enzyme	is	degraded,	causing	less	DNMT	available	to	remethylate	the	DNA	after	replication.	
Subsequent	 rounds	 of	 replication	 lead	 to	 genome-wide	 hypomethylation	 and	 the	
accumulation	of	DNA	damage.	Adapted	from	[75].	 	
•  DAC (   ) is converted into the 
active form and incorporated into 
the nucleus 
•  DAC is incorporated into DNA 
during DNA replication.  
•  At hemi-methylated sites 
DNMT1 (  ) forms a 
covalent bond with DAC as it 
would with cytosine.  
•  The covalent bond between 
DNMT1 and cytosine is 
resolved 
•  The bond between DAC and 
DNMT1 cannot be undone. 
•  DAC traps DNMT1 onto the 
DNA of the daughter strands 
•  Depletion of DNMT1 results in 
loss of 5mC maintenance 
•  Therefore, through subsequent 
rounds of replication 




•  DNMT1 is degraded by the 
proteasome 





3.2. Mechanisms of resistance to DAC treatment 




after	DAC	but	not	with	baseline	5mC	 levels	 [185].	 Therefore	efficacy	 is	most	 likely	
related	 to	 uptake,	 retention	 or	 activation	 of	 the	 drug.	 In	 humans	 the	 transport	 of	
nucleosides	 across	 membranes	 entails:	 equilibrative	 uniporters	 that	 transport	
nucleosides	 down	 a	 concentration	 gradient	 (members	 of	 the	 SLC29A	 gene	 family	
such	 as	 hENT1	 and	 hENT2);	 concentrating	 transporters	 that	 transport	 nucleosides	
against	a	concentration	gradient	(SLC28A	gene	family,	hCNT1	and	hCNT3	proteins);	
organic	 cationic/anionic	 transporters	 that	 use	 facilitated	 transport	 to	 promote	 the	
uptake	 of	 nucleosides	 (SLC22A	 gene	 family,	 OCT	 and	 OAT	 proteins);	 and	 ATP-




Once	 in	 the	 cell,	 DAC	 is	 converted	 into	 the	 active	 form	 (5-aza-2’-deoxycytidine-
triphosphate)	 by	 deoxycytidine	 kinase	 (DCK),	 while	 cytidine	 deaminase	 (CDA)	 can	
inactivate	the	drug	(to	5-aza-2’-deoxyuridine)	[75].	Therefore,	the	ratio	of	CDA/DCK	






Figure 3.2. DAC transport and activation 
DAC	 can	 be	 transported	 into	 the	 cell	 by	 equilibrative	 uniporters	 (hENTs);	 concentrating	
transporters	 (hCNTs);	 organic	 cationic/anionic	 transporters	 (OCT	and	OATs).	Deoxycytidine	
kinase	(DCK)	can	then	convert	DAC	into	the	active	form	that	can	be	incorporated	into	DNA	
by	polymerase	 (Pol)	 during	DNA	 replication.	 Cytidine	deaminase	 (CDA)	 can	 inactivate	DAC	















3.3. Aims and objectives 
In	this	chapter	the	DNA	demethylating	agent,	DAC,	is	studied	for	the	potential	use	in	
the	 treatment	 of	 HNSCC	 and	 a	 drug-repurposing	 screen	 is	 used	 to	 determine	
whether	 efficacy	 can	 be	 increased	 through	 combination	 therapy.	 	 These	 aims	 are	
explored	through	the	following	objectives:		
• The	 response	 to	 DAC	 is	 examined	 in	 four	 HNSCC	 cell	 lines	 and	 in	 primary	
human	oral	keratinocytes	
• Differences	 in	 the	 response	 to	 DAC	 are	 investigated	 through	






• Giesma	 /	 Jenner	 staining,	 FACS	 analysis,	 Ki67	 staining	 and	 RNA	






3.4. Cell viability assay  
In	this	report	the	CellTiter	Blue	cell	viability	assay	was	used	to	determine	changes	in	
viability	 of	 HNSCC	 cell	 lines	 in	 response	 to	 drug	 treatments.	 Viable	 cells	 convert	
resazurin	into	resorufin.	Therefore,	the	amount	of	each	compound	in	a	sample	gives	
a	relative	measure	of	viable	cell	density.	This	provides	a	means	of	high	throughput	
drug	 testing.	 However,	 it	 is	 important	 to	 note,	 that	metabolic	 changes	 could	 also	
alter	the	results.		




The	addition	of	500nM	DAC	 to	 the	 treatment	does	not	alter	 the	 curve,	 suggesting	
that	24h	treatment	with	DAC	has	no	effect	on	viability	at	this	concentration	and	that	
the	 drug	 does	 not	 interfere	with	 the	 assay;	 therefore	 this	 reagent	 can	 be	 used	 to	
measure	the	effect	of	DAC	on	the	viability	of	HNSCC	cells	 (Figure	3.3).	Both	curves	
begin	 to	plateau	at	~1x105	 cells	 /	well	 suggesting	 that	 the	accuracy	of	 the	 reagent	






Figure 3.3. CellTiter Blue cell viability assay 
To	test	the	efficacy	of	the	cell	viability	experiment	(Section	2.2.2)	CellTiter	Blue	reagent	was	
added	to	a	 titration	of	VU40T	cells	+/-	500nM	DAC	cultured	 for	24h.	The	 reagent	contains	
the	compound	resazurin	that	is	visible	as	a	blue	colour	in	the	media	and	can	be	read	at	an	
absorbance	 of	 600nM.	 Viable	 cells	 convert	 this	 into	 resorufin,	 which	 is	 pink	 and	 the	
absorbance	 can	 be	 read	 spectrophotometrically	 at	 570nM.	 The	 middle	 panel	 shows	 a	
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3.5. The efficacy of DAC treatment varies in HNSCC cell lines 
To	determine	the	efficacy	of	DAC	treatment	 in	HNSCC	a	panel	of	relevant	cell	 lines	
(HNSCC	 cell	 lines	 VU40T,	 HN12,	 UDSCC2,	 SCC040	 and	 primary	 human	 oral	
keratinocyte	cells,	HOK)	were	subject	to	a	titration	of	DAC	(0.0625,	0.125,	0.25,	0.5,	
1,	1.5,	2,	4,	10µM),	 following	which	viability	was	determined	 (Figure	3.4).	The	 four	
HNSCC	cell	lines	stratified	into	two	distinct	groups:	those	that	respond	to	nanomolar	
doses	 of	 DAC	 (VU40T	 and	 HN12)	 and	 those	 that	 showed	 minimal	 response	 to	




culture	 cannot	 exceed	 500nM.	 The	 two	 responsive	 cell	 lines,	 HN12	 and	 VU40T,	
showed	an	 initial	response	from	as	 little	at	50nM	and	a	drop	 in	viability	of	roughly	
40%	at	500nM	DAC	(Figure	3.4).	However,	UDSCC2	and	SCC040	did	not	respond	to	
clinically	 relevant	 doses;	 UDSCC2	 did	 not	 respond	 to	 DAC	 at	 any	 concentration	
tested,	while	SCC040	only	responded	to	the	clinically	irrelevant	dose	of	10µM	(Figure	
3.4).	None	 of	 the	 cell	 lines	 tested	 showed	 IC50	≤	 500nM	DAC.	 Primary	 human	oral	
keratinocyte	 cells,	 HOK,	 were	 used	 to	 represent	 non-cancerous	 tissue.	 These	
grouped	with	the	non-responsive	HNSCC	cells,	only	responding	to	clinically	irrelevant	
concentrations	of	the	drug,	above	4µM	(Figure	3.4).		
DAC	 treatment	 exerts	 its	 effects	 via	 two	 main	 mechanisms:	 global	 DNA	
demethylation	 and	 DNA	 damage.	 Both	 of	 these	 are	 dependent	 upon	 DAC	





analysis	was	used	 to	determine	basal	RNA	 levels	 for	DNMT-1,	 -3A,	 and	 -3B	 (Figure	
3.5).	 In	general,	HNSCC	cell	 lines	showed	higher	 levels	of	DNMTs	than	primary	oral	
keratinocytes.	However,	while	DNMT	expression	varied	between	cell	 lines,	 this	did	
not	correspond	with	sensitivity	to	DAC.	 
The	 global	 level	 of	 DNA	 methylation	 after	 96h	 of	 500nM	 DAC	 treatment	 was	
determined	using	 a	DNA	dot	blot.	 Encouragingly,	 5mC	 changes	 corresponded	with	
the	 sensitivity	 to	 DAC	 previously	 described.	 DAC-responsive	 cell	 lines	 showed	 a	
significant	 decrease	 in	 5mC	after	DAC	 treatment,	while	 unresponsive	 cell	 lines	 did	
not	 (Figure	 3.5,	 Supplementary	 data	 4).	 There	was	 no	 significant	 difference	 in	 the	











Figure 3.4. HNSCC cells show variable sensitivity to DAC treatment 
A	DAC	 titration	was	undertaken	over	a	96h	period	on	4	HNSCC	cell	 lines	and	primary	oral	
keratinocytes	(HOK).	Viability	was	determined	as	described	in	section	2.2.2.	The	results	show	
differing	 efficacy	 of	 the	 drug	 between	 cell	 lines	 with	 HN12	 and	 VU40T	 showing	 a	 rapid	
reduction	 in	viability	while	SCC040	cells	appeared	resistant	to	concentrations	of	DAC	up	to	
4µM	and	UDSCC2	was	 resistant	 to	up	 to	10µM.	A.	 All	 concentrations	 applied.	B.	 Clinically	
relevant	concentrations	only.	Results,	shown	relative	to	the	vehicle	only	control,	are	mean	+	
SEM	 (n=3)	 C.	 The	 concentration	 of	 DAC	 required	 to	 reduce	 growth	 by	 50%	 (IC50)	 values	
calculated	from	the	curves	in	A.	N/A:	not	determined.		
	 	
SCC040 VU40T HN12 UDSCC2 HOK
IC50 (μM) 10.61 2.17 0.81 N/A 8.93
DAC	(uM)
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Figure 3.5. Methylation changes in response to DAC treatment 
A.	 The	 relative	mRNA	 levels	 of	DNMT	enzymes	 in	HNSCC	 cell	 lines	 and	HOK	primary	 cells	
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RNA	 sequencing	 was	 performed	 on	 DAC-responsive	 (HN12,	 VU40T)	 and	
unresponsive	 (SCC040,	 UDSCC2)	 cell	 lines	 to	 examine	 whether	 differences	 in	 the	
transcriptional	 profile	 could	 account	 for	 the	 response	 to	 DAC.	 The	 four	 cell	 lines	
were	 initially	 compared	 in	 an	 unbiased	 manner:	 a	 Venn	 diagram	 was	 used	 to	
determine	the	whether	any	genes	were	jointly	expressed	in	the	responsive	cell	lines	
and	lacking	in	the	unresponsive	cell	 lines	(Figure	3.6).	To	do	this,	a	threshold	FPKM	
value	 of	 1	 was	 used	 to	 discard	 lowly	 expressed	 genes	 from	 the	 comparison.	 The	
majority	of	genes	(5591)	are	expressed	in	all	HNSCC	cell	lines	while	255	genes	were	
expressed	only	 in	DAC-responsive	 cell	 lines	 (HN12	and	VU40T)	 and	309	genes	–	 in	
DAC-resistant	 cells	 (UDSCC2	 and	 SCC040).	 These	 groups	 were	 subject	 to	 gene	
ontology	 (GO)	 analysis	 for	 biological	 processes	 using	 the	 analysis	 software	 DAVID	
[188].	The	GO	term	‘drug	transport’	was	enriched	in	the	DAC-responsive	group	and	
included	 the	 genes	 SLC15A2	 and	 SLC22A5	 (Supplementary	 data	 5).	 To	 further	




SLC29A1	 was	 expressed	 in	 all	 cell	 lines,	 and	 had	 higher	 FPKM	 values	 in	 the	 DAC-
responsive	 cell	 lines.	 qRT-PCR	 results	 confirmed	 higher	 expression	 of	 the	 drug	
transporters	SLC22A5	 and	SLC15A2	 and	 the	nucleoside	 transporter	SLC29A1	 in	 the	
DAC	 responsive	 cell	 lines	 over	 the	 unresponsive	 cells,	 with	 significantly	 higher	









terms	 associated	 with	 the	 regulation	 of	 metabolism	 of	 nucleobase	 containing	
compounds	 were	 enriched	 in	 the	 DAC-unresponsive	 group	 (Figure	 3.8,	
Supplementary	data	5).	
In	conclusion,	DAC-responsive	cell	lines	are	characterised	by	increased	expression	of	
genes	 involved	 in	drug	transport	and	DAC-unresponsive	cell	 lines	are	characterised	
by	 genes	 involved	 in	 the	metabolism	of	 nucleobase	 containing	 compounds	 (Figure	
3.6,	 Figure	 3.8).	 Therefore,	 the	 differential	 response	 to	 DAC	 treatment	 could	 be	
attributed	to	either	or	both	of	these	results.		
	
Figure 3.6. Differential RNA expression between DAC responsive and 
unresponsive cell lines	
RNA	 sequencing	 of	 HNSCC	 cell	 lines.	 RNA	was	 aligned	 using	 HiSAT2	 and	 expressed	 genes	
determined	using	StringTie.		All	genes	with	an	FPKM	>1	for	each	cell	line	are	compared	using	



















p= 0.041  




Table 3.1. DAC responsive cell lines exhibit increased expression of SLC29A1 
The	 FPKM	 values	 for	 a	 user	 defined	 list	 of	 genes	 with	 a	 putative	 involvement	 in	 DAC	
transport	or	activation	from	the	transcriptome	of	HNSCC	cell	 lines.	Genes	with	an	FPKM<1	
not	considered	as	expressed.		
Gene UDSCC2 HN12 SCC040 VU40T Function 
SLC22A1 0.01 0.01 0.05 0.02 
Organic cationic/anionic transporters 
(OCT/OAT): promote the uptake of 
nucleoside analogues 
SLC22A2 0 0 0 0 
SLC22A3 0 0.03 0.06 0.62 
SLC22A4 0.46 0.72 0.5 0.19 
SLC22A6 0 0 0 0 
SLC22A7 0 0 0 0 
SLC22A8 0 0 0 0 
SLC28A1 0 0 0 0 
Concentrating transporters (CNT): transport 
nucleoside analogues across a concentration 
gradient 
SLC28A2 0 0 0 0 
SLC28A3 0 0 0 0 
SLC29A1 2.36 20.49 13.69 34.00 
Equilibrium nucleoside transporters (ENT): 
facilitate the transport of nucleoside 
analogues down the concentration gradient SLC29A2 0.18 0.15 0.80 0.05 
ABCC10 2.33 1.81 7.77 3.68 
ATP dependent exporters – 
can remove nucleosides from the cell 
ABCC11 0.04 0.01 0.01 0.03 
ABCC4 0 0 0 0 
ABCC5 0.01 0.01 0.02 0 
DCK 31.82 28.84 20.43 35.73 Coverts DAC into the active form 











Figure 3.7. DAC responsive cell lines exhibit increased expression of SLC15A2, 
SLC22A5 and SLC29A1 
qRT-PCR	analysis	of	drug	 transporters.	Results	are	mean	+	SEM	(n=3)	and	significance	was	
















































































Figure 3.8. Enrichment of nucleobase-metabolism related genes in DAC-




map	 for	 GO	 term	 0045934	 (negative	 regulation	 of	 nucleobase	 containing	 compound).	
Outlined	in	red	are	GO	terms	significantly	enriched	(p<0.05)	in	the	DAC-unresponsive	group.	
B.	The	log10	p-values	for	the	GO	terms	outlined	in	A.		 	
Term ID Description log10 p-value 
GO:1901362 organic cyclic compound biosynthetic process -5.9586 
GO:0034654 nucleobase-containing compound biosynthetic process -5.4202 
GO:0018130 heterocycle biosynthetic process -5.3197 
GO:0019438 aromatic compound biosynthetic process -5.251 
GO:0019219 regulation of nucleobase-containing compound metabolic process -3.7011 
GO:1901360 organic cyclic compound metabolic process -3.1308 
GO:0044271 cellular nitrogen compound biosynthetic process -2.9469 
GO:0044249 cellular biosynthetic process -2.5045 
GO:0045934 negative regulation of nucleobase-containing compound metabolic process -2.4962 
GO:0006725 cellular aromatic compound metabolic process -2.3233 
GO:0006139 nucleobase-containing compound metabolic process -2.1858 
GO:1901576 organic substance biosynthetic process -2.1524 






3.6. A drug repurposing screen identifies paracetamol, valproic 
acid and zinc acetate as being able to sensitise HNSCC cells to 
DAC treatment 
Data	 has	 indicated	 that	 the	HNSCC	 cell	 lines	 examined	 are	 highly	 variable	 in	 their	
response	to	DAC,	however	they	all	have	IC50	values	higher	than	the	Cmax	of	~500nM.	
A	DAC	 sensitising	 assay	was	 developed	 to	 determine	whether	 the	 efficacy	 of	 DAC	
treatment	in	HNSCC	could	be	increased	through	combination	therapy.	A	screen	was	
performed	on	DAC-responsive	 cell	 line,	 VU40T,	 and	unresponsive	 cell	 line,	 SCC040	
using	 a	 panel	 of	 100	 off-patent	 drugs	 (Supplementary	 data	 1).	 Cells	 were	 treated	
with	one	of	the	panel	of	drugs,	+/-	500nM	DAC	for	96h,	following	which	viability	was	
determined	(Figure	3.9).	For	the	unresponsive	cell	line,	none	of	the	100	drugs	tested	
were	able	 to	 increase	the	efficacy	of	DAC	treatment	 (Figure	3.9).	However,	 for	 the	
DAC-responsive	 cell	 line,	 zinc	 acetate,	 valproic	 acid	 and	 paracetamol	were	 able	 to	
increase	the	efficacy	of	DAC	(Figure	3.9).	This	pattern	was	replicated	when	the	other	
DAC-responsive	 and	 unresponsive	 cell	 lines	 were	 examined:	 HN12	 cells	 were	
sensitized	 by	 paracetamol	 and	 zinc	 acetate;	 while	 UDSCC2	 cells	 were	 not	 (Figure	
3.10).	HOK	cells	were	highly	sensitive	to	both	zinc	acetate	and	valproic	acid	but	not	
paracetamol,	and	paracetamol	was	unable	to	increase	the	sensitivity	of	HOK	cells	to	
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Figure 3.9. A drug-repurposing screen identified paracetamol, zinc acetate and 














































































































































Figure 3.10. Paracetamol, zinc acetate and valproic acid are able to sensitise 
HNSCC cell lines to DAC treatment 
A.HNSCC	cell	lines	and	primary	oral	keratinocyte	cells	were	treated	with	drugs	at	the	Cmax	
concentration	either	alone	(filled	bars)	or	in	combination	with	500nM	DAC	(empty	bars)	for	
96h.	 Viability	 was	 determined	 and	 results	 are	 shown	 relative	 to	 the	 vehicle	 only	 control.	
Results	 are	mean	 +/-	 SEM	 (n=3).	NT=	 vehicle	 only;	 Zinc=	 zinc	 acetate;	 VPA=	 valproic	 acid;	





Sensitivity to DAC 
Treatment (%) 
Sensitising Drugs 
VU40T 36.63 (***) Zinc Acetate (*) ,Valproic acid (*) ,Paracetamol(*) 
SCC040 4.021 (ns) None 
HN12 44.63 (***) Zinc Acetate(ns) , Paracetamol(**) 
UDSCC2 4.84 (ns) None 




















































































3.7. DAC and paracetamol work in synergy to reduce viability 
in HNSCC cells 
To	 determine	 whether	 DAC	 and	 paracetamol	 were	 working	 in	 synergy	 to	 reduce	
viability	 in	 HNSCC	 cells	 the	 Chou-Talalay	 method	 was	 employed	 [107].	 The	 main	
benefit	of	this	method	is	its	simplicity	[107].	Experimentally,	in	place	of	interrogating	
all	 possible	 dose	 combinations	 between	 the	 two	drugs,	 only	matched	 titrations	 of	
each	 drug	 alone	 and	 in	 combination	 are	 required.	 The	 results	 of	 the	 combined	
titration	are	treated	equivalent	to	a	third	drug,	thereby	simplifying	the	experimental	
design	 and	 mathematical	 analysis	 [107].	 	 DAC-responsive	 cells,	 HN12	 and	 VU40T,	









The	CompuSyn	 software	also	 calculates	 the	dose	 reduction	 index	 (DRI).	DRI	 values	
determine	how	many	times	 less	each	drug	can	be	used	when	used	 in	combination	
(Table	 3.2).	 For	 example,	 2.26µM	 of	 DAC	 or	 595µM	 of	 paracetamol	 is	 needed	 to	






replaced	 with	 therapeutically	 relevant	 ones	 (Table	 3.2).	 A	 similar	 result	 can	 be	
observed	for	HN12	cells.	HN12	cells	exhibit	minimal	response	to	paracetamol	alone;	
this	is	mirrored	by	very	high	DRI	values	for	paracetamol	(Table	3.2,	Figure	3.11).		
To	 confirm	 the	 efficacy	 of	 the	 viability	 assay	 and	 to	 determine	 whether	 any	
morphological	 changes	 are	 observed	 following	 DAC	 and	 paracetamol	 treatment	
Giemsa/Jenner	 staining	 was	 performed	 on	 DAC-responsive	 VU40T	 cells.	 The	 cells	
were	untreated	(NT)	or	treated	with	500nM	DAC	+/-	132.3µM	paracetamol	for	96h.	
Cells	were	 collected	and	 stained	every	24h.	Minimal	 change	 in	 cell	morphology	or	
density	was	observed	after	48h	of	treatment.	However,	at	72h	and	96h,	DAC	treated	
cells	 showed	 a	 reduction	 in	 cell	 number,	 in	 accordance	 with	 the	 viability	 results	
(Figure	 3.4,	 Figure	 3.13).	 After	 96h,	 this	 decrease	 is	 amplified	 by	 the	 addition	 of	
paracetamol,	although	paracetamol	alone	caused	no	apparent	change	in	cell	density	














































































Figure 3.12. DAC and paracetamol work in synergy to reduce viability in HNSCC 
cells	
	The	Chou-Talalay	method	was	used	 to	determine	 synergy	 from	 the	 results	 in	 Figure	3.11.	






Dose	(µM) DRI Dose	(µM) DRI 
DAC 	Para DAC Para DAC Para DAC Para 
10 0.01 105 0.30 10.18 0.004 186 0.49 80 
25 0.16 251 1.22 7.11 0.06 1962 1.19 147 
50 2.26 595 4.99 4.97 0.85 20653 2.92 269 
75 31 1414 20.35 3.47 11.92 217412 7.15 493 
97 9300 9200 426 1.59 3630 35450000 49.5 1827 
	





























Figure 3.13. Morphology of DAC and Paracetamol treated VU40T cells	
VU40T	 cells	were	 treated	with	DAC	+/-	paracetamol	 for	96h.	Cells	were	harvested	at	48h,	
72h	 and	 96h,	 fixed	 in	 methanol	 and	 Giemsa/Jenner	 stained	 to	 visualise	 changes	 in	
















3.8. Combined treatment with DAC and paracetamol slows 
down proliferation in VU40T cells 
Reduced	viability	 can	be	 caused	due	 to	 several	mechanisms,	 including;	 the	 rate	of	
apoptosis	 and	 necrosis	 could	 be	 increased,	 or	 the	 rate	 of	 proliferation	 decreased.	
Annexin	V	and	propidium	iodine	staining	and	FACS	analysis	was	used	to	determine	
whether	 VU40T	 cells	 treated	 with	 DAC,	 paracetamol	 or	 both	 were	 undergoing	
apoptosis	or	necrosis	 (Figure	3.14).	 In	 this	 assay,	 annexin	V	 is	used	as	a	marker	of	
apoptosis,	 while	 cells	 will	 only	 stain	 with	 PI	 if	 the	 cell	 membrane	 is	 damaged,	 a	
feature	of	necrotic	or	 late	apoptotic	cells.	Therefore,	 live	cells	can	be	distinguished	
from	necrotic	 cells	which	 are	positive	 for	 PI;	 apoptotic	 cells	which	 are	positive	 for	
annexin	V	and	 late	 apoptotic	 cells	which	are	positive	 for	both.	A	 slight	 increase	 in	
apoptosis	 and	necrosis	 could	be	observed	 from	as	 early	 as	 48h	of	DAC	 treatment,	
this	effect	was	increased	after	72h	and	96h	(Figure	3.14).	Paracetamol	alone	had	no	





was	 calculated	 for	 each	 treatment	 (Figure	 3.15).	 Treatment	with	 DAC	 significantly	






Reduced	 proliferation	may	 indicate	 that	 the	 cell	 cycle	 has	 been	 stalled.	 Therefore	
propidium	iodide	staining	and	FACS	analysis	were	used	to	determine	whether	VU40T	
cells	 treated	with	DAC	and	paracetamol	were	progressing	 through	 the	cell	 cycle	at	
the	 same	 rate	 as	 untreated	 cells	 (Figure	 3.16).	 In	 this	 assay,	 cells	 were	 fixed	 in	
ethanol	to	cause	cell	cycle	arrest,	PI	was	then	 intercalated	 into	the	DNA,	and	FACS	





the	 cells	 are	 stalled	 at	 the	G1	or	 S	 phase	 checkpoints	 (Figure	 3.16).	However,	 this	
result	was	not	significant	(Figure	3.16).	DAC	and	combined	treatment	samples	have	






Figure 3.14. Paracetamol does not increase cell death caused by DAC treatment  
VU40T	 cells	 were	 treated	 with	 DAC	 +/-	 paracetamol	 for	 48,	 72	 or	 96h	 and	 stained	 with	
annexin	V	and	propidium	iodide.	Cells	positive	for	each	label	were	then	counted	using	FACS.	
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treatment	 per	 replicate.	 SPSS	 software	 was	 used	 to	 calculate	 a	 paired	 t-test	 for	 each	
treatment	against	the	untreated	samples,	and	the	combined	treatment	against	DAC	alone.	
*p<0.05,	**	p<0.01.		 	





































Figure 3.16. Cell cycle changes after treatment with DAC and paracetamol 
VU40T	 cells	were	 treated	with	DAC	 +/-	 paracetamol	 for	 96h,	 fixed	 in	 ethanol	 and	 stained	
with	PI	 prior	 to	 sorting	by	 FACS.	A.	Representative	histograms	 showing	 the	 levels	 of	 PI	 vs	
count.	Peaks	define	populations	of	cells	in	each	stage	of	the	cell	cycle	and	are	gated	as	such.	
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3.9. Combined treatment with DAC and paracetamol alters the 
transcriptional profile of DAC-responsive cells 
RNA	 sequencing	 was	 performed	 on	 VU40T	 cells	 after	 96h	 treatment	 with	 500nM	
DAC	 +/-	 132.3µM	 paracetamol	 to	 investigate	 the	 effect	 of	 treatment	 on	 the	
transcriptome	 (Figure	 3.17-Figure	 3.19).	 The	 majority	 (62.7%)	 of	 expressed	 genes	
were	 consistent	 between	 the	 treatment	 groups	 (Figure	 3.17).	 DAC	 treatment	
induced	 the	 expression	 of	 a	moderate	 amount	 of	 genes	 relative	 to	 control	 (11%)	
while	 fewer	 genes	 were	 activated	 by	 paracetamol	 (6.2%)	 and	 only	 4.8%	 of	 genes	
were	 specific	 to	 the	 combined	 treatment	 group	 (Figure	 3.17).	 These	 data	 suggest	
that	any	transcriptional	changes	in	response	to	treatment	are	primarily	due	to	DAC.	
Clustering	 of	 the	 most	 differentially	 expressed	 genes	 confirms	 this	 observation:	
untreated	and	paracetamol	treated	cells	exhibit	a	similar	expression	profile	which	is	
distinct	from	DAC	and	DAC	+	Para	treated	cells	(Figure	3.17).	 
Treated	 samples	 were	 compared	 against	 the	 vehicle-treated	 control	 using	 the	
DeSeq2	software	(Figure	3.18).	The	results	were	divided	into	6	groups:	 i)	genes	up-
regulated	 by	 paracetamol	 treatment	 (n=151);	 ii)	 genes	 down-regulated	 by	
paracetamol	 treatment	 (n=127);	 iii)	genes	up-regulated	by	DAC	treatment	 (n=658);	
iv)	 genes	 down-regulated	 by	 DAC	 treatment	 (n=293);	 v)	 genes	 up-regulated	 by	
combined	treatment	(n=915)	and;	vi)	genes	downregulated	by	combined	treatment	
(n=721).	Genes	from	each	group	were	subject	to	GO	analysis	to	determine	whether	
they	 were	 enriched	 for	 any	 biological	 processes	 (Supplementary	 data	 7).	 No	 GO	
terms	 were	 found	 to	 be	 significantly	 associated	 with	 the	 paracetamol	 down-








regulated	by	 combined	 treatment	were	enriched	 for	 similar	 terms	down-regulated	
by	DAC	 alone,	 however	 they	 had	 substantially	 lower	 p-values,	 suggesting	 that	 the	






Figure 3.17. Treatment with DAC and paracetamol alters the transcriptional profile 
of VU40T cells 
RNA	was	extracted	and	 Illumina	 sequencing	was	performed	 in	VU40T	cell	 cultures	 treated	
with	DAC	+/-	paracetamol	for	96h.	Sequences	were	aligned	to	the	genome	using	HiSAT2.	A.	
StringTie	was	 used	 to	 determine	which	 genes	were	 expressed,	 and	 the	 top	 25%	 for	 each	
treatment	 group	 are	 shown	 as	 a	 Venn	 diagram.	 Number	 represent	 percentage	 of	 total	
genes.	B.	All	differentially	expressed	genes	(STD>1)	are	shown	as	a	heatmap	generated	using	
ClustVis	 software	 where	 both	 samples	 (columns)	 and	 genes	 (rows)	 are	 clustered	 using	
correlation	distance	and	average	linkage	and	unit	variance	scaling	is	applied..		
DAC NT 
























Figure 3.18. Gene ontology analysis of DAC and paracetamol treated VU40T cells 
RNA	 was	 extracted	 and	 Illumina	 sequenced	 from	 VU40T	 cells	 treated	 with	 DAC	 +/-	
paracetamol	 for	 96h.	 Sequences	 were	 aligned	 to	 the	 genome	 using	 HiSAT2.	 Differentially	
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Figure 3.19. Combined treatment with DAC and paracetamol decreases the 
expression of genes involved in the cell cycle, DNA replication and repair 
Genes	from	chosen	ontological	groupings	(Figure	3.14)	are	displayed	as	a	heatmap	using	the	






3.10. Discussion and conclusion 
Altered	 promoter	 methylation	 is	 understood	 to	 contribute	 to	 the	 initiation	 and	
development	 of	 HNSCC;	 therefore,	 the	 disease	 is	 a	 good	 candidate	 for	 DAC	
treatment	[29,	100,	101].	However,	this	study	has	shown	considerable	variability	 in	
the	 response	 of	 HNSCC	 cell	 lines	 to	 DAC,	 with	 the	 cell	 lines	 stratifying	 into	 two	
distinct	 groups:	 those	 that	 did	 not	 respond	 to	 DAC	 and	 those	 that	 responded	 to	
nanomolar	concentrations.	The	DNA	methylation	change	in	response	to	DAC	in	each	
cell	 line	 mirrors	 these	 results,	 suggesting	 that	 efficacy	 of	 the	 drug	 is	 directly	
proportional	to	the	ability	of	DAC	to	demethylate	the	DNA.	This	would	suggest	that	
sensitivity	is	dependent	upon	the	activation,	incorporation	or	retention	of	the	drug.	
Accordingly,	 the	 RNA	 expression	 of	 drug	 transport	 genes	 SLC15A2,	 SLC22A5	 and	
SLC29A1	are	higher	in	DAC-responsive	cell	lines	than	unresponsive	cell	lines.	Follow	
up	 experiments	 are	 needed	 to	 confirm	whether	 this	 could	 be	 contributing	 to	 the	
variable	 sensitivity	 observed.	 Interestingly,	 genes	 involved	 in	 the	 regulation	 of	
nucleobase-containing	 compound	 metabolism	 were	 enriched	 in	 the	 gene	 set	
associated	 with	 DAC-unresponsive	 cell	 lines	 suggesting	 that	 there	 may	 be	 a	
difference	 in	 the	 nucleotide	 turnover	 in	 DAC-unresponsive	 cells	 compared	 with	
responsive	 ones.	 This	 could	 contribute	 to	 the	 variable	 sensitivity	 observed	 as	 high	
dNTP	pools	can	contribute	to	DAC	resistance;	therefore	this	is	another	area	of	future	
research	[184].		
To	 improve	 upon	 the	 response	 of	 HNSCC	 cell	 lines	 to	 DAC	 treatment	 a	 DAC	
sensitising	 assay	 was	 designed.	 The	 screen	 had	 no	 initial	 bias	 towards	





the	 100	 drugs	 tested	were	 able	 to	 sensitise	 unresponsive	 cells	 to	 DAC	 treatment.	
This	 is	 in	 agreement	 with	 the	 theory	 previously	 proposed,	 and	 suggests	 that	
targeting	 the	 activation	 or	 uptake	 of	 DAC	 is	 the	 primary	 means	 of	 conferring	
sensitivity	 to	 unresponsive	 cases.	 In	 the	 DAC-responsive	 cell	 lines,	 valproic	 acid	
(VPA),	zinc	acetate	and	paracetamol	were	all	able	to	increase	sensitivity	to	DAC.	The	
potential	 benefits	 of	 combining	 VPA	 with	 DAC	 have	 been	 described	 elsewhere,	




Recent	 work	 suggests	 that,	 especially	 at	 low	 doses,	 DAC	 acts	 by	 inducing	 the	
expression	 of	 double	 stranded	 endogenous	 retroviruses	 that	 trigger	 an	 immune	
response	 [158,	 180].	 The	 RNA	 sequencing	 results	 described	 in	 this	 chapter	 are	 in	














drugs	were	shown	to	work	 in	synergy	 to	 reduce	viability	 in	DAC-responsive	HNSCC	
cells,	allowing	toxic	concentrations	of	each	drug	to	be	replaced	by	clinically	relevant	
ones.	 While	 DAC	 alone	 can	 induce	 cell	 death,	 the	 addition	 of	 paracetamol	
significantly	 slows	down	 the	 rate	 of	 proliferation.	 Therefore,	 this	 could	 have	 great	
therapeutic	 potential,	 as	 combined	 treatment	 would	 protect	 against	 cancer	

















Chapter 4. Mechanisms 
underlying the synergistic 
relationship between DAC and 
paracetamol 
4.1. Paracetamol 
Paracetamol	 (or	 acetaminophen	 in	 the	USA)	 is	 a	 popular	 analgesic	 and	 antipyretic	
with	a	similar	spectrum	of	action	to	non-steroidal	anti-inflammatory	drugs	(NSAIDs)	
[191].	 	 It	was	 first	 synthesised	by	Morse	 in	1878	during	a	 search	 for	derivatives	of	
acetanilide.	Acetanilide	had	been	in	use	at	the	time	as	an	antipyretic	and	analgesic,	
however	 it	 was	 found	 to	 have	 some	 serious	 side	 effects	 including	 severe	
methemoglobinemia,	 prompting	 a	 search	 for	 less	 toxic	 derivatives	 [192].	 The	 two	
main	 outcomes	 of	 this	 search	 were	 paracetamol	 and	 phenacetin.	 Phenacetin	 was	
favoured	and	paracetamol	set-aside	 for	several	decades	 [192].	 In	1948,	Brodie	and	
Axelrod	determined	 that	 the	 active	metabolite	 in	 both	phenacetin	 and	 acetanilide	








4.2. The mechanism of action of paracetamol 
Interestingly,	despite	widespread	usage	and	extensive	history,	the	exact	mechanism	
of	 action	of	 paracetamol	 is	 still	 under	debate.	Upon	 searching	 the	 literature	 three	
main	theories	emerge	to	explain	the	analgesic	effects	of	paracetamol:	 Inhibition	of	
the	 cyclooxygenase	 (COX)	 pathway	 through	COX-2;	 specific	 inhibition	 of	 COX-3;	 or	
conversion	to	the	analgesic	N-arachidonylphenolamine	(AM404).	
4.2.1. Inhibition of the cyclooxygenase pathway 
The	 spectrum	 of	 action	 of	 paracetamol	 is	 similar	 to	 that	 of	 non	 steroidal	 anti-
inflammatory	 drugs	 (NSAIDs),	 and	 as	 such	 it	 was	 initially	 classified	 as	 one	 [191].	
NSAIDs	 act	 on	 the	 cyclooxygenase	 (COX)	 pathway,	 by	 inhibiting	 COX	 enzymes	 to	
prevent	 the	 conversion	 of	 arachidonic	 acid	 into	 prostaglandin	 H2	 (PGH2).	 In	 the	
absence	of	COX	inhibitors	PGH2	is	rapidly	converted	into	one	of	a	number	of	effector	
prostaglandins	(PG)	or	thromboxane	(TXA)	that	exert	their	effects	through	G-protein	
coupled	 receptors	 (Figure	 4.1).	 Two	 COX	 enzymes	 catalyse	 the	 conversion	 of	




























Figure 4.1. The cyclooxygenase pathway	
Cyclooxygenase	(COX)	proteins	(PTGS-1/2	genes)	convert	arachidonic	acid	into	prostaglandin	
H2	 (PGH2).	 This	 is	 then	 rapidly	 converted	 into	 one	 of	 a	 number	 of	 effector	 prostaglandins	
(PG-E2,	F2,	I2,	and	D2)	or	thromboxane	(dark	grey	boxes).	These	exert	their	effects	through	G-
protein	coupled	receptors	(light	grey	boxes).	EP-1/2/3/4:	prostaglandin	E2	receptors	1/2/3/4	
(PTGER-1/2/3/4	 genes);	 FP:	 Prostaglandin	 F2	 receptor	 (PTGFR	 gene);	 PPARδ:	 peroxisome-
proliferator-activated	 receptor	 δ;	 IP:	 prostaglandin	 I2	 receptor	 (PTGIR	 gene);	 DP-1/2	
prostaglandin	D2	receptor-1/2	(PTGDR1/2	genes);	TP:	thromboxane	receptor	(TBXA2R	gene).		
PGES=	prostaglandin	E2	synthase	(PTGES	gene);	PGFS:	prostaglandin	F2	synthase	(FAM213B	
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4.2.2. Inhibition of putative cyclooxygenase 3 
In	2002,	Simmons	and	colleagues	discovered	a	splice	variant	of	COX-1	(encoded	for	
by	the	PTGS1	gene),	where	the	first	 intron	is	retained	in	the	canine	cerebral	cortex	
[200].	 They	 termed	 it	COX-3,	determined	 that	 it	 possessed	 cyclooxygenase	activity	
and	 that	 some	 analgesic	 drugs	 including	 paracetamol,	 and	 the	 NSAID,	 ibuprofen	
preferentially	inhibited	COX-3	over	COX-1	or	COX-2	[200].		
The	 first	 intron	 of	 the	 canine	 PTGS1	 gene	 is	 90	 nucleotides	 long,	 therefore	 the	
resulting	mRNA	remains	in	frame	and	a	functional	COX	protein	would	result	[200].	In	
humans	and	 rodents	 the	 inclusion	of	 intron	1	would	 lead	 to	a	 frame	shift,	 causing	
premature	 termination	 and	 a	 truncated,	 inactive	 protein	 [201].	 Intron	 1-retained	
PTGS1	 transcripts	have	been	detected	 in	a	variety	of	human	 tissues.	This	primarily	
results	in	truncated	proteins,	however	single	base	deletions	can	prevent	premature	
termination	 from	 occurring	 and	 result	 in	 active	 proteins	 [202].	When	 cloned	 into	




4.2.3. Conversion of Paracetamol to N-arachidonoylphenolamine (AM404) 
Zygmunt	 Hogestatt	 and	 colleagues	 (2005),	 noted	 that	 there	 was	 a	 structural	
similarity	 between	 paracetamol	 and	 the	 metabolite	 N-arachidonoylphenolamine	
(AM404)	[203].	AM404	is	one	of	a	group	of	bioactive	N-acylamines	that	can	produce	





arachidonic	 acid	 to	 form	 AM404	 [203]	 (Figure	 4.2).	 Oral	 administration	 of	
paracetamol	 and	 microinjection	 of	 AM404	 produced	 comparable	 antinociception.	
The	 conversion	of	paracetamol	 to	AM404	 relies	on	 the	 fatty	 acid	 amide	hydrolase	
enzyme	(FAAH)	as	no	AM404	is	produced	in	FAAH-/-	mice	[203]. 
The	 analgesic	 effects	 of	 AM404	 can	 be	 attributed	 to	 two	 pathways:	 AM404	 can	




antagonists	 can	 be	 used	 to	 achieve	 analgesia	 and	 while	 paracetamol	 lacks	 TRPV1	


























In	 conclusion,	 the	 exact	 mechanism	 by	 which	 paracetamol	 produces	 analgesia	
remains	 unclear.	 	 The	most	widely	 discussed	 theory	 that	 paracetamol	 inhibits	 the	
COX-2	enzyme	has	some	convincing	results,	however	 inconsistencies	exist	between	
the	 spectrum	of	 action	of	paracetamol,	 known	COX-2	 inhibitors	 and	NSAIDs	 [205].	
The	 discovery	 of	 an	 active	 splice	 variant	 of	 PTGS1	 (COX-1)	 in	 canine	 brain	 was	
thought	 to	 overcome	 these	 discrepancies;	 yet	 this	 result	 was	 not	 reproduced	 in	




of	 paracetamol	 no	 mechanism	 proposed	 to	 date	 can	 definitively	 explain	 how	 it	
works.		
4.3. Paracetamol overdose  
In	 the	 UK	 and	 US,	 the	 most	 common	 cause	 of	 acute	 liver	 failure	 is	 paracetamol	
overdose	 [193].	 This	 tends	 to	 be	 caused	 by	 excessive	 self-medication	 and	 lack	 of	
awareness	 of	 the	 presence	 of	 paracetamol	 in	 common	 cold	 and	 flu	 medicines.	
Furthermore	toxicity	can	be	increased	by	chronic	alcohol	use	and	malnutrition	[192,	
193].	 A	 small	 portion	 of	 all	 paracetamol	 consumed	 is	 converted	 into	 N-Acetyl-p-
benzoquinone	 imine	 (NAPQI)	 by	 cytochrome	 p450	 (CYP450)	 [206].	 At	 therapeutic	
doses	 of	 paracetamol	 NAPQI	 is	 detoxified	 by	 irreversibly	 binding	 to	 reduced	
glutathione	 (GSH).	When	paracetamol	 is	 taken	 in	 excess,	NAPQI	 accumulates,	GSH	
depletes	 and	 NAPQI	 can	 covalently	 bind	 to	 cellular	 proteins	 [207].	 This	 leads	 to	




4.3)[193,	 207].	 The	 antidote	 to	 paracetamol	 overdose	 is	 treatment	 with	 N-




and	 damaged,	 necrotic	 hepatocytes	 and	 the	 cells	 from	 paracetamol	 treated	 rats	
show	 increased	necrosis	 [206,	 207,	 210].	 Paracetamol	overdose	 leads	 to	 increased	
phosphorylation	of	anti-apoptotic	proteins	Bcl	2	and	Bcl	xl,	induces	the	expression	of	
the	pro-apoptotic	protein	Bim	and	causes	translocation	of	pro-apoptotic	protein	Bax	
to	 the	mitochondria	 [206,	 207,	 210].	 After	 a	 toxic	 dose	 of	 paracetamol,	 sustained	
activation	 of	 JNK	 was	 observed	 and	 treatment	 with	 the	 JNK	 inhibitor	 SP600125	
provided	 protection	 against	 paracetamol	 overdose	 [206].	 This	 protection	 was	 not	
accompanied	 by	 a	 change	 in	 the	 extent	 of	 GSH	 depletion	 [206].	 Therefore,	 after	




















Figure 4.3. The mechanism of paracetamol overdose	
Left:	5%	of	all	paracetamol	consumed	is	converted	into	the	toxic	metabolite	NAPQI.	This	 is	
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4.4. Paracetamol and cancer  
The	long	term	or	frequent	use	of	the	NSAID,	aspirin,	is	associated	with	a	reduced	risk	
of	 cancer	 [211-213].	 	 Many	 studies	 have	 tried	 to	 expand	 upon	 this	 to	 determine	
whether	 a	 similar	 association	 exists	 for	 non-aspirin	 NSAIDs	 and	 paracetamol.	 The	
results	are	varied	between	different	cancer	types.	In	the	non-melanoma	skin	cancers	





4.4.1. Inhibition of the cyclooxygenase pathway 
The	COX-2/PGE2	pathway	is	associated	with	inflammation,	growth	and	survival	and	is	
thought	to	play	an	 important	role	 in	 the	 ‘inflammogenesis	of	cancer’	 [194].	COX-2,	
encoded	 by	 gene	 PTGS2,	 is	 overexpressed	 in	 many	 solid	 tumours,	 including	
colorectal,	 liver,	 pancreatic,	 breast,	 lung	 and	 head	 and	 neck	 [216].	 COX-2	 is	
overrepresented	in	both	premalignant	lesions	and	invasive	HNSCC	[216].		This	tends	
to	be	associated	with	elevated	levels	of	PTGS2	and	a	poor	prognosis.	In	healthy	cells	
the	 pro-inflammatory	 prostaglandin,	 PGE2,	 is	 balanced	 out	 by	 the	 other	
prostaglandins;	when	COX-2	expression	is	deregulated	the	balance	shifts	in	favour	of	
PGE2	leading	to	chronic	inflammation	and	cancer	[194].	The	COX-2/PGE2/EP	pathway	
is	 thought	 to	 be	 able	 to	 supress	 the	 activity	 of	 dendritic	 cells	 (DCs),	 natural	 killer	
(NK)-cells	 and	 T-cells,	 repressing	 type	 1	 immunity	 while	 promoting	 type	 2	 and	




overexpression	 was	 found	 to	 be	 associated	 with	 reduced	 response	 to	
immunotherapy	[196].	Accordingly	the	use	of	selective	COX-2	inhibitors,	and	NSAIDs,	
could	 significantly	 reduce	 the	 risk	 of	 cancer	 and	 have	 been	 shown	 to	 overcome	
tumour	immune	evasion	[196].		
4.4.2. High dose paracetamol as a cancer therapeutic 
Several	studies	have	examined	the	link	between	high	dose	paracetamol,	either	alone	
or	 in	 combination	 with	 other	 drugs,	 and	 cancer	 cell	 death.	 A	 phase	 1	 trial	 on	 19	
patients	 with	 advanced	 cancer	 examined	 the	 effect	 of	 high	 dose	 paracetamol	
treatment	with	NAC	rescue,	and	determined	a	partial	response	rate	of	15.8%	[209].	
In	neuroblastoma	cells,	 staurosporine	alone	can	 induce	apoptosis,	when	combined	
with	 high	 dose	 paracetamol	 staurosporine-induced	 cell	 death	 is	 increased	 [217].	
Furthermore	 combined	 treatment	 is	 accompanied	 by	 a	 reduction	 in	 GSH	 [217].	
Similarly,	 in	 ovarian	 cancer	 cells	 high	 dose	 paracetamol	 enhances	 the	 cytotoxic	











Figure 4.4. The tumour suppressive effects of paracetamol 
Left:	 In	 many	 cancers	 COX-2	 is	 overexpressed,	 leading	 to	 an	 increase	 in	 the	 pro-
inflammatory	prostaglandin	PGE2	 levels	 and	 contributing	 the	 ‘inflammogenesis	 of	 cancer’.	
Paracetamol	 has	 been	 proposed	 to	 inhibit	 COX-2,	 causing	 a	 reduction	 of	 PGE2	 levels.	
Middle:	 FAAH	 is	 thought	 to	 convert	paracetamol	 to	 the	metabolite	AM404.	This	 indirectly	
activates	 the	 cannabinoid	 receptor,	 CB1.	 Cannabinoids	 and	 similarly	 acting	 drugs	 are	
potential	cancer	therapeutics,	thought	to	induce	apoptosis	via	CB1.	Right:	A	small	amount	of	
all	paracetamol	is	converted	by	CYP450	into	the	metabolite	NAPQI;	this	is	usually	detoxified	
by	 GSH;	 however	 when	 paracetamol	 is	 taken	 in	 excess	 GSH	 levels	 deplete	 and	 NAPQI	
accumulates	leading	to	activation	of	the	apoptosis	and	necrosis	pathways	via	JNK.	High	dose	
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4.5. Aims and objectives 
The	 previous	 chapter	 has	 described	 a	 synergistic	 relationship	 between	 DAC	 and	
paracetamol	that	can	reduce	viability	in	HNSCC	cell	lines.	This	could	indicate	one	of	
two	 mechanistic	 possibilities:	 either	 DAC	 is	 altering	 the	 mechanism	 of	 action	 of	












4.6. DAC alters the COX pathway 
Paracetamol	is	understood	to	act	on	the	cyclooxygenase	pathway.	Therefore,	HNSCC	
cells	were	treated	with	a	titration	of	DAC	with	or	without	132.3µM	paracetamol	for	
96h	and	the	relative	RNA	 levels	of	 the	COX	enzymes	 (encoded	 for	by	genes	PTGS1	
and	 PTGS2)	 determined.	 PTGS1	 expression	 was	 not	 significantly	 changed	 by	 DAC	
and/or	 paracetamol	 treatment	 in	 all	 cell	 lines	 examined.	 A	 significant,	 dose-
dependent	increase	in	PTGS2	gene	expression	was	observed	after	DAC	treatment	in	
DAC-responsive	HNSCC	cell	 lines,	HN12	and	VU40T,	while	a	similar	pattern	was	not	
observed	 for	 the	 DAC-unresponsive	 cell	 lines,	 UDSCC2	 and	 SCC040	 (Figure	 4.5).	
Similarly	the	protein	levels	of	COX-2	were	increased	after	DAC	treatment	in	the	DAC	
responsive	 cell	 line,	 but	were	 in	 fact	minimally	 decreased	 in	 the	unresponsive	 cell	
line	(Figure	4.5).	Paracetamol	alone	caused	no	significant	change	to	COX-2	protein	or	
















cells	 the	 increased	 PGE2	 observed	 after	 DAC	 was	 reversed	 by	 the	 addition	 of	
paracetamol	or	valdecoxib,	back	to	the	level	of	untreated	cells	(Figure	4.6).			
PGE2	exhorts	 its	 effects	 through	 G-protein	 coupled	 receptors	 (EP-1-4,	 encoded	 by	
PTGER-1-4	genes)	[194].	DAC-responsive	cell	lines	showed	increased	RNA	expression	
of	 these	 receptors	 after	DAC	 treatment	 (Figure	4.7).	 For	VU40T	 cells,	 a	 significant,	
dose-dependent	 increase	in	PTGER1	was	observed	after	treatment	with	DAC;	while	
in	 HN12	 cells	 PTGER2	 RNA	 levels	 were	 significantly,	 and	 PTGER3	 insignificantly,	
upregulated	from	100nM	DAC	(Figure	4.7).	DAC-unresponsive	cell	lines,	UDSCC2	and	
SCC040,	did	not	show	increased	PTGER	expression.	
The	 results	 thus	 far	 suggested	 that	 the	 efficacy	 of	 combined	 treatment	 may	 be	
dependent	 upon	 upregulation	 of	 the	 COX-2/PGE2/EP	 pathway	 by	 DAC	 treatment	
(Figure	4.8).	 In	HNSCC,	increased	expression	of	COX-2	correlates	with	tumour	stage	





Meier	 plot	 shows	 a	 trend	 of	 lower	 survival	 for	 patients	 with	 alterations	 in	 these	
genes,	however	the	association	was	not	significant	(Figure	4.9)	[8,	222].			Therefore	
upregulation	 of	 this	 pathway	 may	 be	 a	 negative	 result	 of	 DAC	 treatment.	




PGE2	 levels	 after	 treatment	 with	 DAC	 and	 paracetamol	 (Figure	 4.6).	 To	 test	 this	
theory,	the	ability	of	other	COX	inhibitors	to	sensitize	HNSCCs	to	DAC	treatment	was	
examined	(Figure	4.10).	Ibuprofen	is	a	generic	COX	inhibitor.	Unlike	paracetamol,	the	
addition	 of	 ibuprofen	 at	 the	 Cmax	 concentration	 did	 not	 increase	 sensitivity	 to	
500nM	DAC	in	any	of	the	cell	lines	tested	(Figure	4.10).	Interestingly,	treatment	with	
ibuprofen	 increased	viability	 in	HNSCC	cells,	but	not	normal	oral	keratinocytes	and	













PCR	 analysis	 of	 PTGS1	 (COX-1)	 (A)	 and	 PTGS2	 (COX-2)	 (B)	 performed.	 C.	 Proteins	 were	
extracted	from	VU40T	and	SCC040	cells	and	immunoblotted	for	COX-2.	Additional	blots	are	
shown	 in	 Supplementary	 data	 6.	 A-C:	 DAC-responsive	 cell	 lines	 are	 shown	 in	 red,	 while	
unresponsive	cell	 lines	are	displayed	 in	grey.	Results	display	COX-2	normalised	against	 the	


















































































































































Figure 4.6. DAC increases the levels of PGE2 in DAC-responsive VU40T cells 


























































Figure 4.7. DAC increases the expression of the PGE2 receptors 
HNSCC	cells	were	treated	with	a	titration	of	DAC	+/-	132.3µM	paracetamol	for	96h	following	
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Figure 4.8. DAC treatment alters the cyclooxygenase pathway	


















Figure 4.9. Alterations in the COX-2/PGE2 pathway in HNSCC 
The	 cBioPortal	 online	 software	 was	 used	 to	 visualise	 genetic	 alterations	 in	 the	
PTGS/PTGES/PTGER	pathway	in	504	HNSCC	samples	analysed	by	the	cancer	genome	atlas	[8,	
222].	 A.	 Alterations	 in	 PTGS-1-2/PTGES-2/PTGER-1-4	 occur	 in	 15%	 of	 HNSCC	 cases	 (only	
altered	cases	are	shown	=	76/	504	cases).	Deep	deletion	 indicates	a	deep	genetic	 loss,	 for	
example	 a	 homozygous	 deletion	 B.	 Specific	 comparison	 of	 HNSCC	 cases	with	 COX-2/PGE2	
pathway	 alterations.	 The	 level	 of	 alcohol	 consumption	 and	 smoking	 consumption;	 HPV	
status;	 tumour	 T	 stage;	 and	 overall	 survival	 time	 are	 shown	 above	 genetic	 alterations	 in	
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Figure 4.10. Other COX inhibitors do not sensitise HNSCC cell lines to DAC 
treatment 
A.	Four	HNSCC	cell	 lines	and	primary	human	oral	keratinocytes	 (HOK)	were	subject	 to	96h	
treatment	with	193.9µM	 ibuprofen	 (Ibup)	or	 132.3µM	paracetamol	 (Para)	 +/-	 500nM	DAC	
following	which	 viability	was	 determined.	 B.	 DAC	 responsive	HNSCC	 cell	 lines,	 VU40T	 and	
HN12,	were	subject	to	96h	treatment	with	a	titration	of	Valdecoxib	+/-	500nM	DAC	following	
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4.7. Genes involved in the conversion of paracetamol to AM404 
are not expressed in HNSCC cells 
In	 recent	 years	 an	 alternate	mechanism,	 involving	 the	 conversion	 of	 paracetamol	
into	the	metabolite	AM404	by	the	enzyme	FAAH	and	subsequent	activation	of	TRPV1	
and	CB1,	 has	 been	proposed	 to	 explain	 the	 analgesic	 effects	 of	 paracetamol	 [192,	
203,	204]	(Figure	4.11A).	RNA	sequencing	of	the	HNSCC	cell	line	showed	little	to	no	
expression	of	these	three	factors,	suggesting	that	this	is	not	a	mechanism	employed	
in	 HNSCC	 cells	 (Figure	 4.11B).	 Furthermore,	while	 FAAH	 and	TRPV1	RNA	 could	 be	









Figure 4.11. Enzymes involved in the conversion of paracetamol into AM404 are 
not altered by DAC treatment in VU40T cells 
A.	Schematic	showing	the	potential	conversion	of	paracetamol	into	the	metabolite	AM404.	
The	FAAH	enzyme	is	responsible	for	converting	paracetamol	into	AM404,	which	leads	to	the	
activation	 of	 TRPV1	 and	 CB1	 and	may	 trigger	 apoptosis.	B.	 RNA	 sequencing	 of	 untreated	




Gene UDSCC2 HN12 SCC040 VU40T 
FAAH 0.084051 0.02141 0.716468 1.154727 
TRPV1 1.4E-05 0.007576 0 0 
















































































































4.8. Combined treatment with DAC and paracetamol may 
mimic paracetamol overdose 
The	potential	use	of	paracetamol	 in	the	treatment	of	established	cancers	has	been	
previously	discussed	 [208,	217,	218].	These	papers	use	 relatively	high	doses	of	 the	
drug	and	rely	on	the	toxic	effects	of	its	metabolite,	NAPQI,	to	induce	cell	death	[208,	
217,	 218].	 In	 contrast,	 the	 current	 project	 has	 described	 clinically	 relevant	
concentrations	of	the	drug;	10-20	times	lower	than	those	previously	described	[208,	
217,	218].	The	CYP450	enzyme,	CYP2E1,	is	understood	to	be	primarily	responsible	for	
the	 conversion	 of	 paracetamol	 into	 NAPQI	 [223].	 Interestingly,	 in	 DAC-responsive,	
VU40T	 cells,	 the	 RNA	 levels	 of	 CYP2E1	 were	 significantly	 and	 dose-dependently	
increased	by	DAC	treatment,	while	unresponsive	cell	lines	showed	no	change	(Figure	
4.12).	This	was	unaltered	by	the	addition	of	paracetamol	(Figure	4.12).	The	protein	




into	 NAPQI	 and	 mimic	 the	 effects	 of	 paracetamol	 overdose	 at	 clinically	 relevant	
concentrations.	Due	 to	 the	highly	 reactive	and	 transient	nature	of	NAPQI	 it	 is	very	
difficult	 to	 measure	 in	 whole	 cell	 systems	 [224,	 225].	 Instead,	 in	 DAC-responsive	
VU40T	cells,	 the	 level	of	glutathione	 (GSH)	was	used	as	a	measure	of	paracetamol	
toxicity	(Figure	4.13).	1mM	of	paracetamol	was	used	as	a	control	and,	as	expected,	





to	 the	 concentration	 of	 GSH	 (Figure	 4.13).	 However,	 when	 the	 two	 drugs	 were	
combined,	 a	 significant	 reduction	 in	 GSH	 was	 observed,	 to	 even	 lower	 than	 that	
detected	 after	 high	 dose	 (1mM)	 paracetamol	 treatment	 (Figure	 4.13).	 These	 data	
support	the	theory	that	DAC	is	increasing	the	conversion	of	paracetamol	into	NAPQI	
and	thereby	mimicking	the	effects	of	paracetamol	overdose	(Figure	4.14).	 
Disulfiram	 (DSF)	 is	 a	 CYP450	 inhibitor,	 known	 to	 inhibit	 CYP2E1.	 VU40T	 cells	were	
treated	with	500nM	DAC	and	132.3μM	paracetamol	for	96h	plus	5,	10	or	50nM	DSF	
for	 the	 final	 24h	or	48h	of	 treatment	 (Figure	4.15).	None	of	 the	 concentrations	of	
DSF	tested	were	able	to	rescue	VU40T	cells	from	the	reduced	viability	caused	by	DAC	











to	 determine	 the	 relative	 RNA	 levels	 of	 CYP2E1.	 B.	 Proteins	 extracted	 from	 VU40T	 and	
SCC040	 cells	 were	 immunoblotted	 for	 CYP2E1.	 Representative	 blots	 from	 3	 independent	
experiments	 for	 CYP2E1	 and	 lamin	 A/C	 control	 are	 shown	 with	 all	 blots	 shown	 in	
Supplementary	data	 6.	Graph	 shows	 the	mean	 intensity	 of	 the	CYP2E1	bar	 relative	 to	 the	
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Figure 4.13. Combined treatment with DAC and paracetamol reduces GSH levels. 
VU40T	 cells	 were	 treated	 with	 132.3µM	 paracetamol	 +/-	 500nM	 DAC	 for	 96h	 following	
which	 glutathione	 (GSH)	 levels	were	 determined	using	 the	GSH-glo	 kit.	 1mM	paracetamol	

































Figure 4.14. Combined treatment with DAC and paracetamol may be mimicking 
the effects of paracetamol overdose 
Schematic	representing	the	paracetamol	overdose	pathway	and	the	potential	mechanism	by	
which	 DAC	 may	 be	 mimicking	 it.	 Left.	 A	 small	 amount	 of	 all	 paracetamol	 consumed	 is	
converted	 into	 the	 toxic	metabolite	 NAPQI	 by	 CYP450	 enzymes,	 primarily	 CYP2E1.	 This	 is	
usually	detoxified	by	binding	to	GSH	[226].	Middle.	When	paracetamol	is	taken	in	excess	the	
GSH	levels	deplete,	NAPQI	accumulates,	binds	to	cellular	proteins	and	promotes	decreased	
ATP	 production,	mitochondrial	 dysfunction	 and	 cell	 death	 [206].	Right.	 DAC	 increases	 the	
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Figure 4.15. Disulfiram does not rescue VU40T cells from combined treatment 
with DAC and paracetamol 
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number	of	 cells	with	 γH2AX	 foci,	with	 significantly	more	 cells	 found	 to	have	10	or	
more	foci	(Figure	4.16).	Paracetamol	did	not	increase	the	number	of	γH2AX	foci	and	
the	 addition	 of	 paracetamol	 to	 DAC	 treatment	 also	 did	 not	 cause	 any	 significant	
increase	(Figure	4.16).		
DAC	causes	a	reduction	 in	DNA	methylation	 in	DAC-responsive	VU40T	cells	but	not	
DAC-unresponsive	 SCC040	 cells	 (Figure	 4.17).	 Interestingly,	 paracetamol	 treatment	
causes	a	relatively	small,	but	significant,	drop	in	DNA	methylation	in	VU40T,	but	not	
SCC040	 cells	 (Figure	 4.17,	 Supplementary	 data	 9).	 This	 can	 be	 attributed	 to	 a	
corresponding	 decrease	 in	 the	 RNA	 expression	 of	DNMT-1,	 -3A	and	 -3B	 in	 VU40T,	
but	not	SCC040	cells	 (Figure	4.18).	For	DNMT1	 this	was	maintained,	and	 increased	
slightly	 by	 the	 addition	 of	 DAC	 to	 the	 treatment	 (Figure	 4.18).	 Interestingly,	
treatment	with	the	specific	COX-2	 inhibitor	valdecoxib	did	not	give	the	same	result	










Figure 4.16. Paracetamol does not increase DAC-induced DNA damage 
VU40T	 cells	 were	 grown	 on	 coverslips	 and	 treated	 with	 500nM	 DAC	 +/-	 132.3µM	
paracetamol	 for	 96hrs.	 Cells	 were	 fixed	 in	 methanol	 and	 immunofluorescent	 staining	 for	
γH2AX	performed.	 For	 each	 biological	 replicate	 100	 cells	were	 counted.	 Results	 are	mean	
+SEM	 (n=3)	 and	 are	 shown	 as	 a	 percentage	 of	 total	 cells	 counted.	 Significance	 was	
determined	 using	 a	 paired	 t-test	with	 Bonferroni	 correction	 against	 the	 untreated	 control	
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Figure 4.17. Paracetamol decreases DNA methylation	
VU40T	and	SCC040	 cells	were	 treated	with	500nM	DAC	+/-	 132.3µM	paracetamol	 for	 96h	
following	 which	 DNA	 was	 extracted	 and	 immunoblotting	 for	 5mC	 performed.	 Blots	 were	
incubated	 in	 methylene	 blue	 to	 stain	 for	 total	 DNA.	 The	 graph	 shows	 the	 5mC	 blot	
normalised	against	the	corresponding	methylene	blue	dot	and	shown	relative	to	the	vehicle	
control.	 Results	 are	mean	 (n=3)	 +	 SEM.	 Significance	was	 determined	 using	 a	 paired	 t-test	
where	 *p<0.05.	 Representative	 blots	 are	 shown	 below	 and	 additional	 blots	 shown	 in	
Supplementary	data	7.		
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Figure 4.18. Paracetamol reduces DNMT gene expression	
VU40T	and	SCC040	 cells	were	 treated	with	500nM	DAC	+/-	 132.3µM	paracetamol	 for	 96h	
following	which	RNA	was	extracted	and	qRT-PCR	performed	for	DNMT1,	-3A	and	-3B.	Results	































































































Figure 4.19. Valdecoxib does not alter the levels of DNA methylation 
VU40T	 cells	 were	 treated	 with	 500nM	 DAC	 +/-	 10mM	 valdecoxib	 (vald)	 or	 132.3µM	
paracetamol	(para)	for	96h.	A.	DNA	was	extracted	and	immunoblotting	for	5mC	performed.	
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4.10. Discussion and conclusion 
The	 aim	 of	 this	 chapter	 was	 to	 determine	 whether	 the	 synergistic	 relationship	
between	 DAC	 and	 paracetamol	 could	 be	 attributed	 to	 paracetamol	 altering	 the	
mechanism	 of	 action	 of	 DAC	 or	 DAC	 altering	 the	 mechanism	 of	 action	 of	
paracetamol.	 Interestingly,	 both	 outcomes	were	 found	 to	 be	 true,	 suggesting	 that	
the	 reduction	 in	viability	described	 is	brought	upon	by	a	combinatorial	effect	 from	
the	disruption	of	several	pathways.		
The	 most	 commonly	 held	 theory	 on	 the	 mechanism	 of	 action	 of	 paracetamol	
involves	 inhibition	 of	 the	 COX	 pathway,	 primarily	 through	 COX-2	 [191,	 195].	
However,	some	authors	contend	that	paracetamol	inhibits	a	splice	variant	of	COX-1,	
referred	to	as	COX-3	[200].	In	the	system	described	here,	this	possibility	is	unlikely	as	
the	 isoform	 is	 found	primarily	 in	 canine	cells,	 and	as	expected,	was	not	present	 in	
the	 HNSCC	 cell	 lines	 used	 [201].	 Instead,	 DAC	 treatment	 resulted	 in	 a	 significant	
increase	 in	 COX-2	 expression	 only	 in	 DAC-responsive	 cell	 lines.	 This	 was	
accompanied	 by	 an	 increase	 in	 the	 downstream	 product,	 PGE2.	 This	 pathway	 is	
understood	 to	 play	 a	 pivotal	 role	 in	 the	 ‘inflammogenesis	 of	 cancer’	 with	 COX-2	
inhibitors	already	being	considered	as	HNSCC	therapeutics	[194,	219-221].	Therefore	
the	 increase	 in	 this	 pathway	 by	 DAC	 treatment	 should	 be	 pro-tumourigenic.	 DAC	
demethylates	 DNA	 in	 an	 indiscriminate	 and	 global	 manner	 and	 hence	 it	 is	
unsurprising	that	some	cancer-promoting	pathways	are	also	activated	by	treatment.	
However,	 the	 efficacy	 of	 the	 drug	 demonstrates	 that	 the	 balance	 between	 the	
activation	of	cancer	promoting	genes	and	the	activation	of	tumour	suppressor	genes	





reactivation	 of	 silenced	 tumour	 suppressor	 genes.	 The	 addition	 of	 paracetamol	 to	
the	 treatment	 may	 then	 remove	 the	 cancer-promoting	 effects	 of	 COX-2	 pathway	
promotion	by	 reducing	production	of	PGE2	and	hence,	as	described,	an	 increase	 in	
cancer	 inhibition	 will	 be	 observed.	 Recently,	 the	 efficacy	 of	 DAC	 in	 cancer	
therapeutics	 has	 been	 attributed	 to	 an	 indirect	 activation	 of	 the	 interferon	 (IFN)	
pathway	[158,	180].	This	could	account	for	the	increased	COX-2	expression	observed	
as	 interferon	 treatment	 has	 been	 shown	 to	 increase	 COX-2	 expression.	 Indeed,	 a	
COX-2	 inhibitor	 was	 shown	 to	 work	 in	 synergy	 with	 IFN-β	 to	 induce	 apoptosis	 in	
human	 hepatoma	 cell	 lines	 and	 mouse	 models	 [227].	 However,	 this	 cannot	 fully	
account	for	the	synergistic	relationship	between	DAC	and	paracetamol	as	neither	the	
COX-2	 specific	 inhibitor	 valdecoxib,	 nor	 the	 COX-generic	 inhibitor	 ibuprofen	 were	
able	to	produce	the	same	result.		
Several	 studies	 have	 described	 the	 potential	 benefits	 of	 high	 dose	 paracetamol	
treatment	 in	 cancer,	 either	 alone,	 or	 in	 combination	 with	 common	
chemotherapeutics	[208,	209,	217,	218].	The	toxicity	of	paracetamol	at	this	dose	is	
dependent	 upon	 the	 conversion	 of	 paracetamol	 into	 the	 toxic	 metabolite	 NAPQI	
[206].	While	NAPQI	is	usually	detoxified	by	glutathione	(GSH),	when	paracetamol	is	
taken	 in	 excess	 GSH	 is	 depleted	 allowing	NAPQI	 to	 accumulate	 and	 bind	 to	 other	
cellular	proteins.	This	can	include	covalent	binding	to	mitochondrial	proteins	leading	
to	 decreased	 production	 of	 ATP	 and	 eventual	 cell	 death	 [193,	 207,	 228].	 In	 the	





understood	 to	 be	 primarily	 responsible	 for	 the	 conversion	 of	 paracetamol	 into	
NAPQI.	 This	 combination	 results	 in	 a	 depletion	of	GSH	greater	 than	 that	 observed	
from	 high	 dose	 paracetamol,	 suggesting	 that	 combined	 treatment	 with	 DAC	 and	
paracetamol	may	be	mimicking	 the	effects	of	paracetamol	overdose.	 Interestingly,	
treatment	with	 the	CYP2E1	 inhibitor,	DSF	 could	not	 rescue	DAC-responsive	HNSCC	
cells	 from	combined	 treatment,	 again	 suggesting	 that	 this	mechanism	 cannot	 fully	
account	 for	 the	 synergistic	 relationship	between	DAC	and	paracetamol.	 This	 result	





of	 the	 COX	 pathway,	 as	 the	 COX-2	 inhibitor	 valdecoxib	 was	 unable	 to	 alter	 5mC	
levels.	Unlike	paracetamol,	valdecoxib	does	not	have	a	synergistic	relationship	with	




in	 G1/G0,	 and	 a	 corresponding	 decreased	 in	 5mC	 is	 observed	 [229].	 This	 could	
partially	account	for	the	reduction	in	5mC	described	here	[229].	
Examination	 of	 the	 putative	 pathways	 that	 could	 contribute	 to	 the	 synergistic	





pathway;	 combined	 treatment	 mimics	 the	 effects	 of	 paracetamol	 overdose;	 and	
paracetamol	can	decrease	DNA	methylation	(Figure	4.20).	Comparable	experiments	
using	 other	 COX	 inhibitors	 were	 not	 successful;	 neither	 was	 rescue	 experiments	
using	an	inhibitor	of	CYP450	enzymes.	This	suggests	that	no	individual	pathway	can	










Figure 4.20. DAC and paracetamol work in synergy to reduce viability in HNSCC 
cells	
Schematic	representing	the	potential	mechanisms	utilised	by	combined	treatment	with	DAC	
and	 paracetamol	 to	 reduce	 viability	 in	 HNSCC	 cells.	 Left.	 DAC	 demethylates	 DNA	 by	
inhibiting	DNMT	 enzymes.	 In	DAC	 responsive	 cells	 paracetamol	 reduces	 the	 expression	 of	
DNMTs	 leading	 to	 reduced	 DNA	 methylation.	Middle.	 Arachidonic	 acid	 is	 converted	 into	




converted	 into	 the	 toxic	 metabolite	 NAPQI	 by	 CYP2E1.	 This	 is	 usually	 detoxified	 by	
glutathione,	 however	 if	 high	 dose	 paracetamol	 is	 present,	 GSH	 depletes	 and	 NAPQI	
accumulates	 leading	 to	 decreased	 ATP	 production	 and	 cell	 death.	 DAC	 increases	 the	




Reactivation of  silence tumour 
suppressor genes 
Decreased ATP production and  
cell death  
















Chapter 5. HNSCC is 
characterised by global changes in 






changes	 in	 HNSCC	 in	 response	 to	 DAC	 treatment.	 However,	 this	 chapter	 will	 first	




5.1 Methods of determining the distribution of 5mC  
The	 ‘gold	 standard’	 of	 5mC	 sequencing	 is	 bisulfite	 sequencing	 (BS-seq).	 In	 this	
technique,	DNA	 is	 treated	with	sodium	bisulfite	to	convert	unmethylated	cytosines	
into	 uracil,	while	methylated	 cytosines	 are	 protected.	 Subsequent	 sequencing	 and	
comparison	 of	 the	 bisulfite-converted	 sample	 with	 the	 reference	 genome	 can	




drawback	to	this	 technique	 is	 the	sequencing	depth	required	[230].	The	associated	
costs	have	lead	to	the	development	of	enrichment-based	techniques	[230].	Reduced	
representation	bisulfite	sequencing	 (RRBS)	utilises	 restriction	enzymes	to	select	 for	
CpG-rich	 regions	 of	 the	 genome	 prior	 to	 BS-seq	 [232].	 This	 provides	 base	 pair	
resolution	 of	 5mC	 but	 leaves	 CpG-poor	 regions	 uncharacterised	 [230].	 Other	
enrichment	based	techniques	do	not	provide	base	pair	resolution;	instead	the	DNA	is	
sheared	and	fragments	containing	5mC	selected	and	sequenced,	this	is	compared	to	
the	background	or	 input	DNA	sequence	and	results	 in	‘peaks’	 in	the	DNA	sequence	
where	 5mC	 is	 enriched.	 Methylation	 restriction	 enzyme	 sequencing	 (MRE-seq)	
utilises	methylation-sensitive	 restriction	enzymes	 to	 select	 for	5mC	 sites;	MBD-seq	
uses	 the	 methyl	 binding	 domain	 of	 MeCP2	 to	 capture	 5mC;	 methylated	 DNA	
immunoprecipitation	 (MeDIP)	 uses	 an	 antibody	 against	 5mC	 to	 specifically	
immunoprecipitate	 5mC-	 containing	 fragments	 of	 DNA	 [168,	 230].	 Of	 the	 5mC-	
enrichment	 methods	 currently	 available	 MeDIP	 provides	 the	 best	 coverage	 of	
repetitive	elements	over	other	5mC	sequencing	methods	and	allows	small	quantities	
of	input	DNA	to	be	used	[230].	
5.2 Methods of determining the distribution of 5hmC 
The	 discovery	 of	 oxidised	 derivatives	 of	 5mC	 brought	 technical	 challenges	 in	
determining	 the	 genomic	 distribution	 of	 these	 bases.	Many	 single	 base	 resolution	
5mC	 detection	 techniques	 are	 unable	 to	 distinguish	 between	 5mC	 and	 5hmC:	






Therefore,	many	 of	 the	 previously	 published	 reports	 of	 5mC	 distribution	 at	 single	
base	resolution	will	represent	5hmC	and	5mC	combined	[233].	Furthermore,	due	to	
the	 relatively	 low	 abundance	 of	 these	 bases	 in	 the	 genome,	 sensitive	 detection	
techniques	are	required.		
Two	 methods	 have	 been	 proposed	 to	 overcome	 the	 limitations	 of	 conventional	
bisulfite	 sequencing:	 TET-assisted	 BS-seq	 (TAB-seq)	 and	 oxidative	 bisulfite	





the	 genome	 by	 directly	 (hMeDIP)	 or	 indirectly	 (Anti-CMS,	 JBP-1,	 GLIM,	 hMe-Seal)	
enriching	 for	 5hmC-marked	 DNA	 [236,	 237]	 (see	 Figure	 5.2).	 Hydroxymethylated	
DNA	 immunoprecipitation	 (hMeDIP)	 involves	 the	direct	 enrichment	 of	 5hmC	using	
an	antibody	against	the	modified	base	[237].	The	main	benefit	of	this	technique	over	
other	5hmC	enrichment	methods	is	its	simplicity;	the	DNA	is	not	damaged	or	lost	in	
chemical	 reactions	 and	 there	 are	 fewer	 variables	 that	 may	 differ	 between	
experiments	 [236].	 Indeed,	 a	 comparison	 of	 hMeDIP	 with	 oxBS-seq	 found	 a	 good	









Figure 5.1. Determining 5hmC at base pair resolution 
Conventional	BS-seq	cannot	determine	the	difference	between	5mC	and	5hmC	or	5fC,	5caC	
and	 unmodified	 C.	 TAB-seq	 involves	 tagging	 5hmC	 with	 a	 glucose	 molecule	 using	 β-
glucosyltransferase	(βGT),	followed	by	conversion	of	5mC	and	5fC	into	5caC	by	recombinant	
TET1.	 After	 BS-seq	 5hmC	 is	 recognised	 as	 C	while	 all	 other	 cytosines	 are	 recognised	 as	 T.	
Oxidative	 bisulfite	 conversion	 (oxBS-seq)	 involves	 the	 conversion	 of	 5hmC	 into	 5fC	 by	
potassium	 perruthenate.	 This	 is	 then	 bisulfite	 converted	 and	 read	 as	 C,	 while	 5mC	 is	
detected	as	T.	After	sequencing	the	results	of	BS	converted	DNA	are	compared	with	oxBS	or	
TAB	converted	DNA.	The	bottom	panels	shows	what	the	results	from	sequencing	converted	
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Figure 5.2. Genome wide affinity-based methods for 5hmC profiling 
In	 hMeDIP,	 an	 anti-5hmC	 antibody	 is	 used	 to	 immunoprecipitate	 DNA	 containing	 5hmC.	
Anti-CMS	 involves	 first	 sodium	 bisulfite	 converting	 5hmC	 into	 cytosine	 5-
methylenesulfonate	 (CMS)	 and	 then	 using	 an	 antibody	 against	 CMS	 to	 enrich	 for	 5hmC-
marked	DNA.	The	JBP-1	technique	involves	first	conjugating	a	glucose	molecule	onto	5hmC	
using	 the	 T4	 bacteriophage	 enzyme	 β-glucosyltransferase	 (βGT).	 The	 J-binding	 protein	 1	
(JBP-1)	can	 then	be	used	 to	enrich	 for	5gmC-marked	DNA.	The	GLIB	 technique	utilises	 the	
same	 first	 step,	however	 this	 is	 followed	by	 treatment	with	 sodium	periodate	 to	generate	
reactive	 aldehyde	 groups,	 which	 can	 be	 biotinylated	 using	 an	 aldehyde-reactive	
hydroxylamine-biotin.	 The	 biotin-conjugated	 modified	 5hmC	 can	 be	 pulled	 down	 with	
streptavidin	 beads.	 hMe-Seal	 entails	 the	 addition	 of	 an	 azide-glucose	 molecule	 to	 5hmC	
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5.3 Potential regulatory functions of Alu elements  
In	 humans	 the	majority	 of	 repetitive	DNA	 is	made	 up	 of	 LINE-1	 and	Alu	 elements	




AT-rich	 DNA	 [79,	 111].	 Interesting,	 when	 comparing	 the	 distribution	 of	 Alu	
subfamilies,	 it	 was	 determined	 that	 younger	 Alu	 elements	 were	 more	 frequently	
found	 in	AT-rich	DNA,	while	older	Alu	elements	were	enriched	 in	DNA	with	a	high	
CG%	[79].	CG-rich	DNA	accumulates	around	genes	and	regulatory	 regions	 [79].	Alu	
elements	 are	 disproportionately	 found	 in	 intragenic	 regions,	 particularly	 introns,	
with	 at	 least	 three	 quarters	 of	 human	 genes	 thought	 to	 be	 associated	 with	 Alu	
elements	 [81,	 83,	 238].	 Therefore	 the	 presence	 of	 Alu	 elements	within	 genes	 and	
regulatory	regions	has	been	selected	for	throughout	evolution,	suggesting	that	they	
may	have	a	regulatory	role	[79].	
5.3.1. Genomic Alu elements 
Alu	elements	resemble	enhancers;	they	are	enriched	in	CpGs	and	contain	numerous	
transcription	 factor	 binding	 sites	 [84,	 238].	 The	 similarity	 of	 Alu	 elements	 to	
enhancers	increases	with	evolutionary	age	from	the	young,	AluYa5,	to	the	old,	AluJo,	
with	 many	 middle-aged	 Alu	 elements	 appearing	 as	 proto-enhancers	 [66].	 This	
corresponds	with	an	 increasing	enrichment	of	active	histone	marks	and	suggests	a	






5.3.2. Embedded Alu RNA 
RNA	Pol	II	inadvertently	transcribes	the	majority	of	Alu	elements	with	an	average	of	
10	embedded	Alu	elements	per	pre-mRNA	molecule	[84,	240].	Inverted	Alu	repeats	







5.3.3. Free Alu RNA 
The	 transcription	of	 independent	Alu	elements	by	RNA	Pol	 III	 can	be	 induced	by	a	
variety	of	stresses	such	as	heat	shock,	toxins	or	viruses	[242].	These	transcripts	are	
mainly	 Alu	 S	 and	 Alu	 J	 and	 do	 not	 encode	 the	 sequences	 required	 for	 their	 own	












Figure 5.3. The potential functions of Alu elements 
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5.4 Aims and Objectives 
HNSCC	 is	 characterised	 by	 genome	 wide	 changes	 in	 the	 distribution	 of	 DNA	
methylation	 and	 hydroxymethylation	 [55,	 110,	 246].	 Methylation	 is	 gained	 at	
promoters	 and	 CpG	 islands,	 and	 lost	 genome	 wide	 and	 over	 repetitive	 DNA	 [11].	
However,	less	is	known	about	5hmC	alterations	in	HNSCC.	In	this	chapter,	MeDIP	and	
hMeDIP	 sequencing	will	 be	used	 to	 compare	 the	genomic	distribution	of	5mC	and	
5hmC	 in	normal	oral	keratinocytes	 (HOK)	with	an	HNSCC	cell	 line.	The	analysis	will	





5.5 Methylated and hydroxymethylated DNA 
immunoprecipitation (MeDIP and hMeDIP) and 
sequencing 
The	MeDIP	and	hMeDIP	methods	were	used	 to	determine	 the	distribution	of	5mC	
and	 5hmC	 in	 normal	 human	 oral	 keratinocytes	 (HOK)	 and	 the	 HNSCC	 cell	 line,	
VU40T.	 For	VU40T	 cells,	 experiments	were	 performed	 and	 sequenced	 in	 duplicate	
for	 MeDIP,	 and	 triplicate	 for	 hMeDIP	 and	 the	 efficacy	 of	 each	 experiment	
determined	by	qRT-PCR	prior	to	library	preparation	(Supplementary	data	8).	For	HOK	
cells	 the	 (h)MeDIP	 experiments	 were	 performed	 in	 triplicate	 and	 pooled	 prior	 to	
sequencing.	Regions	enriched	for	5mC	or	5hmC	(peaks)	were	identified	for	each	cell	
type	 and	 treatment	 using	 Homer	 and	MACS	 for	 hMeDIP	 and	MeDIP,	 respectively	
(Table	5.1).	Alignment	and	peak	calling	of	MeDIP	and	hMeDIP	data	can	be	attributed	
to	 Dr	 W.	 Croft	 and	 Dr	 S.	 Clokie	 respectively.	 Only	 uniquely	 mapped	 reads	 were	
considered	 for	all	 (h)MeDIP	data.	 For	VU40T	cells	where	 the	 replicates	were	used,	
the	 peak	 should	 be	 present	 in	 at	 least	 one	 of	 the	 repeats	 to	 be	 included.	 The	
antibody	will	only	specifically	recognise	5(h)mC	in	the	context	of	CpG	dinucleotides;	
therefore,	any	peaks	without	CpGs	were	removed	and	only	the	retained	peaks	were	





















HOK	 VU40T	 HOK	 VU40T	
Total	Peaks	 547344	 512502	 26678	 41562	
CpG	=0	 1839	 1822	 2358	 10481	
No.	Peaks	retained	 545505	 510680	 24320	 31081	






5.6 DNA hydroxymethylation is found in closer proximity 
to transcription start sites (TSS) and associated with a 





of	 5hmC	 peaks	 and	 exons	 represented	 less	 than	 1%	 of	 both	 (Figure	 5.4).	 In	 this	
regard,	 the	distribution	of	5mC	and	5hmC	is	very	similar.	However,	5hmC-enriched	




exempt	 from	the	TSS	and	 the	centre	of	 transcription	 factor	binding	sites	and	were	
found	at	high	 levels	 surrounding	TFBS’	 (Figure	5.6).	 Similarly,	 both	5mC	and	5hmC	












Figure 5.4. The genomic location of 5mC and 5hmC-enriched regions 
MeDIP	 and	 hMeDIP	 sequencing	 peaks	 were	 assigned	 annotations.	 MeDIP	 peaks	 were	
identified	and	assigned	using	MACS	by	Dr	W.	Croft,	while	hMeDIP	peaks	were	identified	and	
assigned	 using	 Homer	 by	 Dr	 S.	 Clokie.The	 genomic	 location	 of	 5mC	 and	 5hmC-enriched	
regions	is	shown	as	A.	a	pie	chart	and	B.	a	table.		
  












No. Peaks % Peaks No. Peaks % Peaks 
3' UTR 2732 0.50 100 0.41 
5' UTR 163 0.03 7 0.03 
Exon 1543 0.28 12 0.05 
Intergenic 242606 44.47 10381 42.69 
Intron 282498 51.79 13011 53.51 
NA 921 0.17 55 0.23 
non coding 1328 0.24 31 0.13 
Promoter-TSS 6071 1.11 382 1.57 








Figure 5.5. Differential characteristics of 5mC and 5hmC-enriched regions 
Using	 the	 peaks	 defined	 for	 each	 MeDIP	 and	 hMeDIP	 sequencing	 samples	 the	 mean	





Figure 5.6. Relationship between 5mC and 5hmC and transcription start sites and 
transcription factor binding sites 
The	 results	 of	 the	MeDIP	 and	 hMeDIP	 sequencing	 experiments	 were	 aligned	 to	 all	 UCSC	
genes	(A.)	and	transcription	factor	binding	sites	determined	by	the	ENCODE	consortium	(B.)	
[247].	 The	 computeMatrix	 and	 PlotProfile	 tools	 (Galaxy	 Versions	 2.5.0.0)	 were	 used	 to	


















































Figure 5.7. 5mC and 5hmC are underrepresented at CpG islands but enriched in 
CpG island shores 
CpG	islands	(CGI)	were	downloaded	from	USCS	table	browser.	 	Using	BedTools	package	on	
galaxy	 CGI	 shores	 were	 generated	 by	 using	 the	 ‘Slop’	 function	 to	 extend	 CGIs	 by	 +/-	 2kb	
followed	 by	 the	 ‘Subtract’	 tool	 to	 remove	 the	 CGI	 from	 the	 centre	 of	 these	 regions.	 The	
‘intersect	 intervals’	 function	 was	 the	 used	 to	 determine	 the	 proportion	 of	 5mC/	 5hmC-
enriched	 regions	 (peaks)	 that	 overlapped	 (more	 than	 80%	 of	 peak)	 with	 the	 CGI	 or	 CGI	
shores	 [175].	 BEDTools	 ‘RandomBed’	 was	 used	 to	 create	 a	 random	 group	 of	 genomic	
intervals	 comparable	 with	 each	 5(h)mC	 group.	 This	 was	 used	 to	 generate	 the	 expected	




























5.7 5hmC-enriched regions are associated with enhancers 




using	 a	 multivariate	 Hidden	 Markov	 Model	 (HMM)	 to	 model	 combinatorial	
chromatin	 patterns	 [172].	 These	 can	be	 combined	 into	 6	main	 groups:	 promoters,	
enhancers,	 insulators,	 transcribed	 regions,	 repressed	 regions	 and	 inactive	 regions	
[172].	 Both	 5mC	 and	 5hmC	 were	 enriched	 in	 transcribed	 regions	 and	
















Figure 5.8. Chromatin domains associated with 5mC and 5hmC-enriched regions 
Chromatin	domains	were	downloaded	from	USCS	table	browser	[172].		Using	the	BEDTools	
package	on	Galaxy	the	‘intersect	intervals’	function	was	used	to	determine	the	proportion	of	



























5.8 Regions enriched in DNA methylation and 
hydroxymethylation were primarily found at Alu 
elements 









data	 (Figure	 5.10).	 Alu	 Y	 was	 particularly	 enriched	 in	 5hmC	 and	 Alu	 S	 was	
overrepresented	 in	 the	 MeDIP	 data,	 suggesting	 that	 while	 both	 modifications	
preferentially	 mark	 younger	 Alu	 elements,	 the	 control	 of	 the	 Alu	 S	 is	 primarily	
attributed	to	5mC	(Figure	5.10)	[83].		
DNA	 hydroxymethylation	 reads	 were	 aligned	 to	 Alu	 element	 subfamilies	 and	
clustered	using	the	hclust	method		(R	package)	(Figure	5.11).	A	distinct	band	of	5hmC	
can	be	seen	covering	all	Alu	S	elements	and	the	majority	of	Alu	Y	elements.	This	 is	
less	 distinct	 for	 Alu	 J.	 A	 small	 number	 of	 human-specific	 Alu	 Y	 elements	 lack	 this	






Figure 5.9. MeDIP and hMeDIP peaks at repetitive DNA	
A.	HOK	MeDIP	 and	hMeDIP	peaks	were	 separated	based	on	detailed	 annotations	 and	are	
shown	 as	 a	 pie	 chart	 with	 the	 number	 and	 percentage	 of	 total	 peaks	 shown	 alongside.	
MeDIP	peaks	were	identified	and	detailed	annotations	assigned	using	MACS	by	Dr	W.	Croft	
while	 Homer	 was	 used	 by	 Dr	 S.	 Clokie	 for	 the	 hMeDIP	 data.	 B.	 UCSC	 browser	 shot	
representing	an	example	of	HOK	MeDIP	 (dark	blue)	and	hMeDIP	 (light	blue)	sequencing	 in	
relation	 to	 the	 location	 of	 repetitive	 elements	 and	 genes.	 C.	 Zoomed	 in	 image	 of	 5hmC	
distribution	 at	 one	 cluster	 of	 Alu	 elements	 illustrates	 an	 overlap	 between	 5hmC	 and	 Alu	
elements	 (red	 bars)	 but	 not	 other	 repetitive	 elements.	 UCSC	 browser	 shot	 of	 the	 section	














































Figure 5.10. Differential enrichment of 5mC and 5hmC in Alu element families 
The	 results	 of	MeDIP	 and	 hMeDIP	 sequencing	 of	 HOK	 cells	 were	 separated	 based	 on	 Alu	



































Figure 5.11. Enrichment of 5hmC at Alu element subfamilies 
For	each	Alu	element	subfamily	the	5hmC	count	from	HOK	hMeDIP	sequencing	is	shown	+/-
2kb	 of	 the	 centre	 of	 the	 repetitive	 element.	 hMeDIP	 reads	 were	 counted	 over	 each	 Alu	

















































































5.9 DNA methylation and hydroxymethylation at Alu 
elements occurs alongside but does not overlap 
regulatory elements.  
Upon	examining	the	genome	browser	 it	became	apparent	that	 in	gene-rich	regions	
Alu	 elements	 appear	 as	 clusters	 in	 areas	 adjacent	 to	 regulatory	 elements	 and	 are	
consistently	marked	with	5mC	and	5hmC	(Figure	5.12,	upper	panel).	 	 In	gene-poor	
regions,	 Alu	 elements	 are	more	 dispersed	 and	 lack	 5hmC	but	 partially	 retain	 5mC	
(Figure	5.12,	lower	panel).		
To	 further	 investigate	 the	 relationship	 between	 DNA	 modifications	 and	 Alu	
elements,	 four	 groups	of	 regions	were	 isolated	 for	both	5mC	and	5hmC:	5mC	and	
5hmC-enriched	regions	were	analysed	as	 i)	all	5(h)mC	(545,507	and	24,318	regions	
respectively);	 ii)	 5(h)mC	 at	 Alu	 elements	 (483,059	 and	 18,749	 regions)	 and;	 iii)	
5(h)mC	not	at	Alu	elements	(62,448	and	5,569	regions);	(iv)	the	genomic	locations	of	
all	Alu	elements	were	downloaded	from	repeatmasker	[250]	and	non-5mC	and	non-
5hmC	 marked	 Alu	 elements	 were	 isolated	 (1,010,770	 and	 1,025,616	 regions	
respectively).	 These	were	 aligned	 to	 UCSC	 genes.	 Alu	 elements	marked	with	 5mC	
and	5hmC	were	strongly	excluded	from	the	TSS	(Figure	5.13).	Interestingly,	the	drop	
in	 5hmC	 at	 Alu	 elements	 did	 not	 directly	 align	with	 the	 TSS;	 instead	 it	was	 found	
slightly	 to	 the	 right	 (Figure	5.13).	 This	was	distinct	 for	5hmC	over	5mC,	 suggesting	
that	5hmC	at	Alu	elements	is	more	commonly	found	upstream	of	the	TSS,	while	5mC	
is	evenly	distributed	around	 it	 (Figure	5.13).	The	5hmC	 in	HOK	cells	was	compared	
with	ENCODE	DNase	hypersensitive	sites	(DHSs)	from	125	cell	lines;	again	5hmC	was	





elements	 are	 highly	 hydroxymethylated	 surrounding,	 but	 not	 overlapping	 the	DHS	
sites	 (Figure	5.15).	Regions	enriched	 in	5mC	or	5hmC,	both	within	and	outwith	Alu	
elements	were	 exempt	 from	 transcription	 factor	 binding	 sites	 (Figure	 5.16).	 These	
results	 correspond	 to	 the	 distribution	 of	 5mC	 and	 5hmC	 observed	 in	 Figure	 5.12;	
5mC	 and	 5hmC	 at	 Alu	 elements	 is	 found	 in	 close	 proximity,	 but	 not	 overlapping,	









Figure 5.12. 5mC and 5hmC mark Alu elements in gene-rich regions 
UCSC	browser	shots	of	MeDIP	(dark	blue	track)	and	hMeDIP	sequencing	(light	blue	track)	of	
HOK	cells	 shown	alongside	 repeatmasker	 tracks	 for	 the	main	classes	of	 transposon	 (SINEs,	
LINEs,	 LTRs	 and	 DNA	 transposons),	 UCSC	 genes,	 CpG	 islands	 and	 tracks	 for	 transcription	
(Txn)	 factor	ChIP,	DNase	 clusters	and	 layered	H3K27Ac	ChIP	 from	all	 ENCODE	cell	 lines.	 In	
the	top	panel	pale	blue	bands	highlight	areas	rich	in	Alu	elements	and	5mC	and	5hmC,	but	
poor	 in	 regulatory	 elements	 while	 pale	 pink	 bands	 represent	 areas	 rich	 in	 regulatory	










































Figure 5.13. 5mC and 5hmC at Alu elements were excluded from the TSS 










Figure 5.14. 5hmC at Alu elements at DNase hypersensitive sites 
The	hMeDIP	 reads	 that	 overlap	with	Alu	 elements	 downloaded	 from	UCSC	 repeat	masker	
were	 visualised	 using	 Homers’	 Cluster3,	 ‘TreeView’	 function.	 5hmC	 reads	 were	 log	
transformed	 and	 centred	 on	 the	 subsampled	 (28,907)	 entries	 from	
WgEncodeAwgDnaseMasterSites	list	(DHS).	Hierarchical	clustering	was	performed	based	on	
correlation	 similarity	 and	 centroid	 linkage.	 Homers’	 ‘-size	 given’	 	 function	 was	 used	 to	
independently	 scale	 each	 2kb	 region	by	 separating	 the	 region	 into	 bins	 of	 10bp.	 For	 each	
region,	 the	 colour	 represents	 the	number	of	 reads	per	bin	 relative	 to	 the	 total	number	of	
reads	 across	 the	whole	 2kb	 region,	with	 red	 indicating	 an	 enrichment	 of	 5hmC.	 Heatmap	
generated	by	Dr	S.	Clokie.	 	
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Figure 5.16. 5mC and 5hmC enriched regions are excluded from transcription 
factor binding sites 
5mC	and	5hmC	enriched	regions	(peaks)	were	separated	based	on	the	presence	or	absence	
of	an	Alu	element.	The	genomic	coordinates	 for	 these	groups	were	 then	used	 to	align	 the	








5.10 The function of 5mC and 5hmC may differ within and 
outside of Alu elements  
DNA	methylation/	hydroxymethylation/	Alu	element	groups	 from	section	5.9	were	
investigated	 for	 overlap	 with	 functional	 chromatin	 domains	 of	 NHEK	 cells	 (Figure	
5.17,	Supplementary	data	13)	[172].	Heterochromatin	is	represented	as	expected	at	
Alu	 elements	 without	 5mC	 or	 5hmC	 (5mC	 and	 5hmC	 O/E=0.95)	 and	
underrepresented	 in	 regions	 marked	 by	 5hmC	 (O/E:	 All=0.67;	 Alu=0.66;	 Not	
Alu=0.74)	 (Figure	 5.17).	 Alu	 elements,	 5mC	 and	 5hmC	 are	 enriched	 in	 transcribed	




with	 all	 promoter	 groups	 and	 non-Alu	 5mC	 and	 5hmC	 groups	 occupy	 insulators,	
polycomb-repressed	 regions	 and	 poised	 promoters	 (Figure	 5.17).	 Therefore,	 the	







Figure 5.17. Chromatin domains associated with 5mC and 5hmC at Alu elements  
HOK	MeDIP	and	hMeDIP	peaks	were	separated	based	on	whether	they	overlap	with	an	Alu	





domain	 [175].	 BEDTools	 ‘RandomBed’	 was	 used	 to	 create	 a	 random	 group	 of	 genomic	
intervals	comparable	with	each	5(h)mC/	Alu	group.	This	was	used	to	generate	the	‘expected’	







































































5.11 5hmC marked Alu elements are found in regions 
associated with active histone modifications 
Using	 the	 BedTools	 ‘intersect	 intervals’	 function	 [175]	 the	 overlap	 between	 5mC,	
5hmC	and	Alu	 groups	with	histone	modifications	 from	NHEK	 cells	was	determined	
(Figure	5.18,	Supplementary	data	14)	[174].		Alu	elements	and	5hmC	were	found	to	
be	 associated	with	 active	 histone	modifications	 (H3K4me3,	 H3K36me3,	 H3K4me1,	
H3K27me3)	more	 than	repressive	ones	 (H3K27me3,	H3K9me3)	 (Figure	5.18,	Figure	
5.19).	 Indeed,	for	all	bar	the	non-Alu	5hmC	group,	repressive	histone	modifications	





found	 to	 accompany	 5mC,	 5hmC	 and	 Alu	 elements	 (Figure	 5.18).	 The	
observed/expected	ratio	was	higher	for	Alu	elements	marked	with	5hmC	than	either	
Alu	 or	 5hmC	 alone	 (Figure	 5.18).	 Similarly,	 when	 viewed	 across	 the	 whole	
chromosome	 (using	 chr8	 as	 an	 example)	 5hmC	 at	 Alu	 elements	 co-localises	 with	
active	histone	modifications	but	is	exempt	from	regions	of	H3K9me3	(Figure	5.19).		
DNA	methylation	 and	hydroxymethylation	 groups	were	 aligned	with	NHEK	histone	
modification	peaks	to	determine	how	these	regions	overlap	(Figure	5.20).	In	contrast	
to	 the	 results	 described	 above	 (Figure	 5.18),	 5hmC	 at	 Alu	 was	 exempt	 from	 the	





from	 the	 centre	 of	 active	 histone	 modifications,	 and	 co-localised	 with	 the	
heterochromatin	mark	H3K9me3	only	outside	of	Alu	elements	(Figure	5.20).		
In	 conclusion,	 upon	 examining	 the	 UCSC	 genome	 browser,	 clusters	 of	 5mC	 and	
5hmC-marked	 Alu	 elements	 tend	 to	 be	 located	 within	 or	 besides	 genes;	 and	 are	
associated	with,	but	upon	closer	 investigation	not	overlapping,	active	 transcription	
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Figure 5.19. Example of co-localisation of 5hmC-marked Alu elements and active 
histone modifications 
Chromosome	8	is	used	as	a	representative	example	to	show	the	distribution	of	5hmC	peaks	
at	 Alu	 elements	 (blue)	 in	 relation	 to	 NHEK	 DNase	 hypersensitive	 sites	 (DHS	 green),	 NHEK	







Figure 5.20. The relationship between 5mC and 5hmC-enriched regions and 
histone modification peaks 
5mC	and	5hmC-enriched	 regions	were	 separated	based	on	 the	presence	or	 absence	of	 an	
Alu	 element.	 These	 were	 aligned	 to	 NHEK	 histone	 modification	 peaks	 determined	 by	










































5.12 DNA methylation and hydroxymethylation outside of 




outside	 of	 Alu	 elements	 both	 5mC	 and	 5hmC	 associate	 with	 the	 active	 histone	
modification	H3K4me3	in	NHEK	cells	(Figure	5.18).	This	may	represent	differences	in	
activation	or	 repression	of	 genes	between	HOK	 cells	 and	NHEK	 cells.	 In	HOK	 cells,	
both	5mC	and	5hmC	not	 associated	with	Alu	elements	 are	more	 commonly	 found	
















































perform	 gene	 ontology	 analysis	 [177].	 	 5hmC-enriched	 enhancers	were	 associated	
with	 disease	 ontology	 terms	 associated	 with	 epithelial	 cancers,	 including	 HNSCC	
(Figure	 5.23).	 Furthermore,	 5hmC-enriched	 enhancers	 were	 associated	 with	









Figure 5.23. Gene ontology analysis of 5hmC-enriched enhancers 
HOK	 5hmC-enriched	 regions	 that	 overlap	 with	 the	 chromatin	 domain	 ‘strong	 enhancers’	
were	assigned	genes	and	gene	ontology	performed	using	the	online	software	GREAT	human	





5.14 DNA methylation is gained at promoters and CpG 
islands in an HNSCC cell line 
DNA	methylation	and	hydroxymethylation	are	disrupted	in	HNSCC	[57,	99,	100,	102,	
110].	 	 To	 investigate	 the	 relationship	 between	 cytosine	modifications	 and	 HNSCC,	
MeDIP	and	hMeDIP	sequencing	was	performed	on	the	HNSCC	cell	 line,	VU40T,	and	
the	results	compared	with	the	HOK	(h)MeDIP	results.	 In	VU40T	cells,	5mC-enriched	














Figure 5.24. The distribution of 5mC and 5hmC in HNSCC cells  
MeDIP	 and	 hMeDIP	 was	 performed	 on	 HNSCC	 cells	 (VU40T)	 and	 compared	 with	 normal	
human	 oral	 keratinocytes	 (HOK).	 The	 results	 were	 separated	 based	 on	 the	 ‘annotation’	
assigned	to	each	peak	and	are	shown	as	A.	pie	charts	and	B.	a	table.	VU40T	results	are	the	
mean	of	three	independently	sequenced		and	analysed	hMeDIP	experiments	and	two	MeDIP	





VU40T HOK VU40T  HOK  
No. Peaks % No. Peaks % No. Peaks % No. Peaks % 
Promoter 
(TSS) 
12492 2.45 6071 1.11 417 1.35 382 1.57 
Exon 29321 5.74 1543 0.28 69 0.22 12 0.05 
TTS 9685 1.90 7643 1.40 335 1.08 338 1.39 
Intron 250776 49.11 282498 51.79 15135 48.73 13011 53.51 
Intergenic 192928 37.78 242606 44.47 14884 47.87 10381 42.69 































































Figure 5.25. 5mC is gained in CpG islands in HNSCC 
The	UCSC	table	browser	was	used	to	download	CpG	islands	onto	Galaxy.	Using	the	Bedtools	
‘intersect	intervals’	function,	the	amount	of	overlap	between	VU40T	MeDIP	and	HOK	MeDIP	
















































Figure 5.26. Characteristics of 5mC and 5hmC-enriched regions in VU40T cells 
For	 peaks	 obtained	 from	 the	 HOK	 and	 VU40T	 MeDIP	 and	 hMeDIP	 sequencing	 the	 mean	
absolute	 distance	 to	 the	 transcription	 start	 site	 (TSS)	 (A.),	 CpG	 content	 (B.)	 and	 GC%	 (C.)	
were	 calculated.	 VU40T	 results	 were	 averaged	 from	 two	 MeDIP	 and	 three	 hMeDIP	
sequencing	experiments.	Error	bars	show	STD.	
	 	













































5.15 Promoters that gain 5mC in HNSCC are associated with 
decreased expression in VU40T cells 
Gene	ontology	and	KEGG	pathway	analysis	was	performed	on	promoters	that	gained	
methylation	 in	 VU40T	 cells	 (Figure	 5.27).	 	 The	 KEGG	 pathway	 term	 ‘nicotine	
addiction’	 should	 be	 noted,	 as	 smoking	 is	 one	 of	 the	main	 risk	 factors	 for	 HNSCC	
(Figure	5.27).	 	However,	 in	general,	most	ontological	groupings	did	not	correspond	
with	tumour	suppressive	functions	(Figure	5.27).		To	further	investigate	the	function	
of	 promoter	methylation	 in	 VU40T	 cells,	MeDIP	 peaks	 containing	 promoters	were	
separated	 into	 three	 groups:	 those	 which	 gained	 methylation	 in	 HNSCC	 (VU40T	
specific:	 4999	 genes);	 those	which	 lost	methylation	 in	 HNSCC	 (HOK	 specific:	 3036	
genes);	 and	 those	where	 the	methylation	was	 unchanged	 (constant:	 2483	 genes).	
Using	 the	 VU40T	 transcriptome,	 the	 expression	 level	 (FPKM)	 of	 genes	 with	 5mC	
marked	 promoters	 was	 determined	 for	 each	 group	 (Figure	 5.28).	 VU40T	 specific	
promoters	 were	 associated	 with	 expressed	 genes	 (FPKM>1)	 at	 a	 lower	 frequency	
than	 the	 other	 two	 groups,	 and	 in	 general	 corresponded	with	 lower	 FPKM	 values	
(Figure	 5.28).	 Therefore,	 promoters	 that	 gain	 5mC	 in	 HNSCC	 are	 less	 likely	 to	 be	
associated	 with	 genes	 expressed	 in	 VU40T	 cells	 (Figure	 5.28).	 However,	 as	 no	
comparison	 with	 the	 HOK	 transcriptome	 was	 performed	 we	 cannot	 determine	
whether	these	genes	would	have	been	expressed	prior	to	5mC	gain.	 	 (Figure	5.28).	
However,	 the	 majority	 of	 genes	 (77%)	 that	 lost	 promoter	 methylation	 in	 HNSCC	



















Figure 5.28. Expression of genes with methylated promoters 
The	 results	 of	 the	 VU40T	 and	 HOK	 MeDIP	 experiments	 were	 separated	 based	 on	 the	
presence	 of	 a	 5mC	 peak	 in	 only	 the	 HOK	 sample	 (HOK	 specific),	 only	 the	 VU40T	 sample	
(VU40T	specific)	or	in	both	samples	(constant).	For	each	group	the	expression	level	(FPKM)	
of	promoters	marked	with	5mC	was	determined	from	the	VU40T	transcriptome.	The	results	



































Constant HOK Specific VU40T Specific 
No. genes % No. genes % No. genes % 
<1 1849 74.47 2341 77.11 4325 86.53 
1-5 160 6.44 150 4.94 221 4.42 
5-10 91 3.66 121 3.99 132 2.64 
10-50 267 10.75 288 9.49 232 4.64 
50-100 51 2.05 69 2.27 41 0.82 
































5.16 In HNSCC cells Alu elements are depleted of 5mC and 
5hmC 
As	 previously	 discussed	 (Section	 5.8),	 5mC	 and	 5hmC	 are	 primarily	 found	 at	 Alu	
elements	 in	normal	oral	keratinocytes	(HOK	cells).	 In	HNSCC,	only	32%	of	5mC	and	
5hmC-enriched	 regions	 contained	 Alu	 elements	 (Figure	 5.29).	 Instead,	 5mC	 and	
5hmC	 are	 more	 enriched	 in	 LINEs,	 simple	 repeats	 and	 regions	 not	 containing	




Interestingly,	 the	 most	 evolutionarily	 old	 family,	 Alu	 J,	 show	 decreased	 5mC	 but	













(dark	 shade)	 and	 hMeDIP	 (lighter	 shade)	 sequencing	 results	 alongside	 repeatmasker	
repetitive	DNA	and	ENCODE	regulatory	elements.	MeDIP	peaks	were	identified	and	detailed	




































































Figure 5.30. Enrichment of 5mC and 5hmC across Alu elements families in normal 
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5.17 Discussion and Conclusion 
Transposable	 elements	 occupy	 a	 vast	 proportion	 of	 the	 human	 genome,	
considerably	 higher	 than	 that	 occupied	 by	 genes	 [79].	 	 In	 humans,	 the	 primate	
specific	 Alu	 elements,	 have	 expanded	 to	 cover	 ~10-11%	 of	 the	 genome	 and	 are	
enriched	in	CG-rich	DNA,	often	found	neighbouring	or	within	genes	[81,	83,	238].	In	
addition	 to	 the	mutagenic	potential	of	 free	Alu	elements,	embedded	Alu	elements	
have	 enhancer-like	 characteristics,	 transcription	 factor	 binding	 sites	 and	 can	 form	
new	exons	 [81,	 82,	 238,	 245,	 254].	 Therefore,	 epigenetic	mechanisms	must	 tightly	
regulate	access	to	Alu	elements	to	maintain	normal	cellular	function.		
This	 chapter	has	described	 the	enrichment	of	Alu	elements	 in	MeDIP	and	hMeDIP	
sequencing	 data	 of	 normal	 oral	 keratinocytes.	 In	 gene-poor	 regions,	 Alu	 elements	
are	evenly	distributed	and	associated	with	5mC,	but	not	5hmC.	However,	 in	gene-
rich	regions,	Alu	elements	tend	to	be	found	in	clusters,	marked	with	both	5mC	and	
5hmC.	 These	 clusters	 of	 Alu	 elements	 were	 found	 neighbouring,	 but	 rarely	
overlapping,	 regulatory	 regions	 such	 as	 TSSs,	 DNase	 hypersensitive	 sites	 or	
transcription	 factor	 binding	 sites.	 Alu	 elements	 marked	 with	 5mC	 and	 5hmC	 are	




of	 these	 transposons	 is	 less	 important	 [79].	 Interestingly,	 the	 middle	 aged	 Alu	 S	





elements	 rely	 on	 a	 more	 transient	 form	 of	 repression.	 Indeed,	 the	 most	 recently	
evolved	 Alu	 family,	 Alu	 Y,	 are	 enriched	 in	 the	 less	 repressive	 DNA	 modification,	
5hmC.	
In	a	study	on	the	distribution	of	DNA	modifications	in	mouse	embryonic	fibroblasts	





modifications	 [255].	 In	 human	 evolution,	 the	 primate-specific	 Alu	 elements	 have	
been	 preferentially	 selected	 for	 in	 regions	 rich	 in	 genes	 and	 regulatory	 elements	
[79].	 Furthermore,	 while	 Alu	 elements	 are	 largely	 excluded	 from	 unmethylated	
domains	they	tend	to	occupy	the	boundaries	[256,	257].	This	chapter	has	described	
an	 enrichment	 of	 5mC	 and	 5hmC	 at	 Alu	 elements	 found	 alongside,	 but	 not	
overlapping,	 active	 chromatin	 marks	 and	 regulatory	 elements.	 Therefore,	 it	 is	
hypothesised	 that,	 like	 mouse-specific	 SINEs,	 Alu	 elements	 act	 as	 boundaries	
controlled	by	DNA	methylation	and	hydroxymethylation	that	help	maintain	access	to	
regulatory	elements.	
In	HNSCC,	 this	 control	 of	 Alu	 elements	 is	 disrupted;	 the	 proportion	 of	MeDIP	 and	
hMeDIP	 peaks	 associated	 with	 Alu	 elements	 is	 reduced	 to	 ~30%	 in	 VU40T	 cells	
compared	to	~80%	in	HOK	cells.	Hypomethylation	of	Alu	elements	is	a	characteristic	
common	to	many	cancers	[87,	111,	114,	256].	Loss	of	5mC	at	transposable	elements	




increased	 transposition	 (summarised	 in	 Figure	 1.15)	 [111].	 Furthermore,	 increased	
expression	 of	 Alu	 elements	 in	 cancer	 has	 been	 associated	with	 the	 production	 of	
small	 RNAs	 that	 silence	 genes	 containing	 intragenic	 Alu	 elements	 [258].	 As	 the	
majority	of	genes	contain	at	 least	one	intragenic	Alu,	this	could	cause	considerable	
changes	 to	 the	 transcriptome	 [84,	 240].	 The	 relationship	 between	 5hmC,	 Alu	
elements	and	cancer	has	not	previously	been	described	and	further	work	is	required	
to	determine	the	functional	consequences	of	Alu	5hmC	loss.		
In	 a	 comparison	 of	 HOK	 and	 VU40T	 cells,	 DNA	 methylation	 appears	 to	 be	
preferentially	lost	from	Alu	S	elements	in	HNSCC	cells.	Recent	Alu	retrotransposition	
events	 come	 from	 members	 of	 the	 Alu	 Y	 family;	 however,	 other	 Alu	 elements	
(particularly	 Alu	 S)	 are	 expressed	 as	 RNA	 that	 is	 unable	 to	 be	 inserted	 into	 the	
genome	 [245,	 249,	 259].	 This	 Alu	 RNA	 can	 silence	 genes	 containing	 intragenic	 Alu	
elements	[258].	Therefore,	demethylation	of	Alu	S	family	members	may	have	been	
selected	 for	 during	 tumour	 progression	 as	 a	 means	 of	 gene	 silencing	 [258].	
Conversely,	 Alu	 J	 elements	 gain	 5hmC	 in	 VU40T	 cells.	 Many	 Alu	 J	 elements	 have	
evolved	into	enhancers	or	proto-enhancers	[238].	As	discussed	here,	and	elsewhere,	
5hmC	 is	associated	with	active	enhancers	 [61,	106].	Therefore,	5hmC	gain	at	Alu	 J	
elements	may	create	novel	enhancers	in	HNSCC.		
Non-repeat	 regions	 gain	 cytosine	 modifications	 in	 HNSCC.	 Promoters	 and	 CpG	








not	 always	 sufficient	 to	 reactivate	 gene	 expression	 [27].	 Instead,	 corresponding	
changes	 in	 histone	 modifications,	 chromatin	 structure	 and	 transcription	 factor	




expected,	 as	 5hmC	 is	 the	 product	 of	 5mC.	 However,	 with	 the	 exception	 of	 DNA	
modification	 loss	 at	 Alu	 elements,	 the	 differences	 between	 HOK	 and	 VU40T	 cells	






When	 considering	 these	 results,	 it	 is	 important	 to	 recognise	 that	 DIP-sequencing	
experiments	are	 subject	 to	bias	 towards	 short,	unmodified	DNA	 repeats	 (generally	
repeating	 dinucleotides	 such	 as	 CA	 repeats)	 [262].	 This	 can	 be	 attributed	 to	 an	
intrinsic	 bias	 in	 the	 IgG	 antibodies	 [262].	 In	 the	 analysis	 performed	 here,	 peaks	
lacking	 CpG	 dinucleotides	 were	 not	 considered,	 partially	 resolving	 this	 issue.	
However,	 this	 does	 not	 remove	 the	 possibility	 of	 nonspecific	 binding	 to	 repeats	









the	 average	 fragment	 generated	 by	 the	 MeDIP	 and	 hMeDIP	 experiments.	 During	
sequencing,	 short	 reads	 are	 produced	 from	 either	 end	 of	 a	 DNA	 fragment	 and	
aligned	by	taking	into	account	the	original	size	of	the	fragment.	This	has	allowed	Alu	
elements	to	be	 included	in	the	analysed	dataset	as	differences	 in	the	neighbouring	
regions	 of	 DNA	 allow	 the	 Alu	 elements	 to	 be	 mapped	 to	 unique	 regions	 in	 the	
genome.	
In	conclusion,	 this	chapter	has	described	how	the	distribution	of	5mC	and	5hmC	 is	
altered	 in	 HNSCC	 (Figure	 5.31,	 Figure	 5.32).	 In	 normal	 cells	 5mC	 and	 5hmC	 are	
excluded	from	the	TSS	and	transcription	factor	binding	sites	and	enriched	in	clusters	
of	Alu	elements	in	gene-rich	regions	(Figure	5.32).	The	function	of	DNA	modifications	
appear	 to	differ	 based	on	 the	presence	or	 absence	of	 an	Alu	 element,	with	 5hmC	
outside	 of	 Alu	 elements	 associated	 with	 tissue	 specific	 enhancers	 and	 bivalent	
chromatin.	However,	in	HNSCC	both	5mC	and	5hmC	are	lost	from	Alu	elements,	and	









Figure 5.31. 5mC and 5hmC changes in HNSCC 
The	 changes	 in	 5mC	 and	 5hmC	 between	 normal	 (HOK)	 and	 HNSCC	 (VU40T)	 cells	 are	
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Figure 5.32. DNA modifications in normal oral keratinocytes and HNSCC cells  
Top	 panel:	 The	 distribution	 of	 5mC	 and	 5hmC	 in	 a	 gene	 rich	 region	 in	 HOK	 cells	 is	
represented	as	a	schematic	alongside	the	associated	histone	modifications.	Active	genes	are	





only	marked	with	 5mC.	Bottom	 panel:	 The	distribution	of	 5mC	and	5hmC	are	 changed	 in	
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Chapter 6. DAC partially restores 
the distribution of 5mC and 5hmC 
in an HNSCC cell line to one 








number	 of	 genes	 not	 controlled	 by	 a	 methylated	 promoter	 are	 upregulated	 by	
DNMTi	treatment,	suggesting	an	indirect	mechanism	may	also	be	at	work	[158,	265].	
This	 led	 to	 the	 proposition	 of	 a	 new	mechanism	 to	 explain	 the	 efficacy	 of	 DNMTi	
treatment	in	cancer,	termed	‘viral	mimicry’	[158,	180].		
6.1. Viral mimicry 
In	an	analysis	of	the	transcriptome	and	methylome	of	63	solid	cancer	cell	lines	after	
treatment	 with	 the	 DNMTi	 5-azacytidine	 (AZA),	 Li	 and	 colleagues	 found	 an	
upregulation	 of	 immune	 related	 genes	 largely	 not	 controlled	 by	 a	methylated	 CGI	













to	 expression	 of	 the	 ERVs	 as	 dsRNA.	 This	 ERV	 dsRNA	 triggers	 the	 dsRNA-sensing	
proteins	 TLR3	 and	MDA5	 to	 activate	 IFN-β1	 and	bring	 about	 an	 immune	 response	
that	kills	 the	cells	 [158,	180].	A	 ‘viral	mimicry’	 term	was	 introduced	 to	explain	 this	
mechanism	of	 delayed	 response	 to	DNMTis	 (Figure	 6.1)[158,	 180].	 A	 similar	 result	
was	 observed	 after	 AZA	 treatment	 in	 a	mouse	model	 of	 epithelial	 ovarian	 cancer,	
leading	to	increased	CD45+	immune	cells,	active	CD8+	T	cells	and	natural	killer	cells	
and	 a	 reduced	 tumour	 burden	 [266].	 Similarly,	 the	 anticancer	 agent,	 RRx-001,	 can	
induce	 a	 viral	 mimicry	 response	 in	 colon	 cancer	 cells	 via	 decreased	 expression	 of	
DNMT1	and	 -3A [267].	 Therefore,	 the	anti-tumourigenic	action	of	DNMTi	 could	be	
due	 to	 both	 the	 direct	 effects	 of	 DNA	 damage	 and	 demethylation	 of	 tumour	
suppressor	 genes	 and	 the	 indirect	 effects	 of	 interferon	 activation	 via	 ERV	
demethylation	[158,	180,	266].	






high	 or	 low	 AIM	 gene	 expression	 suggesting	 an	 immune	 evasion	 phenotype	 that	
could	be	reversed	by	epigenetic	therapy	[265].	Indeed,	in	a	mouse	model	of	ovarian	
cancer,	 treatment	 with	 AZA	 and	 HDACi	 reduced	 the	 immunosuppressive	 tumour	













Figure 6.1. Viral mimicry 
DAC	treatment	decreases	methylation	of	ERVs	 leading	to	their	expression	as	dsRNA.	These	
dsRNAs	 can	 activate	 TLR3,	MDA5	 and	 RIG-1	 in	 the	 cytoplasm,	which	 then	 activate	 TRAF3	
signalling	which	triggers	IKKε	and	TBK1	and	promotes	the	phosphorylation	of	IRF7	and	IRF3.	
IRF7	and	IRF3	enter	the	nucleus	and	stimulate	the	expression	of	IFN-β.	IFN-β	then	activates	





































6.2. 5hmC and DAC treatment 












described	to	work	 in	synergy	to	 increase	apoptosis	 in	cancer	cells	 [268].	Combined	
treatment	was	accompanied	by	increased	ERV	dsRNA	and	immune	gene	expression,	
greater	 than	 that	 seen	 by	 DAC	 alone;	 and	 an	 increase	 in	 global	 and	 ERV-specific	







6.3. Aims and objectives 






















check	 the	 efficacy	 of	 each	 reaction	 prior	 to	 library	 preparation	 and	 sequencing	
(Supplementary	data	8).	MeDIP	experiments	were	also	undertaken	in	normal	human	
oral	keratinocytes	 (HOK	cells)	 treated	with	relatively	high	and	 low	dose	DAC,	while	
hMeDIP	 was	 performed	 only	 on	 untreated	 HOK	 cells.	 HOK	 MeDIP	 and	 hMeDIP	
experiments	were	performed	 in	 triplicate	and	samples	pooled	prior	 to	sequencing.	
The	 total	 number	 of	 peaks	 obtained	 for	 each	 treatment,	 the	 number	 of	 peaks	
discarded	 due	 to	 lack	 of	 CpGs	 and	 the	 number	 of	 peaks	 retained	 for	 analysis	 are	
presented	 in	 Table	 6.1.	 Non-uniquely	 mapped	 reads	 were	 discarded	 from	 the	






Table 6.1. MeDIP and hMeDIP output 
The	total	number	of	5mC	or	5hmC	enriched	regions	(‘peaks’)	obtained	for	each	MeDIP	and	
hMeDIP	experiment.	First	 column:	before	 filtering;	second:	 the	number	of	peaks	 removed	












HOK NT 547344 1839 545505 99.66 
HOK 100nM DAC 606061 2588 603473 99.57 
HOK 1µM DAC 627469 1399 626070 99.78 
VU40T NT 512502 1822 510680 99.64 
VU40T 100nM DAC 648254 11216 637038 98.27 





HOK NT 26678 2358 24320 91.16 
VU40T NT 41562 10481 31081 74.78 
VU40T 100nM DAC 43978 10745 33233 75.57 





6.5. DAC treatment alters the genomic distribution of 5mC and 
5hmC in HNSCC cells 
	
DNA	 dot	 blot	 analysis	 demonstrated	 a	 dose	 dependent	 decrease	 in	 global	 5mC	 in	
VU40T	 cells	 after	 treatment	with	 DAC	 (Figure	 6.2).	 In	 leukemic	 cells	 a	 paradoxical	
increase	in	5hmC	has	been	described	[269].	However,	in	VU40T	cells,	DAC	treatment	
did	not	significantly	alter	the	global	levels	of	5hmC	(Figure	6.2).	
The	 distribution	 of	 5mC	 and	 5hmC	 after	 DAC	 treatment	 in	 VU40T	 cells	 was	
determined	 using	 MeDIP	 and	 hMeDIP	 sequencing	 (Figure	 6.3).	 Interestingly,	 DAC	








low	dose	DAC,	 5mC	was	 found	 less	 frequently	 in	 promoters	 and	 exons,	 and	more	
frequently	 in	 introns	 and	 intergenic	 regions	 (Figure	 6.5).	 Furthermore,	 5mC	 was	
found	 less	 frequently	 at	 CpG	 islands	 (Figure	 6.6).	 Compared	 with	 the	 untreated	
control,	 5hmC	 was	 found	 more	 often	 in	 introns	 and	 less	 frequently	 in	 intergenic	






and	hMeDIP	 sequencing	of	VU40T	 cells	 suggest	 that	DAC	 treatment	 is	 shifting	 the	




Figure 6.2. Global levels of 5mC and 5hmC in DAC treated VU40T cells 
DNA	was	extracted	from	VU40T	cells	treated	with	a	range	of	concentrations	of	DAC	for	96h.	
Following	 this,	 a	 DNA	 dot	 blot	 was	 performed	 using	 an	 antibody	 against	 5mC	 or	 5hmC.	
Methylene	blue	was	used	as	 a	 loading	 control.	 The	 relative	 intensity	of	 the	 5mC	or	5hmC	










































Figure 6.3. DNA methylation and hydroxymethylation changes in response to 
DAC 
VU40T	 cells	 were	 treated	 with	 100nM	 DAC,	 1μM	 DAC	 or	 an	 equivalent	 volume	 of	 the	
vehicle,	 acetic	 acid	 (NT)	 for	 96h.	 DNA	was	 extracted	 and	MeDIP	 and	 hMeDIP	 sequencing	
performed.	The	overlap	between	peaks	from	the	different	treatment	groups	are	shown	as	a	









































Figure 6.5. In HNSCC DAC treatment shifts the distribution of 5mC and 5hmC 
back towards that of normal oral keratinocytes 
The	genomic	location	of	5mC	and	5hmC	across	different	genomic	regions	is	shown	as	a	bar	
graph	 (A)	 and	 a	 table	 (B).	 The	MeDIP	 and	hMeDIP	 results	 of	DAC	 treated	VU40T	 cells	 are	
shown	alongside	untreated	HOK	cells	for	comparison.	NT=	vehicle	only	treated	VU40T	cells.	
VU40T	MeDIP	 (n=2)	 and	 hMeDIP	 (n=3)	 results	were	 analysed	 separately	 and	 the	mean	 is	
shown.	 Error	 bars	 represent	 STD.	MeDIP	 peaks	 were	 identified	 and	 annotations	 assigned	
using	MACS	by	Dr	W.	Croft	and	hMeDIP	analysis	was	carried	out	using	Homer	by	Dr	S.	Clokie.	
5mC 5hmC 







3' UTR 2732 7120 3825 3920 100 122 181 148 
5' UTR 163 1119 414 506 7 12 21 14 
Exon 1543 29321 7903 5724 12 69 73 58 
Intergenic 242606 192928 286848 302331 10381 14884 14741 14053 
Intron 282498 250776 317967 358097 13011 15135 17099 15389 
NA 921 1758 2337 2083 55 65 37 34 
non coding 1328 5481 2614 2394 31 33 56 34 
Promoter (TSS) 6071 12492 7281 10406 382 417 586 431 













3' UTR 0.50 1.39 0.69 0.56 0.41 0.40 0.52 0.48 
5' UTR 0.03 0.22 0.08 0.07 0.03 0.04 0.06 0.05 
Exon 0.28 5.73 1.79 0.83 0.05 0.22 0.25 0.20 
Intergenic 44.47 37.81 44.16 43.50 42.69 47.87 44.76 46.08 
Intron 51.79 49.00 49.84 51.48 53.51 48.73 51.12 50.42 
NA 0.17 0.37 0.40 0.31 0.23 0.21 0.12 0.10 
non coding 0.24 1.08 0.51 0.35 0.13 0.11 0.15 0.12 
Promoter (TSS) 1.11 2.50 1.25 1.50 1.57 1.35 1.71 1.38 
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Figure 6.6. Differential enrichment of 5mC at CpG islands in DAC treated VU40T 
cells  
The	UCSC	table	browser	was	used	to	download	CpG	islands	onto	Galaxy.	Using	the	Bedtools	
‘intersect	 intervals’	 function,	 the	 amount	 of	 overlap	 between	 these	 regions	 and	 MeDIP	
peaks	was	determined.	The	results	are	shown	as	A.	the	percentage	of	total	MeDIP	peaks	and	




















































Figure 6.7. Characteristics of DAC treated VU40T cells 
MeDIP	and	hMeDIP	experiments	were	used	to	determine	the	location	of	5mC	and	5hmC	in	
VU40T	and	HOK	cells.	Untreated	 (NT),	100nM	DAC	 treated	and	1µM	DAC	 treated	 samples	
were	 compared	 in	 regards	 to:	A.	Mean	 distance	 from	 the	 TSS.	B.	Mean	 CpG	 content.	 C.	






















































6.6. DAC treatment does not reactivate tumour suppressor 
genes commonly inactivated in HNSCC 
A	panel	of	tumour	suppressor	genes	commonly	inactivated	in	HNSCC	were	compiled	
from	the	 literature	[98-102].	Additionally,	 the	TCGA	data	from	HNSCC	patients	was	
downloaded	 from	 cBioPortal	 and	 genes	 with	 copy	 number	 variations	 (CNV)	 with	
more	 than	 2%	 frequency	 in	 HNSCC	 and	 mutations	 with	 more	 than	 8%	 frequency	
were	added	to	the	literature	list	[8,	222,	271].	This	list	was	compared	with	the	MeDIP	
data	 for	 untreated	VU40T	 cells	 and	 those	with	 a	 5mC	peak	 in	 the	 promoter	were	
retained	 (Figure	6.8).	The	VU40T	transcriptome,	before	and	after	500nM	DAC,	was	
then	 used	 to	 compare	 changes	 in	 5mC	 after	 DAC	 treatment	 to	 changes	 in	 gene	
expression	(Figure	6.8).	Interestingly,	in	this	panel,	decreased	promoter	methylation	
after	 DAC	 did	 not	 correlate	 with	 increased	 gene	 expression	 (Figure	 6.8).	 This	 is	
indicative	of	 the	combinatorial	nature	of	gene	silencing,	but	also	suggests	 that	 the	









Figure 6.8. A comparison of the expression and methylation changes in VU40T 
cells in response to DAC 
A	panel	of	tumour	suppressor	genes	from	the	literature,	and	genes	with	common	CNVs	(>2%	
frequency)	 or	 mutations	 (>8%	 frequency)	 in	 HNSCC	 was	 compiled.	 Those	 with	 a	 5mC-
enrichced	 region	 (peak)	 in	 the	promoter	of	 vehicle	only	VU40T	 cells	 (NT)	 are	 shown	here.	
Changes	 in	 promoter	 methylation	 after	 100nM	 and	 1μM	DAC	 treatment	 were	 compared	
with	the	VU40T	cell	transcriptome	before	and	after	500nM	DAC.	The	ClustVis	software	was	








6.7. DAC treatment induces a viral mimicry response in VU40T 
cells 
In	 solid	 tumours,	 the	 efficacy	 of	 low	 dose	 DNMTi	 has	 been	 attributed	 to	 the	
demethylation	 of	 endogenous	 retroviruses	 (ERVs)	 [2,	 3].	 These	 are	 expressed	 as	
double	stranded	RNA	(dsRNA)	that	triggers	an	immune	response	that	results	 in	cell	








enriched	 in	 terms	of	 interferon	 signalling	 and	 the	 viral	 life	 cycle	 (Table	 6.2).	Using	
qRT-PCR	 the	 RNA	 levels	 of	 several	 genes	 understood	 to	 be	 involved	 in	 the	 viral	
mimicry	response	were	examined	before	and	after	treatment	with	DAC	(Figure	6.12).	
Increased	expression	of	 interferon	β	(IFN	β);	 its	transcriptional	activator,	 interferon	
regulatory	factor	7	(IRF7);	and	the	dsRNA	sensing	protein,	Melanoma	Differentiation-
Associated	protein	 5	 (MDA5,	 encoded	 for	 by	 IFIH1	 gene)	were	observed	 in	VU40T	
cells	after	DAC	treatment	(Figure	6.12).	Therefore,	the	efficacy	of	DAC	treatment	in	
VU40T	cells	could	be	partially	attributed	to	a	viral	mimicry	response	(Figure	6.13).	






formed	 two	 groups:	 those	 with	 relatively	 high	 IFN	 pathway	 expression	 and	 those	







Figure 6.9. 5mC is lost from endogenous retroviruses (ERVs) after treatment with 
DAC 
The	number	of	MeDIP	 reads	was	 calculated	 for	 indicated	ERV	 families	was	determined	by	

























Figure 6.10. Decreased methylation correlates with increased RNA at some ERVs 
The	 number	 of	MeDIP	 reads	 for	 different	 subfamilies	 of	 ERV	was	 calculated.	 The	 treated	
samples	were	normalised	against	the	untreated	sample.	RNA	sequencing	was	performed	on	










Figure 6.11. DAC treatment increases the levels of double stranded RNA 
VU40T	 cells	 treated	with	 100nM,	 500nM	or	 1µM	DAC	or	 an	 equivalent	 volume	of	 vehicle	
control,	 were	 cultured	 on	 sterilised	 coverslips	 for	 96h.	 These	 were	 then	 subject	 to	
immunofluorescent	analysis	using	the	J2	dsRNA	antibody.	Representative	images	are	shown.	
Relative	 intensity	was	determined	using	 the	 ImageJ	 software	and	 the	 J2	dsRNA	 result	was	
normalised	against	the	corresponding	DAPI	result	[129].	The	graph	shows	the	mean	of	three	
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Table 6.2. DAC treatment is associated with an increased expression of genes 




downregulated	 by	 DAC	 treatment.	 These	 genes	 were	 subject	 to	 ontology	 analysis	 for	
biological	 processes	 and	 the	 top	 enriched	 terms	 are	 shown	 here.	 Terms	 of	 interest	 are	
boxed	in	red.		
	
Increased expression with DAC Decreased expression with DAC 
GO Biological Process  
Fold 
Enrichment GO Biological Process 
Fold 
Enrichment 
response to interferon-alpha (GO:0035455) 8.83 
DNA replication-independent nucleosome 
assembly (GO:0006336) 6.38 
type I interferon signalling pathway (GO:
0060337) 6.64 viral transcription (GO:0019083) 4.15 
cellular response to type I interferon (GO:
0071357) 6.64 viral gene expression (GO:0019080) 4.08 
response to type I interferon (GO:0034340) 6.26 translational initiation (GO:0006413) 3.65 
endodermal cell differentiation (GO:0035987) 5.89 mitotic cell cycle checkpoint (GO:0007093) 3.44 
endoderm formation (GO:0001706) 5.1 sister chromatid segregation (GO:0000819) 3.16 
extracellular matrix disassembly (GO:0022617) 4.97 DNA replication (GO:0006260) 3.04 
endoderm development (GO:0007492) 4.24 nuclear chromosome segregation (GO:0098813) 2.97 
cornification (GO:0070268) 4.17 chromosome segregation (GO:0007059) 2.72 
formation of primary germ layer (GO:0001704) 3.96 protein targeting (GO:0006605) 2.67 
cell junction organization (GO:0034330) 3.8 ribosome biogenesis (GO:0042254) 2.62 
cell junction assembly (GO:0034329) 3.69 translation (GO:0006412) 2.61 
regulation of viral life cycle (GO:1903900) 3.6 peptide biosynthetic process (GO:0043043) 2.54 
gastrulation (GO:0007369) 3.48 
establishment of protein localization to organelle 
(GO:0072594) 2.52 
extracellular matrix organization (GO:0030198) 3.44 DNA repair (GO:0006281) 2.48 
extracellular structure organization (GO:
0043062) 3.43 amide biosynthetic process (GO:0043604) 2.48 
regulation of viral process (GO:0050792) 3.37 cell division (GO:0051301) 2.45 
cell-cell junction organization (GO:0045216) 3.21 
ribonucleoprotein complex biogenesis (GO:
0022613) 2.35 
regulation of symbiosis, encompassing mutualism 
through parasitism (GO:0043903) 2.94 cellular component disassembly (GO:0022411) 2.34 
response to endoplasmic reticulum stress (GO:






Figure 6.12. DAC treatment increases the expression of dsRNA and viral response 
genes 
RNA	was	extracted	and	qRT-PCR	performed	on	VU40T	cells	treated	with	100nM	DAC,	500nM	
DAC	or	 an	 equivalent	 volume	of	 vehicle.	 Results	 are	 shown	 relative	 to	 the	 vehicle	 control	
with	error	bars	representing	SEM	(n=3).	SPSS	software	was	used	to	calculate	paired	t-tests	





































Figure 6.13. In VU40T cells DAC induces a viral mimicry response 
DNMTi	treatment	is	understood	to	cause	a	viral	mimicry	response.	This	is	represented	as	a	
schematic.	 The	 effect	 of	 DAC	 on	 this	 pathway	 in	 VU40T	 cells,	 as	 discussed	 in	 the	 results	
above,	 is	 shown	 in	 red.	 In	 VU40T	 cells	 DAC	 demethylated	 ERVs,	 leading	 to	 an	 increase	 in	






































Figure 6.14. Immune genes upregulated by DAC treatment cluster together in 
HNSCC patient samples 
Interferon	pathway	genes	upregulated	by	DAC	treatment	were	entered	 into	the	cBioPortal	
website	[222,	271].	The	heatmap	shows	the	expression	of	these	genes	(rows)	in	523	HNSCC	
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6.8. In HNSCC cells 5mC and 5hmC are partially restored at 
Alu elements after DAC treatment  
Chapter	 5	 has	 discussed	 how	 5mC	 and	 5hmC	 are	 lost	 from	 repetitive	 DNA,	
particularly	 Alu	 elements,	 in	HNSCC.	 Therefore	 the	MeDIP	 and	 hMeDIP	 results	 for	
DAC	 treated	 VU40T	 cells	 were	 separated	 based	 on	 detailed	 annotations.		
Interestingly,	treatment	with	DAC	increased	the	proportion	of	both	5mC	and	5hmC	
at	Alu	elements	 (Figure	6.15).	 	As	discussed	above,	 the	proportion	of	5mC	at	non-
repeat	 regions	 (e.g.	 exons	 and	 promoters)	 and	 LTRs	 (e.g.	 ERVs)	was	 decreased	 by	
DAC	 (Figure	 6.15).	 	 Conversely,	 5hmC	was	 lost	 from	 simple	 repeats	 (Figure	 6.15).		
The	 relationship	between	5mC	and	5hmC	after	DAC	 treatment	 is	distinct	 for	SINEs	
compared	 with	 other	 forms	 of	 repetitive	 DNA	 (Figure	 6.16).	 	 For	 the	 majority	 of	
repetitive	DNA	classes	5mC	is	decreased,	and	5hmC	unchanged	by	DAC	(Figure	6.16).		
However,	 SINEs	 (and	 in	 particular	 Alu	 elements)	 show	 increased	methylation	 and	
hydroxymethylation	 after	 DAC	 treatment	 (Figure	 6.16).	 	 Interestingly,	 L1	 elements	
also	show	an	increase	in	5mC	and	5hmC	(Figure	6.16).			
MeDIP	and	hMeDIP	peaks	were	separated	into	three	groups	based	on	the	response	
to	 DAC	 treatment:	 peaks	 unchanged	 by	 DAC	 (constant);	 peaks	 gained	 by	 DAC	
treatment	 (DAC-specific);	 and	 peaks	 lost	 by	 DAC	 treatment	 (NT-specific)	 and	 the	
detailed	annotations	of	these	groups	was	determined	(Figure	6.17).	The	results	were	
similar	 for	 both	 low	 and	 high	 dose	 DAC	 treatment	 (Figure	 6.17).	 Encouragingly,	
regions	 that	 lose	 5mC	after	DAC	are	primarily	 associated	with	non-repeat	 regions,	
suggesting	 that	 DAC	 treatment	 does	 not	 severely	 alter	 genome	 stability	 (Figure	










(Figure	 6.18).	 Both	 5mC	and	5hmC	were	 gained	 at	 both	Alu	 S	 and	Alu	 Y	 elements	
(Figure	 6.18).	 These	 results	 suggest	 that	 in	 VU40T	 cells	 DAC	 treatment	 is	 partially	
restoring	the	distribution	of	5mC	and	5hmC	at	Alu	elements	to	that	of	normal	oral	
keratinocytes	(HOK	cells)	(Figure	6.18).	
The	 VU40T	 transcriptome,	 before	 and	 after	 treatment	 with	 500nM	 DAC	 was	
compared	with	 a	 transposable	 element	 reference	 sequence	 using	 CuffCompare	 to	









Figure 6.15. DNA methylation and hydroxymethylation at repetitive DNA after 
treatment with DAC 
MeDIP	and	hMeDIP	peaks	were	separated	based	on	detailed	annotation.	For	MeDIP	detailed	
annotations	were	 assigned	 using	MACS	 by	 Dr	W.	 Croft	 and	 hMeDIP	 peaks	were	 assigned	
using	Homer	 by	Dr	 S.	 Clokie	 A.	 The	 bar	 graph	 shows	 the	 relative	 proportion	 of	 repetitive	
elements	 in	HOK	cells	and	VU40T	cells	 treated	with	varying	concentrations	of	DAC.	MeDIP	
sequencing	 experiments	 for	 VU40T	 cells	 were	 performed	 in	 duplicate	 and	 compiled	 for	
analysis,	 and	 in	 triplicate	 for	 hMeDIP	 sequencing	 experiments.	 Error	 bars	 show	 STD.	 	 For	
HOK	cells,	MeDIP	and	hMeDIP	experiments	were	performed	in	triplicate	and	pooled	prior	to	
sequencing.	B.	An	example	UCSC	browser	shot	showing	5mC	and	5hmC	 lost	between	HOK	
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Figure 6.16. Changes in methylation and hydroxymethylation at repetitive DNA in 
VU40T cells after DAC treatment  
The	total	number	of	both	uniquely	and	non-uniquely	mapped	5hmC	and	5mC	reads	within	
repetitive	 element	 subfamilies	 was	 determined	 by	 counting	 the	 number	 of	 reads	
intersecting	with	the	‘repeatmasker’	data	from	the	UCSC	browser,	using	‘multicov’	function	
from	the	bedTools	suite	(Dr	S.	Clokie).		A.	Bar	graph	showing	the	number	of	5hmC	(n=3)	and	
5mC	 (n=2)	 reads	 for	 each	 repetitive	element	 family.	B.	 The	ClustVis	 software	was	used	 to	
generate	 a	 heatmap	 where	 rows	 were	 clustered	 using	 correlation	 distance	 and	 average	









Figure 6.17. Changes in the distribution of 5mC and 5hmC over repetitive DNA in 
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Figure 6.18. Differential enrichment of 5mC and 5hmC at Alu element families in 
VU40T cells treated with DAC 
The	 results	of	MeDIP	 (n=2)	 and	hMeDIP	 (n=3)	 sequencing	of	HOK	and	untreated	 (NT)	 and	
100nM	and	1μM	DAC	treated	VU40T	cells	were	separated	based	on	the	presence	of	an	Alu	
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Figure 6.19. In HNSCC, increased 5mC and 5hmC at Alu elements correlates with 
decreased Alu expression 
The	number	of	MeDIP	and	hMeDIP	reads	for	different	subfamilies	of	Alu	was	calculated.	The	
1μM	DAC	treated	samples	were	normalised	against	the	untreated	sample.	RNA	sequencing	
was	 performed	 on	 VU40T	 cells	 treated	 with	 500nM	 DAC	 or	 an	 equivalent	 volume	 of	 the	
vehicle.	 The	 aligned	 RNA	was	 compared	with	 a	 transposable	 element	 reference	 sequence	




















































































































































































6.9. DAC treatment does not alter the distribution of DNA 




















Figure 6.20. DAC treatment leads to minimal changes in 5mC in HOK cells 
MeDIP	was	performed	on	VU40T	and	HOK	cells	after	96h	treatment	with	1μM	DAC,	100nM	
DAC	or	an	equivalent	volume	of	vehicle.	Top:	The	overlap	of	5mC-enriched	regions	between	
treatment	 groups	 is	 shown	 as	 a	 Venn	 diagram.	 Numbers	 show	 total	 numbers	 of	 peaks	
present	in	each	category.	Bottom:	Volcano	plots	show	5mC	changes	between	untreated	and	
DAC	 treated	 cells.	 For	 VU40T	 cells	 the	 MeDIP	 sequencing	 experiment	 was	 performed	 in	
duplicate	and	the	results	combined	for	analysis.	For	HOK	cells,	 the	MeDIP	experiment	was	


































































Figure 6.22. Characteristics of HOK MeDIP peaks after DAC treatment 
For	HOK	5mC-enriched	regions	the	average	distance	to	the	TSS	(A);	CpG%	(B);	and	GC%	(C)	
were	calculated.	HOK	MeDIP	experiments	were	performed	in	triplicate	and	pooled	prior	to	

















































































Figure 6.23. DNA methylation of repetitive DNA in HOK cells after treatment 
with DAC 
HOK	MeDIP	peaks	were	 separated	based	on	detailed	annotations	 and	are	 shown	as	 a	bar	
graph	 representing	 the	proportion	of	each	 repeat	class	 in	 the	 total	number	of	peaks.	HOK	



























































Figure 6.24. DAC treatment alters the distribution of 5mC in VU40T cells, but not 
HOK cells. 






6.10. Discussion and conclusion 
The	efficacy	of	DAC	treatment	has	been	attributed	to	its	ability	to	demethylate	DNA.	
Indeed,	 in	 HNSCC	 cell	 lines,	 DAC	 causes	 a	 global	 reduction	 in	 5mC.	 The	 work	
presented	 here	 demonstrates	 that	 in	 an	 HNSCC	 cell	 line	 DAC	 does	 not	
indiscriminately	demethylate	 the	genome.	 Instead,	DAC	partially	 restores	5mC	and	
5hmC	patterns	to	those	seen	in	normal	oral	keratinocytes	(Figure	6.25,	Figure	6.26).	





In	 a	 comparison	 of	 the	 methylome	 of	 HNSCC	 cells	 with	 that	 of	 normal	 oral	
keratinocytes,	 5mC	 was	 detected	 more	 frequently	 in	 promoters,	 exons	 and	 CpG	
islands	(CGI)	(Chapter	5).	This	is	 in	keeping	with	the	literature	and	is	understood	to	
contribute	 to	 HNSCC	 development	 and	 progression	 [11,	 99-102].	 In	 VU40T	 cells,	
losses	 in	 5mC	 after	 DAC	 primarily	 occur	 at	 non-repeat	 regions.	 DAC	 demethylates	
promoters,	exons	and	CGIs	to	levels	similar	to	those	of	HOK	cells.	From	these	results,	
it	can	be	hypothesised	that	 in	this	system	DAC	does	not	cause	global	5mC	loss	and	
genomic	 instability	and	 instead	 targets	aberrantly	methylated	promoters	and	CGIs.	
However,	 when	 the	 methylation	 and	 RNA	 levels	 of	 tumour	 suppressor	 genes	
previously	 implicated	 in	 HNSCC	 were	 examined,	 promoter	 demethylation	 by	 DAC	






needed	 to	 activate	 repressed	 genes	 [27].	 Further	 work	 is	 required	 to	 determine	
whether	 other	 genes	 are	 reactivated	 by	 promoter	 demethylation	 after	 DAC	 and	
what	pathways	these	are	 involved	 in.	However,	 the	results	presented	here	suggest	




promoter	 [158,	 265].	 This	 led	 to	 the	 proposition	 that	 DNMTi	 can	 induce	 viral	
mimicry,	 where	 ERVs	 are	 expressed	 as	 dsRNA	 that	 triggers	 an	 immune	 response	
[158,	180,	266-268].	Previous	work	in	this	area	has	focused	on	the	delayed	response,	
where	methylation	 and	RNA	are	measured	 several	 days	 after	 removal	 of	 the	 drug	
[158,	180].	However,	in	VU40T	cells,	96h	treatment	with	both	high	and	low	dose	DAC	
is	sufficient	to	directly	cause	some	aspects	of	viral	mimicry:	ERVs	are	demethylated	
and	 expressed;	 dsRNA	 is	 increased	 and;	 immune	 and	 anti-viral	 genes	 are	
upregulated.	 This	 suggests	 that	 the	 efficacy	 of	 DAC	 in	 VU40T	 is	 at	 least	 partially	
attributed	 to	 viral	 mimicry,	 however,	 further	 work	 involving	 knockdowns	 of	
interferon	or	viral	pathway	genes	are	needed	to	confirm	this.	
In	 normal	 oral	 keratinocytes	 (HOK	 cells),	 Alu	 elements	 are	 enriched	 in	 5mC	 and	







however,	 this	 is	partially	 repaired	by	DAC	 treatment	 (Figure	6.26).	 	 Increased	5mC	
and	5hmC	was	observed	in	VU40T	cells	after	both	high	and	low	dose	DAC.	Therefore,	
DAC	 treatment	 helps	 to	 re-establish	 the	 control	 of	 Alu	 elements	 by	 DNA	
modifications.	 This	 corresponds	 with	 a	 decrease	 in	 Alu	 RNA,	 suggesting	 that	 the	
modifications	 function	 in	 repressing	 Alu	 transcription.	 Alu	 RNA	 can	 insert	 into	 the	
genome	causing	a	variety	of	mutations	and	Alu	RNA	that	cannot	retrotranspose	can	





The	 majority	 of	 5mC	 changes	 in	 HNSCC	 are	 distinct	 from	 5hmC	 changes.	 These	
findings	 are	 in	 keeping	 with	 the	 literature	 where	 cancer	 and	 tissue	 specific	
differences	 in	 5mC	 inversely	 correlate	 with	 5hmC	 [260,	 261].	 The	 same	 can	 be	
observed	in	VU40T	cells	after	DAC	treatment;	while	5mC	is	decreased	in	promoters	
and	CpG	rich	regions	close	to	the	TSS,	5hmC	is	decreased	in	 intergenic	regions	and	
CpG	 poor	 regions	 further	 from	 the	 TSS	 (Figure	 6.25).	 This	 could	 be	 attributed	 to	
decreased	TET2	RNA	after	DAC.	The	exception	 is	at	Alu	elements,	where	both	5mC	
and	5hmC	are	decreased	 in	HNSCC	and	 increased	by	DAC	 treatment	 (Figure	6.25).		
This	suggested	that	Alu	elements	have	a	distinct	form	of	epigenetic	control.		
When	 comparing	 the	 results	 of	 MeDIP	 and	 hMeDIP	 sequencing	 experiments,	 it	








gain	 after	 DAC;	 Alu	 elements	 may	 be	 protected	 from	 global	 modification	 loss.	






bisulfite	 conversion	 of	 specific	 Alu	 elements	 are	 required	 in	 order	 to	 determine	
whether	DAC	treatment	causes	DNA	modification	gain	at	Alu	or	if	Alu	elements	are	
protected	from	global	DNA	modification	loss.		
In	 previous	 chapters	 the	 potential	 efficacy	 of	 DAC	 treatment	 in	 HNSCC	 has	 been	
described	 (Chapter	 3).	 While	 some	 HNSCC	 cell	 lines	 respond	 to	 nanomolar	
concentrations	 of	 the	 drug,	 normal	 oral	 keratinocytes	 (HOK	 cells)	 are	 resistant	 to	
treatment.	In	this	chapter	these	results	have	been	expanded	upon	to	describe	DNA	
modification	 changes	 in	 response	 to	 DAC.	 Encouragingly,	 while	 HNSCC	 cells	 show	
considerable	 changes	 in	 the	 distribution	 of	 5mC	 after	DAC	 treatment,	 normal	 oral	
keratinocytes	 do	 not.	 DAC	 partially	 restores	 the	 distribution	 of	 5mC	 and	 5hmC	 in	
VU40T	cells	to	those	of	normal	oral	keratinocytes	and	re-establishes	the	positioning	
of	both	modifications	at	Alu	elements.	Therefore,	 the	efficacy	of	DAC	treatment	 in	














Figure 6.25. The distribution of 5mC and 5hmC is altered in HNSCC, and partially 
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Figure 6.26. The distribution of 5mC and 5hmC in normal oral keratinocytes, 
HNSCC cells and HNSCC cells treated with DAC  
Top	 panel:	 The	 distribution	 of	 5mC	 and	 5hmC	 in	 a	 gene	 rich	 region	 in	 HOK	 cells	 is	
represented	as	 a	 schematic	 alongside	 the	associated	histone	modifications.	Middle	 panel:	
The	 distribution	 of	 5mC	 and	 5hmC	 are	 changed	 in	HNSCC.	Bottom	 panel:	 	 In	HNSCC	DAC	
treatment	 partially	 restores	 the	 distribution	 of	 5mC	 and	 5hmC	 to	 that	 of	 normal	 oral	
keratinocytes.	 This	 has	 three	 main	 outcomes	 represented	 by	 pink	 boxes:	 1)	 DAC	
demethylates	 ERVs,	 allowing	 them	 to	 be	 expressed	 as	 dsRNA	 and	 activate	 the	 immune	
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Chapter 7. Discussion and Future 
Work 
 In normal oral keratinocytes Alu elements are enriched in 7.1.
DNA methylation and hydroxymethylation 
An	important	finding	of	this	thesis	was	the	enrichment	of	both	5mC	and	5hmC	at	Alu	
elements	 in	 normal	 oral	 keratinocytes	 (HOK	 cells).	 Methylated	 and	
hydroxymethylated	 Alu	 elements	 were	 found	 in	 clusters	 in	 gene	 rich	 regions,	
neighbouring	 regulatory	 elements	 and	 active	 histone	modifications.	 In	 the	 human	
genome	 Alu	 elements	 are	 most	 prevalent	 in	 GC-rich	 DNA,	 neighbouring	 and	
overlapping	 genes	 [79].	 While	 Alu	 elements	 are	 excluded	 from	 unmethylated	
domains	and	CpG	islands,	they	are	found	at	the	boundaries	of	these	domains	[256].	




may	 anchor	 nucleosomes	 to	 regions	 neighbouring	 genes	 and	 regulatory	 elements;	
preventing	 transcription	 of	 the	 transposable	 element	 while	 protecting	 the	
neighbouring	regulatory	region	from	methylation	and	nucleosome	invasion.		
Interestingly,	VU40T	cells	are	characterised	by	less	5mC	and	5hmC	at	Alu	elements,	
and	 more	 5mC	 at	 CGI.	 Similarly,	 in	 VU40T	 cells,	 5mC	 is	 lost	 from	 CGI	 after	 DAC	






and	 hMeDIP	 sequencing	 results	 with	 the	 results	 of	 DNase	 hypersensitive	 site	
sequencing,	 before	 and	 after	 DAC,	 would	 help	 determine	 how	 changes	 in	 Alu	
methylation	or	hydroxymethylation	correspond	with	changes	in	chromatin	structure.	
Additionally,	 a	 variation	 of	 the	 CRISPR-Cas9	 system	 could	 be	 used	 to	 target	 Alu	





lack	 retrotransposition	 potential	 [245,	 259].	 This	 is	 understood	 to	 be	 due	 to	
epigenetic	 silencing.	 Compared	with	HOK	 cells,	 the	 enrichment	 of	 Alu	 elements	 in	
the	 VU40T	 MeDIP	 and	 hMeDIP	 data	 is	 considerably	 reduced.	 Lack	 of	 DNA	
modifications	 at	 Alu	 elements	 could	 lead	 to	 their	 expression,	 causing	 increased	
mutations	 and	 silencing	 of	 Alu	 containing	 genes	 [84,	 258].	 To	 confirm	 this	
hypothesis,	 the	 HOK	 transcriptome	 could	 be	 compared	 with	 the	 VU40T	
transcriptome	 to	 determine	whether	 increased	Alu	 RNA	 is	 observed	 in	 the	HNSCC	
cell	 line.	 Encouragingly,	 DAC	 treatment	 partially	 restored	 5mC	 and	 5hmC	 at	 Alu	
elements.	This	corresponded	with	a	decrease	in	Alu	RNA	expression.	Therefore,	DAC	
may	 partially	 restore	 the	 control	 of	 Alu	 element	 expression	 in	 HNSCC	 cells.	 To	




retrotransposition	 potential	 of	 expressed	 Alu	 elements,	 and	 the	 expression	 of	 Alu	
element	containing	genes	would	need	to	be	investigated.			
In	 conclusion,	 I	 propose	 that	 in	 gene	 rich	 regions,	 clusters	 of	 Alu	 elements	 act	 as	
boundaries	 that	 protect	 neighbouring	 regulatory	 regions	 from	 methylation	 and	
nucleosome	 occupancy.	 DNA	 modifications	 control	 both	 the	 expression	 of	 the	
underlying	 retrotransposons	 and	 the	 function	 of	 the	 boundary	 element.	 Indeed,	
after	DAC	treatment	the	gain	in	DNA	modifications	at	Alu	elements	corresponds	with	
both	decreased	Alu	RNA	levels	and	decreased	CpG	island	methylation.		
 DAC as a potential therapeutic in HNSCC                                                                                                                7.2.





dependent	 on	 the	 uptake,	 activation	 or	 retention	 of	 the	 drug.	 The	 drug	 transport	
genes	SLC15A2,	SLC22A5	and	SLC29A1	are	candidate	biomarkers	for	response	to	DAC	
in	HNSCC,	as	 their	expression	 is	higher	 in	DAC	responsive	cell	 lines	compared	with	
unresponsive	 cells.	 However,	 the	 number	 of	 HNSCC	 cell	 lines	 examined	 here	 is	
relatively	small	and	follow	up	experiments	with	more	DAC	treated	samples	is	needed	





transporter	 makes	 DAC-responsive	 cell	 lines	 unresponsive	 to	 DAC	 treatment	 or	
adding	the	transporter	makes	unresponsive	cell	lines	responsive.	
7.2.2. DAC shifts the distribution of 5mC and 5hmC back towards that of 
normal cells 
MeDIP	and	hMeDIP	sequencing	was	used	to	determine	the	distribution	of	5mC	and	
5hmC	 in	 normal	 oral	 keratinocytes	 (HOK)	 and	 an	 HNSCC	 cell	 line,	 VU40T,	 and	 to	
investigate	the	effect	of	DAC	on	this	distribution.	Interestingly,	DNA	methylation	and	
hydroxymethylation	 changes	 that	 occurred	 in	 HNSCC	 were	 partially	 restored	 by	
treatment	with	DAC.		
Promoters,	 exons	 and	 CpG	 islands	 gain	 methylation	 in	 HNSCC	 [11,	 99-101].	
Encouragingly,	 DAC	 preferentially	 demethylates	 non-repeat	 regions	 such	 as	
promoters	 and	 exons,	 and	 the	 enrichment	 of	 5mC	 at	 CGI	 is	 reduced	 by	 DAC.	
However,	 in	 HNSCC	 cells,	 decreased	 promoter	 5mC	 did	 not	 correlate	 with	 an	
increase	 in	 tumour	 suppressor	 gene	 (TSG)	 expression.	 Therefore,	 combined	
treatment	 with	 other	 epigenetic	 drugs	 may	 be	 required	 to	 activate	 these	 TSG.	
However,	 in	VU40T	 cells,	DAC	alone	 is	 sufficient	 to	decrease	 viability,	 therefore,	 it	
can	 be	 hypothesised	 that	 the	 reactivation	 of	 these	 TSGs	 is	 not	 required	 for	 DAC	
efficacy.		
In	 VU40T	 cells,	 DAC	 results	 in	 a	 decrease	 in	 5mC	 at	 ERVs,	 increased	 dsRNA	 and	
increased	expression	of	 immune	 responsive	genes.	 These	 results	 suggest	 that	 viral	
mimicry	 is	 occurring	 [158,	 180].	 This	 process	 appears	 to	 centre	 on	 the	 interferon	




genes.	 Interestingly,	 in	 HNSCC	 patient	 samples,	 expression	 levels	 of	 these	 genes	
cluster	 together;	 patients	 either	 show	 relatively	 high	 or	 low	 expression	 of	 DAC-
induced	 interferon	 genes.	 This	 suggests	 that	 a	 subset	 of	 HNSCC	 patients	 may	 be	
more	 responsive	 to	 DAC.	 To	 expand	 upon	 this	 work,	 it	 would	 be	 interesting	 to	
determine	whether	the	expression	of	these	genes	correlates	with	response	to	DAC	in	





DAC	or	 that	DAC	 leads	 to	 an	 active	 gain	 in	DNA	modifications	 at	 the	 transposable	
element	 sites.	 Oxidative	 bisulfite	 conversion	 and	 pyrosequencing	 of	 Alu	 elements	
would	 help	 to	 determine	 whether	 5mC	 and	 5hmC	 are	 increased	 at	 Alu	 elements	
after	DAC.	Furthermore,	 this	would	provide	base	pair	 resolution	of	5mC	and	5hmC	
distribution	over	the	repeats.	Interestingly,	Alu	elements	show	the	most	substantial	
changes	 in	 5mC	 and	 5hmC	 between	 HOK	 and	 VU40T	 cells,	 and	 in	 VU40T	 cells	 in	
response	 to	 DAC.	 Therefore,	 this	 could	 have	 considerable	 implications	 on	 the	
mechanism	of	DAC	efficacy	and	suggests	that	at	Alu	elements	DNA	modifications	are	
more	dynamic	than	at	other	sites	in	the	DNA.		
7.2.3. Primary oral keratinocytes are not responsive to DAC treatment 












regions	more	 susceptible	 to	 epigenetic	 therapy	 [27,	 38,	 45,	 96].	 Accordingly,	 DAC	
treatment	 is	 understood	 to	 preferentially	 reactivate	 genes	 silenced	 in	 cancer	 [96,	
263,	 264].	 Therefore,	DAC	may	 target	 regions	 of	 5mC	 specific	 to	HNSCC,	 and	 thus	









were	 decreased	 at	 Alu	 elements	 in	 HNSCC,	 and	 increased	 after	 DAC.	 However,	
elsewhere,	changes	in	5mC	and	5hmC	were	specific	for	each	modification.	This	is	in	






by	an	 increase	 in	TET2	 gene	expression.	Therefore,	 correlating	 the	5mC	and	5hmC	
changes	with	 the	results	of	a	TET2	ChIP	would	confirm	the	 involvement	of	TET2	 in	
converting	5mCà5hmC,	and	perhaps	also	5hmCà5fC/	5caC/C	after	DAC	treatment.	





 DAC and Paracetamol work in synergy to reduce viability 7.3.
in HNSCC cell lines 
The	 results	 of	 a	 DAC	 sensitising	 assay	 determined	 that	 the	 common	 analgesic,	
paracetamol	 functions	 in	 synergy	 with	 DAC	 to	 reduce	 viability	 in	 DAC	 responsive	
HNSCC	cell	lines.	Combined	treatment	allowed	toxic	concentrations	of	either	drug	to	
be	 replaced	 by	 clinically	 relevant	 ones.	 The	 mechanism	 behind	 this	 synergistic	




COX-2	 inhibition	 [192,	 276].	 In	 DAC	 responsive	 cell	 lines,	 DAC	 increased	 COX-2	
expression	 causing	 a	 corresponding	 increase	 in	 the	 COX-2	 product,	 PGE2.	 Adding	
paracetamol	or	the	COX-2	specific	inhibitor,	valdecoxib,	restored	PGE2	levels	to	that	
of	untreated	cells.	The	COX-2/PGE2	pathway	is	associated	with	inflammation,	growth	








Paracetamol	 overdose	 occurs	 when	 the	 levels	 of	 its	 toxic	 metabolite,	 NAPQI,	
overwhelm	 glutathione	 (GSH)	 stores	 [224].	 A	 small	 amount	 of	 all	 paracetamol	
consumed	 is	converted	 into	NAPQI	by	CPY450	enzymes,	primarily	CYP2E1	 [223].	 In	
DAC	 responsive	 cells	 DAC	 demethylates	 and	 increases	 the	 expression	 of	 CYP2E1,	
leading	 to	 a	 reduction	 in	 GSH.	 Therefore,	 DAC	 may	 increase	 the	 conversion	 of	
paracetamol	to	NAPQI	and	mimic	the	effects	of	paracetamol	overdose	at	therapeutic	
concentrations.	 The	 CYP450	 inhibitor,	 disulfiram,	 did	 not	 rescue	 VU40T	 cells	 from	
combined	 treatment.	 However,	 GSH	 levels	 were	 not	 investigated,	 therefore,	 it	
cannot	 be	 confirmed	 that	 disulfiram	 can	 restore	 the	 rate	 of	 conversion	 of	
paracetamolàNAPQI.	Further	work	in	this	area	could	include	investigating	whether	
GSH	 or	 the	 antidote	 to	 paracetamol	 overdose,	 NAC,	 are	 able	 to	 prevent	 the	
synergistic	relationship	between	DAC	and	paracetamol.		
Interestingly,	in	DAC	responsive	cell	lines,	paracetamol	treatment	led	to	a	reduction	
in	 5mC	 via	 reduced	 DNMT	 expression.	 Therefore,	 the	 synergistic	 relationship	
between	the	two	drugs	could	be	due	to	 increased	DNA	demethylation.	MeDIP	and	
DNMT	ChIP	could	be	performed	on	DAC	and	paracetamol	treated	cells	to	determine	
how	 the	addition	of	paracetamol	 to	DAC	 treatment	alters	 the	distribution	of	5mC.	





effect	 of	 paracetamol	 on	 these	 pathways	 needs	 to	 be	 investigated	 in	 order	 to	
determine	how	paracetamol	causes	reduced	DNMT	expression	in	HNSCC	cells.	
In	 conclusion,	 the	mechanistic	 studies	presented	here	 show	 that	 several	 pathways	
are	 altered	 by	 the	 combined	 treatment,	 and	 suggests	 that	 these	 cooperate	 to	
produce	the	synergistic	relationship	described.		




that	 they	 have	 already	 been	used	 in	 combination	 [121].	 Therefore,	 the	 synergistic	
effect	 of	 DAC	 and	 paracetamol	 may	 confound	 the	 outcomes	 of	 past	 or	 ongoing	
clinical	 trials.	 Furthermore,	 it	 is	 imperative	 to	 determine	 whether	 DAC	 and	
paracetamol	 act	 in	 synergy	 in	 haematological	 cancers,	 where	 DAC	 treatment	 is	
already	 in	 use.	 Finally,	 paracetamol	 is	 an	 appealing	 drug	 for	 repurposing	 as	 it	 is	
widely	 available	 and	 inexpensive.	 For	 HNSCC,	 combined	 treatment	 with	 DAC	 and	
paracetamol	 may	 prove	 to	 be	 the	 additional	 therapeutic	 option	 that	 is	 urgently	
required.	
 Conclusion 7.4.
The	 primary	 aim	 of	 this	 thesis	 was	 to	 investigate	 the	 relationship	 between	 DNA	
modifications	 and	 HNSCC	 and	 to	 examine	 the	 efficacy	 of	 the	 DNA	 demethylating	






cells	 DAC	 increased	 ERV	 expression	 and	 induced	 a	 viral	 mimicry	 response.	
Furthermore,	DAC	 re-established	 5mC	 and	 5hmC	 at	 Alu	 elements,	 leading	 to	 their	
repression.	Finally,	DAC	and	paracetamol	were	found	to	work	 in	synergy	to	reduce	
viability	 in	 HNSCC	 cell	 lines,	 providing	 an	 appealing	 new	 therapeutic	 option.	




Figure 7.1. DAC as a potential therapeutic option in the treatment of HNSCC 
The	main	conclusions	of	this	thesis	are	represented	as	a	schematic.	DAC	has	potential	as	a	
therapeutic	 in	HNSCC.	1.	Half	of	HNSCC	cell	 lines	 tested	 respond	 to	DAC	 treatment	and	 in	
DAC	 responsive	 cell	 lines	 efficacy	 can	 be	 increased	 through	 combined	 treatment	 with	
paracetamol.	 2.	 Primary	 oral	 keratinocytes	 are	 not	 responsive	 to	 DAC	 treatment.	 3.	 DAC	
shifts	the	distribution	of	5mC	and	5hmC	in	HNSCC	cells.	
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imatinib	 27	 phenoxymethyl	penicillin,		 77	
zinc	acetate	 28	 5'aminosalicyclic	acid/	mesalazine	 78	
valproic	acid,		 29	 finasteride	 79	
rifampicin	 30	 colchicine,		 80	
metronidazole	 31	 levothyroxine	sodium	 81	
praziquantel	 32	 methotrexate,		 82	
flutamide,		 33	 mifepristone	 83	
clomipramine	 34	 nicotine		 84	
testosterone,		 35	 cefaclor	 85	
calciferol/ergocalciferol	 36	 cyanocobalamin	(vitamin	B12)		 86	
doxycycline,		 37	 medroxyprogesterone	acetate,		 87	
tetracycline	 38	 bezafibrate	 88	
ibuprofen,		 39	 paroxetine,		 89	
norethisterone	 40	 trimethoprim	 90	
itraconazole	 41	 water	 91	
methyldopa	 42	 naloxone	hydrochloride	 92	
fenofibrate,		 43	 simvastatin,		 93	
clofibric	acid	 44	 flecainide	acetate	 94	
clobetasol	propionate	 45	 pilocarpine	HCl	 95	
paracetamol	(acetaminophen),		 46	 fluconazole	 96	
alverine	citrate	 47	 acitretin	 97	
mefenamic	acid	 48	 Memantine	 98	
prochlorperazine	 49	 Bortezamib	 99	










reads: Not Aligned Aligned n=1 Aligned n>1 
VU40T 34941803 1675948 28457784 4808071 
HN12 16587553 2461265 12229921 1896367 
UDSCC2 18726353 2478684 14146982 2100687 
SCC040 16556164 2348947 12288730 1918487 
VU40T 500nM DAC 22397597 2241080 17458914 2697603 
VU40T 132.3uM Para 18505914 1853625 14322656 2329633 




Supplementary data 3. MeDIP and hMeDIP sequenced reads 
The	total	number	of	reads	sequenced	for	MeDIP,	hMeDIP	and	input	DNA	are	outlined	for	all	
samples	 analysed.	 	 Using	 Bowtie2,	 Dr	 Sam	 Clokie	 aligned	 reads	 to	 the	 human	 genome	
(hg19).	The	table	also	shows	the	number	and	percentage	of	reads	aligned.		
	 	




1 24,476,992 23,244,909 94.97 
2 25,460,459 24,521,995 96.31 
3 8,336,836 7,870,773 94.41 
VU40T 100nM DAC 
1 25,987,848 25,169,967 96.85 
2 26,683,840 25,957,794 97.28 
VU40T 1uM DAC 
1 15,676,959 13,778,876 87.89 
2 27,395,777 25,988,864 94.86 
3 10,319,152 9,527,629 92.33 
HOK NT 1 36,493,086 36,010,648 98.68 
     




1 23,799,568 23,799,568 98.37 
2 13,835,182 13,533,894 97.82 
VU40T 100nM DAC 
1 21,670,412 21,252,088 98.07 
2 16,048,337 15,689,139 97.76 
VU40T 1uM DAC 
1 45,402,331 44,511,849 98.04 
2 16,737,593 16,470,694 98.41 
HOK NT 1 29,986,781 29,755,476 99.23 
HOK 100nM DAC 1 39,121,678 38,808,718 99.20 
HOK 1uM DAC 1 24,379,915 24,199,440 99.26 
     
Input Replicate Total number of reads sequenced 
Aligned reads 
Number Percentage 
HOK NT 1 31,846,500 31,694,473 99.52 






Supplementary data 4. DNA dot blot analysis of 5mC levels in HNSCC cell lines 
HNSCC	cell	lines	were	treated	with	500nM	DAC	(+)	or	an	equivalent	volume	of	vehicle	(-)	for	
96h	following	which	DNA	was	extracted	and	DNA	dot	blotting	performed	using	an	antibody	
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Supplementary data 5. Gene ontology terms associated with DAC responsive cell 
lines 
Genes	 expressed	 (FPKM>1)	 in	 only	 in	 DAC	 responsive	 (HN12	 and	 VU40T)	 cell	 lines	 were	
subject	to	gene	onotology	biological	processes	(GO	BP)	analysis	using	DAVID.		
	 	
Term P-Value Benjamini 
positive	regulation	of	catagen 0.00021 0.17 
negative	regulation	of	protein	kinase	activity 0.0097 0.99 
positive	regulation	of	mesenchymal	cell	apoptotic	process 0.017 0.99 
AMP	catabolic	process 0.017 0.99 
activation	of	meiosis 0.017 0.99 
embryonic	hindlimb	morphogenesis 0.023 0.99 
cardioblast	differentiation 0.025 0.99 
embryonic	nail	plate	morphogenesis 0.025 0.99 
palate	development 0.026 0.98 
cellular	response	to	estradiol	stimulus 0.028 0.97 
embryonic	forelimb	morphogenesis 0.029 0.96 
drug	transport 0.041 0.98 
negative	regulation	of	fat	cell	differentiation 0.048 0.99 
cell	differentiation	involved	in	embryonic	placenta	development 0.049 0.98 
BMP	signaling	pathway	involved	in	heart	development 0.049 0.98 
pore	complex	assembly 0.049 0.98 
translation 0.062 0.99 
positive	regulation	of	protein	localization	to	Cajal	body 0.065 0.99 
protein	folding 0.065 0.99 
positive	regulation	of	translation 0.073 0.99 
polyamine	biosynthetic	process 0.073 0.99 
positive	regulation	of	osteoblast	differentiation 0.09 0.99 
cell	morphogenesis 0.096 0.99 
negative	regulation	of	bone	resorption 0.096 0.99 
positive	regulation	of	DNA	damage	response,	signal	transduction	by	p53	class	mediator 0.096 0.99 




Supplementary data 6. Gene ontology terms associated with genes differentially 
expressed in DAC responsive versus DAC unresponsive HNSCC cell lines 
DeSeq2	was	performed	 to	determine	differentially	expressed	genes	 in	 the	DAC	 responsive	




term	ID description log10	p-value 
GO:0008150 biological_process -14.5243 
GO:0008152 metabolic	process -3.065 
GO:0009987 cellular	process -8.8761 
GO:0032502 developmental	process -3.2636 
GO:0045892 negative	regulation	of	transcription,	DNA-templated -5.1518 
GO:0048856 anatomical	structure	development -2.4921 
GO:0050911 detection	of	chemical	stimulus	involved	in	sensory	perception	of	smell -11.1851 
GO:0065007 biological	regulation -6.5544 
GO:0071840 cellular	component	organization	or	biogenesis -4.762 
GO:0030030 cell	projection	organization -4.4547 
GO:0044237 cellular	metabolic	process -4.4895 
GO:1901360 organic	cyclic	compound	metabolic	process -3.1308 
GO:0009058 biosynthetic	process -2.4908 
GO:0071704 organic	substance	metabolic	process -1.7122 
GO:0006725 cellular	aromatic	compound	metabolic	process -2.3233 
GO:1901362 organic	cyclic	compound	biosynthetic	process -5.9586 
GO:0046483 heterocycle	metabolic	process -2.0783 
GO:0048519 negative	regulation	of	biological	process -3 
GO:0051606 detection	of	stimulus -8.1701 
GO:0007186 G-protein	coupled	receptor	signaling	pathway -4.8041 
GO:0006357 regulation	of	transcription	from	RNA	polymerase	II	promoter -1.4711 
GO:0050789 regulation	of	biological	process -5.1831 
GO:0018130 heterocycle	biosynthetic	process -5.3197 
GO:0016070 RNA	metabolic	process -2.0711 
GO:0019438 aromatic	compound	biosynthetic	process -5.251 
GO:0070268 cornification -1.9872 
GO:0044271 cellular	nitrogen	compound	biosynthetic	process -2.9469 
GO:0006139 nucleobase-containing	compound	metabolic	process -2.1858 
GO:0006996 organelle	organization -2.8996 
GO:0044249 cellular	biosynthetic	process -2.5045 
GO:0006351 transcription,	DNA-templated -6.007 
GO:2000112 regulation	of	cellular	macromolecule	biosynthetic	process -4.2147 
GO:1901576 organic	substance	biosynthetic	process -2.1524 
GO:0019222 regulation	of	metabolic	process -2.983 
GO:0048858 cell	projection	morphogenesis -1.5901 
GO:0022607 cellular	component	assembly -1.3768 
DAC-	responsive 
term	ID description log10	p-value 
GO:0007606 sensory	perception	of	chemical	stimulus -5.767 
GO:0008150 biological_process -3.1593 
GO:0009987 cellular	process -3.9469 
GO:0034660 ncRNA	metabolic	process -4.5452 
GO:0044085 cellular	component	biogenesis -4.1349 
GO:0050790 regulation	of	catalytic	activity -1.7852 
GO:0051179 localization -2.3747 
GO:0051234 establishment	of	localization -1.6345 
GO:0071840 cellular	component	organization	or	biogenesis -5.1518 
GO:0007186 G-protein	coupled	receptor	signaling	pathway -1.6364 




Supplementary data 7. 
Gene ontology terms 
associated with genes 
differentially 






























GO:0006091 generation	of	precursor	metabolites	and	energy -3.21	 	 
GO:0022900 electron	transport	chain -6.29	 	 





GO:0019637 organophosphate	metabolic	process -1.63	 	 	 
DA
C	
GO:0002376 immune	system	process -9.21GO:0008152 metabolic	process -6.63
GO:0008150 biological_process -2.80GO:0009987 cellular	process -3.12
GO:0009987 cellular	process -3.35GO:0023052 signaling -2.02
GO:0032501 multicellular	organismal	process -1.38GO:0034660 ncRNA	metabolic	process -10.90
GO:0032502 developmental	process -2.61GO:0046907 intracellular	transport -2.71
GO:0034097 response	to	cytokine -11.60GO:0071840 cellular	component	organization	or	biogenesis -10.95
GO:0042127 regulation	of	cell	proliferation -6.56GO:0071353 cellular	response	to	interleukin-4 -1.33
GO:0044699 single-organism	process -6.75GO:0071704 organic	substance	metabolic	process -6.78
GO:0050896 response	to	stimulus -2.63GO:0000278 mitotic	cell	cycle -6.07
GO:0051704 multi-organism	process -2.18GO:0006996 organelle	organization -7.70
GO:0065007 biological	regulation -3.87GO:0008283 cell	proliferation -1.95
GO:0006396 RNA	processing -2.21GO:0009058 biosynthetic	process -4.41
GO:0044763 single-organism	cellular	process -5.23GO:0019080 viral	gene	expression -3.14
GO:0043900 regulation	of	multi-organism	process -4.12GO:0006807 nitrogen	compound	metabolic	process -6.11
GO:0030155 regulation	of	cell	adhesion -1.79GO:1901360 organic	cyclic	compound	metabolic	process -9.56
GO:0040012 regulation	of	locomotion -4.18GO:0044700 single	organism	signaling -2.01
GO:0051270 regulation	of	cellular	component	movement -4.91GO:0044238 primary	metabolic	process -6.53
GO:1901564 organonitrogen	compound	metabolic	process -1.57GO:0006725 cellular	aromatic	compound	metabolic	process -9.16
GO:0051239 regulation	of	multicellular	organismal	process -6.15GO:0044237 cellular	metabolic	process -7.21
GO:0046903 secretion -2.63GO:0007059 chromosome	segregation -1.69
GO:0050793 regulation	of	developmental	process -5.35GO:0006413 translational	initiation -2.60
GO:0032879 regulation	of	localization -2.04GO:0007049 cell	cycle -5.37
GO:0048518 positive	regulation	of	biological	process -4.97GO:0043170 macromolecule	metabolic	process -2.64
GO:0006952 defense	response -8.70GO:0046483 heterocycle	metabolic	process -9.03
GO:0048522 positive	regulation	of	cellular	process -3.72GO:0009124 nucleoside	monophosphate	biosynthetic	process -2.12
GO:0048519 negative	regulation	of	biological	process -4.13GO:0034641 cellular	nitrogen	compound	metabolic	process -11.50
GO:0048523 negative	regulation	of	cellular	process -2.93GO:0000184 nuclear-transcribed	mRNA	catabolic	process,	
nonsense-mediated	decay 
-1.75
GO:0044710 single-organism	metabolic	process -2.84GO:0044260 cellular	macromolecule	metabolic	process -3.64
GO:0051707 response	to	other	organism -6.95GO:0044249 cellular	biosynthetic	process -4.63
GO:0006955 immune	response -4.49GO:0043603 cellular	amide	metabolic	process -5.01
GO:0009607 response	to	biotic	stimulus -6.56GO:0006260 DNA	replication -6.94
GO:1902578 single-organism	localization -2.01GO:0090305 nucleic	acid	phosphodiester	bond	hydrolysis -1.83
GO:0009605 response	to	external	stimulus -6.63GO:0006259 DNA	metabolic	process -6.99
GO:0007166 cell	surface	receptor	signaling	pathway -3.11GO:0010467 gene	expression -1.78
GO:0048583 regulation	of	response	to	stimulus -1.87GO:0034470 ncRNA	processing -8.31
GO:0050794 regulation	of	cellular	process -3.84GO:0006312 mitotic	recombination -2.63
GO:0006954 inflammatory	response -4.19GO:0006396 RNA	processing -7.26
	 	 GO:0022616 DNA	strand	elongation -3.23
	 	 GO:0032543 mitochondrial	translation -2.16
	 	 GO:0000722 telomere	maintenance	via	recombination -2.02
	 	 GO:0006139 nucleobase-containing	compound	metabolic	process -9.48










GO:0006396 RNA	processing -2.67GO:0003008 system	process -4.13
GO:0008150 biological_process -3.21GO:0006412 translation -37.77
GO:0009605 response	to	external	stimulus -3.22GO:0007155 cell	adhesion -2.00
GO:0009888 tissue	development -5.65GO:0008150 biological_process -15.30
GO:0009987 cellular	process -3.59GO:0008152 metabolic	process -40.33
GO:0032501 multicellular	organismal	process -2.06GO:0009987 cellular	process -22.36
GO:0032502 developmental	process -2.59GO:0022610 biological	adhesion -2.07
GO:0044699 single-organism	process -6.12GO:0022613 ribonucleoprotein	complex	biogenesis -35.69
GO:0051239 regulation	of	multicellular	organismal	process -5.41GO:0023052 signaling -8.40
GO:0065007 biological	regulation -5.06GO:0032501 multicellular	organismal	process -1.46
GO:0044763 single-organism	cellular	process -7.20GO:0071840 cellular	component	organization	or	biogenesis -35.17
GO:0051270 regulation	of	cellular	component	movement -3.44GO:0007059 chromosome	segregation -12.80
GO:0040012 regulation	of	locomotion -2.53GO:0006974 cellular	response	to	DNA	damage	stimulus -17.44
GO:0042127 regulation	of	cell	proliferation -3.18GO:0007154 cell	communication -7.39
GO:0051336 regulation	of	hydrolase	activity -3.28GO:0044763 single-organism	cellular	process -4.46
GO:0032879 regulation	of	localization -4.58GO:0032259 methylation -5.06
GO:0046903 secretion -1.86GO:0051301 cell	division -9.99
GO:0048523 negative	regulation	of	cellular	process -4.51GO:0030029 actin	filament-based	process -2.29
GO:0023051 regulation	of	signaling -2.53GO:0006091 generation	of	precursor	metabolites	and	energy -2.17
GO:0016192 vesicle-mediated	transport -1.46GO:0007049 cell	cycle -23.95
GO:0010646 regulation	of	cell	communication -1.93GO:0044237 cellular	metabolic	process -44.37
GO:0048518 positive	regulation	of	biological	process -2.60GO:0019637 organophosphate	metabolic	process -4.46
GO:0048522 positive	regulation	of	cellular	process -2.44GO:1901135 carbohydrate	derivative	metabolic	process -1.58
GO:0048519 negative	regulation	of	biological	process -4.65GO:0009056 catabolic	process -5.24
GO:0065008 regulation	of	biological	quality -1.76GO:0006793 phosphorus	metabolic	process -2.17
GO:0006955 immune	response -2.10GO:1901796 regulation	of	signal	transduction	by	p53	class	
mediator 
-2.42
GO:1902578 single-organism	localization -2.87GO:0006614 SRP-dependent	cotranslational	protein	targeting	to	
membrane 
-19.93
GO:0006952 defense	response -3.00GO:0043624 cellular	protein	complex	disassembly -11.89
GO:0010033 response	to	organic	substance -2.41GO:0044710 single-organism	metabolic	process -1.92
GO:0048583 regulation	of	response	to	stimulus -2.00GO:0034660 ncRNA	metabolic	process -28.93
GO:0034660 ncRNA	metabolic	process -2.01GO:0051276 chromosome	organization -20.43
GO:0050794 regulation	of	cellular	process -3.73GO:0006839 mitochondrial	transport -1.74
	 	 GO:0006725 cellular	aromatic	compound	metabolic	process -38.98
	 	 GO:0022411 cellular	component	disassembly -5.39
	 	 GO:1901360 organic	cyclic	compound	metabolic	process -37.31
	 	 GO:0046483 heterocycle	metabolic	process -38.33
	 	 GO:0009058 biosynthetic	process -26.33
	 	 GO:0006807 nitrogen	compound	metabolic	process -38.36
	 	 GO:0050877 neurological	system	process -3.76




	 	 GO:0051641 cellular	localization -8.88
	 	 GO:0044700 single	organism	signaling -8.37
	 	 GO:0090305 nucleic	acid	phosphodiester	bond	hydrolysis -4.95
	 	 GO:0009451 RNA	modification -1.85
	 	 GO:0019083 viral	transcription -19.10
	 	 GO:0006260 DNA	replication -18.34
	 	 GO:0043414 macromolecule	methylation -1.55
	 	 GO:0000956 nuclear-transcribed	mRNA	catabolic	process -16.15
	 	 GO:0044260 cellular	macromolecule	metabolic	process -30.93
	 	 GO:0044085 cellular	component	biogenesis -26.93
	 	 GO:0016072 rRNA	metabolic	process -31.72
	 	 GO:0043170 macromolecule	metabolic	process -25.55
	 	 GO:0034641 cellular	nitrogen	compound	metabolic	process -53.60
	 	 GO:0043603 cellular	amide	metabolic	process -29.53
	 	 GO:0006259 DNA	metabolic	process -25.75
	 	 GO:0010629 negative	regulation	of	gene	expression -2.27
	 	 GO:0016071 mRNA	metabolic	process -12.37
	 	 GO:0015980 energy	derivation	by	oxidation	of	organic	compounds -2.46
	 	 GO:1901576 organic	substance	biosynthetic	process -26.27
	 	 GO:0044238 primary	metabolic	process -39.78
	 	 GO:0061641 CENP-A	containing	chromatin	organization -2.01
	 	 GO:0010467 gene	expression -19.19
	 	 GO:0006396 RNA	processing -26.20
	 	 GO:0071704 organic	substance	metabolic	process -37.87
	 	 GO:0097031 mitochondrial	respiratory	chain	complex	I	biogenesis -3.17
	 	 GO:0019538 protein	metabolic	process -6.53
	 	 GO:0015833 peptide	transport -2.28
	 	 GO:0044267 cellular	protein	metabolic	process -10.38
	 	 GO:0000819 sister	chromatid	segregation -8.72
	 	 GO:0043933 macromolecular	complex	subunit	organization -17.79
	 	 GO:0007186 G-protein	coupled	receptor	signaling	pathway -3.58
	 	 GO:1901564 organonitrogen	compound	metabolic	process -13.04
	 	 GO:0007267 cell-cell	signaling -1.80
	 	 GO:0006996 organelle	organization -25.40
	 	 GO:0071826 ribonucleoprotein	complex	subunit	organization -7.37
	 	 GO:0042254 ribosome	biogenesis -38.08
	 	 GO:0071824 protein-DNA	complex	subunit	organization -1.74
	 	 GO:0000280 nuclear	division -6.59






Supplementary data 8. Western blot analysis 
VU40T	 and	 SCC040	 cells	were	 treated	 for	 96h	with	 132.3µM	paracetamol,	 500nM	DAC	or	
both	followed	by	protein	extraction	and	western	blotting	for	COX-2	(upper	panels),	CYP2E1	
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Supplementary data 9. DNA dot blot analysis of DAC, paracetamol and 
valdecoxib treated HNSCC cell lines 
VU40T	and	SCC040	cells	were	 treated	 for	96h	with	132.3µM	paracetamol	 (P),	500nM	DAC	
(D),	valdecoxib	 (V),	combined	treatment	 (PC/VD)	or	vehicle	only	 (A).	DNA	dot	blotting	was	
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Supplementary data 10. MeDIP and hMeDIP qRT-PCR check 
Prior	to	 library	preparation	MeDIP	and	hMeDIP	experiments	were	subject	to	qRT-PCR	with	
primers	corresponding	to	regions	enriched	in	5mC	or	5hmC	(RARβ	and	BFIPB2	respectively)	
or	 lacking	 5mC	 or	 5hmC	 (KRT6A	 and	 Neg	 control).	 MeDIP	 results	 are	 the	 mean	 of	 2	
experiments.	 Vehicle	 only	 (NT)	 and	 1µM	DAC	 treated	 hMeDIP	 results	 are	 the	 mean	 of	 3	











































































































Supplementary data 11. Overlap between 5mC and 5hmC peaks and NHEK 
chromatin domains 
NHEK	 chromatin	 domains	were	 downloaded	 from	 the	UCSC	 table	 browser.	On	Galaxy	 the	































Supplementary data 12. Alu element subfamilies 
All	 Alu	 elements	were	 downloaded	 from	 repeatmasker	 and	 separated	 by	 subfamiles.	 The	
graphs	show	the	number	of	Alu	elements	 (count)	of	different	sizes	 in	each	subfamily.	This	
gives	 a	 visual	 representation	 of	 the	 amount	 of	 each	 subfamily	 present	 in	 the	 the	 human	
genome	and	shows	that	the	majority	of	Alu	elements	are	~300bp.	
  
AluJb AluJo AluJr AluJr4 AluSc AluSc5 AluSc8
AluSg AluSg4 AluSg7 AluSp AluSq AluSq10 AluSq2
AluSq4 AluSx AluSx1 AluSx3 AluSx4 AluSz AluSz6
AluY AluYa5 AluYa8 AluYb8 AluYb9 AluYc AluYc3
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Supplementary data 13. Overlap between HOK 5mC and 5hmC Alu groups and 
NHEK chromatin domains 
The	results	of	HOK	MeDIP	and	hMeDIP	sequencing	were	separated	based	on	the	presence	of	
an	Alu	element.	All	Alu	elements	were	downloaded	 from	repeat	masker	and	 those	 lacking	
5mC	or	 5hmC	 in	HOK	 cells	were	determined.	NHEK	 chromatin	domains	were	downloaded	
from	the	UCSC	table	browser.	On	Galaxy	the	BedTools	‘intersect	intervals’	function	was	used	


































































Supplementary data 14. Overlap between HOK 5mC and 5hmC Alu groups and 
NHEK histone modifications 
The	results	of	HOK	MeDIP	and	hMeDIP	sequencing	were	separated	based	on	the	presence	of	
an	Alu	element.	All	Alu	elements	were	downloaded	 from	repeat	masker	and	 those	 lacking	
5mC	 or	 5hmC	 in	 HOK	 cells	 were	 determined.	 NHEK	 histone	 modification	 peaks	 were	
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Supplementary data 15. DNA dot blot analysis of 5mC and 5hmC of DAC treated 
VU40T cells 
VU40T	 cells	 were	 incubated	 with	 100nM	 (B),	 500nM(C),	 1µM	 (D)	 DAC	 or	 an	 equivalent	
volume	 of	 vehicle	 (A)	 for	 96h.	 DNA	was	 extracted	 and	DNA	 dot	 blotting	 performed	 using	
antibodies	against	5mC	(top)	and	5hmC	(bottom).	Blots	were	incubated	in	methylene	blue	to	
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